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Summary 
Summary 
 
Indwelling devices and prosthesis are increasingly used in modern medicine practices. Failures of 
prosthetic joint devices constitute an important complication. Especially, the management of patients 
with a septic failure is characterized by difficulties in the diagnosis and by frequent treatment failures, 
with infection relapses. Thus, the goal of our studies was to establish and evaluate innovative methods 
for the diagnosis, prophylaxis and treatment of prosthetic infections. 
 
The accurate differentiation between septic and aseptic loosening of the implants is difficult. 
Nuclear medicine methods are promising, non-invasive procedures aiming to visualize the specific 
accumulation at sites of infection of an injected radiotracer. However, reliable pre-clinical protocols 
suitable for screening of radiotracers are missing. In our study, we compared in vitro and in the tissue 
cage mouse model of implant infection: 99mTc-UBI, 99mTc-ciprofloxacin, 99mTcN-CIPROCS2 and 111In-
DTPA-biotin for targeting E. coli and S. aureus. Radiochemical purity of the labeled agents ranged 
between 94 % and 98 %. Stability in serum was high for all tracers. In vitro binding assays displayed a 
rapid and non-displaceable bacterial binding for all tested agents. Using the tissue cage mouse model, 
the tested agents accumulated in vivo in infected sites, being 99mTc-ciprofloxacin and 111In-DTPA-
biotin from 4 h p.i. discriminative for both E. coli and S. aureus infections, whereas 99mTc-UBI 29-41 
and 99mTcN-CiproCS2 discriminated only for E. coli infected cages. The measured tissue cage to blood 
(T/NT) ratios remained lower than 3, a finding that in our opinion may constitute a limiting factor for 
the use of the tested tracers in patients. 
Following, we evaluated the potentials for targeting infections of the novel transcobalamin II non-
binder 99mTc-labeled derivative of Vitamin B12 (99mTc-PAMA(4)-Cbl). Vitamin B12 (Cbl) is an 
essential co-factor, accumulated by rapidly replicating prokaryotic and eukaryotic cells. For 
comparison, we tested in parallel the labeled native vitamin 57Co-Cbl and the 99mTc-PAMA(4)-Cbl 
derivative. In vitro binding to a S. aureus and an E. coli strain was specific and could be antagonized 
by addition of unlabeled Cbl. 99mTc-PAMA(4)-Cbl showed lower in vitro binding than 57Co-Cbl to E. 
coli, but similar binding to S. aureus. In vivo, 57Co-Cbl showed gradual accumulation into the cage 
fluids, and discriminated only for E. coli infected cages. On the contrary, 99mTc-PAMA(4)-Cbl showed 
a rapid kinetic, it was rapidly cleared from most tissues and was able to discriminate both S. aureus 
and E. coli infected from sterile cages at time points longer than 4 h p.i.. Thus, the new 99mTc-
PAMA(4)-Cbl derivative may represent a promising candidate for bacterial imaging in humans. 
In addition, we demonstrated the validity of the mouse tissue cage model for screening radiotracers 
targeting infections. The negative control, 99mTc-DTPA, showed rapid accumulation and clearance 
from both sterile and infected cages, whereas, the positive control, 67Gallium citrate, accumulated 
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selectively in infected cages between 48 h and 72 h p.i. 
 
Early and accurate detection of methicillin-resistant Staphylococcus aureus (MRSA) is essential in 
the hospital and the outpatient setting. We established a calorimetry assay for discrimination of MRSA 
from methicillin susceptible S. aureus (MSSA). The assay consisted of paired heat measurements of 
batch cultures in pure medium and in medium supplied with cefoxitin. Relative heat was calculated as 
ratio between the total heat, measured in the presence and absence of cefoxitin. Using a relative heat 
cutoff of 0.4, 19 of 20 MRSA (95%) and 10 of 10 MSSA (100%) clinical isolates were correctly 
identified within 5 h. Thus, microcalorimetry may be successfully applied in routine screening for 
MRSA and potentially be extended to screen resistance patterns of other pathogens and antibiotic 
agents. 
 
Ga3+ is a semi-metal element competing for iron-binding sites of transporters and enzymes. We 
investigated the activity of gallium maltolate (GaM), against laboratory and clinical strains of MSSA, 
MRSA and methicillin susceptible or resistant S. epidermidis (MSSE, MRSE). The MICs of GaM 
were higher for S. aureus (375-2000 µg/ml) than S. epidermidis (94-200 µg/ml). Minimal biofilm 
inhibitory concentrations (MBIC) were 3000-≥6000 (S. aureus) and 94-3000 µg/ml (S. epidermidis). 
In time-kill studies, GaM exhibited a slow and dose-dependent killing mechanism. Sub-inhibitory 
concentrations of GaM inhibited growth-related heat production measured in a batch calorimeter. The 
GaM minimal heat inhibitory concentrations (MHIC) correlated well with the MIC values. Thus, GaM 
exhibited activity against staphylococci, but high concentrations were required. These data supports 
the potential use of GaM for local application, including treatment of wound infections, MRSA 
decolonization and implant coating.  
 
Finally, we investigated the efficacy of linezolid, alone and in combination with rifampin 
(rifampicin), against MRSA in a guinea pig model of foreign-body infection. In vitro, linezolid was 
bacteriostatic against the tested strain. In time-kill studies, development of rifampin resistance was 
observed with rifampin alone, but was prevented by the addition of linezolid. After the administration 
of single intraperitoneal doses, linezolid concentrations into sterile cage fluids remained above the 
MIC during 12 h. Antimicrobial treatments administered to animals with cage implant infections were 
given twice daily for 4 days. Linezolid alone reduced planktonic bacteria in cage fluid during 
treatment. Efficacy in eradication of cage-associated infection was achieved only when linezolid was 
combined with rifampin, with cure rates being between 50% and 60%. For comparison, the 
levofloxacin-rifampin combination was tested and demonstrated the highest cure rate (91%). Thus, the 
linezolid-rifampin combination may be a treatment option for implant-associated infections caused by 
quinolone-resistant MRSA. 
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1.1 Bacterial Infections 
It is estimated that the adult human body is colonized by 1014 microorganisms, which constitute the 
natural microflora. Bacteria constitute the most common microorganisms forming the normal human 
flora, and they inhabit inner and outer body surfaces such as skin, mucosae of the upper respiratory 
tract, the oral cavity, the intestinal tract, and the urogenital tract.  
Adherence of bacteria to host epithelial cells is the first step for colonization and distribution on 
the different body surfaces. The adherence occurs by specific recognition and binding of protein or 
polysaccharide structures expressed at the surfaces of the host skin and mucosa. Following, the degree 
of hydration, the pH, the temperature, and the presence or absence of oxygen and nutrients influence 
the possible growth and persistence of microorganisms on body surfaces, and their heterogeneous 
distribution in different regions of the human body [1, 2].  
The relationship between the colonizing bacteria and the host could be of symbiosis, 
commensalisms, and parasitism. The first two differ from each other for the presence and the absence, 
respectively, of benefits between the colonizing agent and the host. Symbiontic or commensal 
microorganisms inhabit the human body without harming or causing disease. The maintenance of an 
equilibrium within these microflora populations is of great importance and protects towards the 
invasion of both opportunistic and exogenous parasites.  
Parasitism is based on the benefits acquired by a pathogenic bacterium invading the host and 
causing an infection. A bacterial infection is the process occurring when the microbe manifests its 
pathogenicity, and thus its capacity of inducing disease, by invading and causing a damage (locally or 
systemically) of the host organism. Pathogenicity of a bacterium could be exerted also without the 
induction of an infection; an example is the ingestion by the host of bacterial toxins previously 
released in food or water. The expression of “virulence factors” (adhesins, cation-chelators and toxins) 
enables the pathogen to subvert the host immune defenses, invade the host and cause a disease. 
Consequently the infection may remain localized at the site of colonization, or, through hematgenous 
or lymphatic route, spread to new organs and tissues.  
Bacterial virulence factors are essential determinants of the pathogen invading mechanism (tropism 
of an infection, intracellular or extracellular persistence, adherence and growth in biofilms) and the 
symptoms of the induced disease (release of toxins, activation of the immune system). The virulence 
of a pathogen is often measured as the minimal inoculum of the invading organism able to cause an 
infection, and it is a good indicator of the type (local or systemic) and the severity of the clinical 
symptoms that can be induced. Consequently, the infectious disease could result in an acute infection, 
whit a short and severe course, or a chronic, low-grade and long lasting infection [1, 2]. 
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Infections can be classified according to the pathogen in: 
• Opportunistic infections: infections caused by microbes belonging to the normal host flora 
and that initiate an infective process consequently to environmental changes, antimicrobial 
treatment, traumas and injuries, the reduction of the host immune defenses, or the 
migration to a new body-compartment;  
• Exogenous infections: caused by pathogen organisms, which do not belong to the normal 
flora but are transmitted to healthy hosts from a contaminated environment (food and 
water) or from infected carriers (humans or animals). The main routes of transmission of 
exogenous pathogens from an infected carrier are the air and aerosol, sexual intercourse, 
blood transfusions or animal bites. 
 
Exogenous infections can be classified according to the site of acquirement in: 
• Community-acquired infections: when the transmission occurs within the community; 
• Healthcare-acquired infections: when the pathogen is transmitted within a hospital or a 
health-care institution;  
 
Finally, iatrogenic infections are those developed consequently to a medical procedure such as 
pharmaceutical treatment or surgery, and could be caused either by endogenous or exogenous 
pathogens.   
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1.2  Prosthetic joint-associated Infections  
Indwelling devices and prosthesis are increasingly used in modern medicine practices for restoring 
a function of defective body tissues or organs, or for aesthetic purposes. Especially, orthopedic devices 
for joint replacement constitute the major procedure for patients with joint pain and compromised 
mobility, or fracture fixation [3].  
Unfortunately, failure of prosthetic joints devices can occur and constitute an important 
complication. Even if the aseptic loosening of the implants is more frequent, septic failures are more 
severe, causing high morbidity and extensive costs. The management of patients with implant 
infections is complicated by frequent infection relapses, and thus, extensive studies have been 
dedicated in the last decades to establish and optimize therapy guidelines [4, 5].  
 
1.2.1 Pathogenesis of prosthetic joint infections 
None of the biomaterials used in medicine is totally inert in the body. Thus, the host immune 
system responds to the presence of an implant with a localized low-grade inflammation, resulting first 
in the formation of a membrane of fibrinogen, fibronectin and collagen in which the device becomes 
encapsulated. Secondly, the phagocytic efficacy of infiltrated ploymorphonuclear cells (PMNs) or 
macrophages in proximity of the foreign-body decreases, a phenomenon named as “frustrated 
phagocytosis”. These factors create an interface surrounding the device surface, highly favorable for 
microbial adherence [3, 6-11].  
Indeed, implant-associated infections are characterized by the adhesion and the growth of 
microorganism, mainly opportunistic bacteria, on the surface of the foreign-body. The initial 
adherence of the pathogen to the implant occurs through unspecific factors (surface tension, surface 
shape, hydrophobicity and electrostatic forces) or specific factors (adhesins mediated interactions) and 
it is dependent on the invading pathogen, the host and the biomaterial of the implanted device [4].  
The bacterial adherence to the prosthesis surface is followed by an irreversible attachment and 
maturation in a complex three-dimensional structure known as biofilm (figure 1). In the biofilm the 
bacterial cells are embedded in a highly hydrated and porous polymeric extracellular matrix, and 
persist in a stationary growth-phase. Gene expression and phenotype are regulated within the biofilm 
cells through intercellular signalling described as quorum sensing, which leads to structural and 
functional heterogeneity of the biofilm. From the mature biofilm, planktonic bacteria detach and 
depending on their virulence could cause either a local or a systemic infection [7, 9].  
 
CHAPTER 1 
 19 
 
Figure 1. Development of microbial biofilms on an implant surface (illustration adapted from by K. Kasnot, Scientific 
American, 2001). 
 
The biofilm constitute an excellent survival mechanism for the pathogen, in which bacteria are 
protected from the immune system and become phenotypically tolerant towards the most used 
antimicrobial agents. As consequence, the presence of a foreign-body has been reported to increase the 
virulence of slime-producers opportunistic or exogenous pathogens. Indeed, for strains of 
staphylococci has been demonstrated that the number of minimal colony forming units (CFU) required 
to persist and initiate the infectious process in proximity of an implant is dramatically low (≈100 CFU) 
[5, 6, 9]. Table 1 reports the most common pathogens isolated from prosthetic infections. 
Recently, small colony variants (SCV) have been described and isolated from several infection 
types. SCV bacteria lack functionality of the electron transport cascade, grow slowly and are resistant 
to most replication phase-dependent and cell-wall-active antimicrobials. Especially, Staphylococcus 
aureus SCV have been reported in prosthetic infection and have been a main risk factor for treatment 
failures, persistence and relapse of infection [3, 12].  
 
Table 1. Frequency of most common identified microorganisms causing prosthetic joint-associated 
infections (adapted from Trampuz et al [5])  
Microorganism Frequency (%) 
Staphylococcus aureus 30-43 
Coagulase-negative staphylococci 17-21 
Polymicrobial 5-13 
Gram-negative bacilli  5-14 
Anaerobes 2-5 
Enterococci 3-7 
Streptococci 11-12 
Other/Unknown 5-6 
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1.2.2 Classification of prosthetic joint infections 
Prosthetic joint-infections have been classified depending on the delay of the first symptoms from 
the date of surgery, as: early, delayed and late infections [4, 5, 13].  
Early and delayed prosthetic infections occur either within 3 months or between 3 and 24 months, 
respectively, after surgery. They constitute the most common cause of implant infection and they are 
generally caused by inoculation of the implant during the surgery (perioperative), or infection of the 
wounds shortly after surgery. In early prosthesis infections, highly virulent pathogens such as S. 
aureus and gram-negative bacilli are generally involved. The symptoms recorded are analogue to the 
ones of an acute infection with local swelling and pain, erythema and fever. On the contrary, when the 
infective pathogens are low virulent, such as S. epidermidis and other coagulase-negative 
staphylococci, or Propionibacterium acnes, the infection usually becomes symptomatic later than 3 
months after surgery, and it is defined as delayed. The delayed infections manifest due to a chronic 
inflammation reaction from the host and the symptoms are hardly distinguished from the ones of an 
aseptic failure [4, 5, 11, 14].  
Finally, late infections manifest 24 months after surgery and are usually caused by haematogenous 
seeding during bacteremia originated from a distant infection focus, such as infection of the skin, soft 
tissues, the oral cavity, the urogenital or the respiratory tract. Late infections are mainly caused by high 
virulent bacteria and present all symptoms of acute infections [3, 13, 15].   
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1.3 Diagnosis of Prosthetic Joint-associated Infections 
The correct diagnosis of prosthetic joint infection, and their differentiation from aseptic failure of 
the implant, is essential for choosing the optimal treatment procedures. Several pre- and intra-operative 
tests have been standardized and are currently routinely used (table 2). Early and late infections are 
often predicted by evidence of clinical symptoms such as fever, swelling and pain, and presence of a 
sinus tract. The most challenging have become the identification of chronic delayed infections, due to 
the lack of clinical symptoms discriminative for infections and also reduced specificity of most 
laboratory tests. 
 
Table 2. Conventional pre-operative and intra-operative tests for the diagnosis of prosthetic joint-
associated infections (adapted from Trampuz et al. [16]) 
Category Diagnostic test 
Pre-operative  
Clinical history and examination 
Persistent joint pain; 
Fever, chills or rigors without known etiology; 
Erythema, warmth or effusion of the joint; 
Sinus tract; 
Hematological tests Leukocyte count and differential; erythrocyte sedimentation rate; C-reactive protein level 
Synovial fluid aspiration Leukocyte count and differential; Gram stain and culture 
Radiographic imaging Plain radiography, computer tomography 
Radionuclide bone scanning Scintigraphy by a technetium-99m scan, 
67Ga-citrate, 111In-leukocytes, 
99mTc-immunoglobulines 
Positron emission tomography 18F-fluorodeoxyglucose 
Intra-operative  
Periprosthetic tissue Hystopathology; Gram stain and culture 
Explanted prosthesis Culture 
 
Based on the criteria to be evaluated, the diagnostic tests could be classified as: indirect, when 
abnormalities in the patient biochemical and physiologic parameters are used as predictors of 
infection, and direct, when the indicator for the infection process is the confirmed presence of the 
invading microbe in the peri-prosthetic fluid and tissues (figure 2). Laboratory cultures and 
microbiologic methods, histopathology examinations, imaging techniques and sonication of explanted 
devices have been widely used and evaluated, but there is no single method, which has reached 
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satisfying accuracy, sensitivity and specificity. Thus, the accurate diagnosis of prosthetic infections is 
usually achieved by performing both direct and indirect tests [4, 8, 17, 18].  
 
 
Figure 2. Organization chart of direct and indirect methods adopted for the diagnosis of prosthetic joint infections (PJI).  
 
1.3.1 Laboratory tests 
Indirect methods. Conventional laboratory tests for diagnosis of infections such as increased 
neutrophil counts, elevated C-reactive protein level, and erythrocyte sedimentation rate, constitute 
simple, low-invasive and fast tests assessing host parameters predicting an ongoing infection.  
Leukocyte count and differential in blood and synovial fluid constitute a simple and commonly 
performed method. However, blood leukocyte counts are usually extremely variable in patients with 
prosthetic joint failure, and thus, even in repetitive sampling, the discrimination between infections 
and aseptic inflammation is limited. On the other hand, synovial fluid leukocyte counts is an accurate 
test, and counts >1.7×109 cells/l have been reported having a sensitivity and specificity of 94% and 
88%, respectively. Or, in acute infections (early and late infection), a finding of more than 65% 
granulocytes, has a sensitivity and specificity for infection of 97% and 98%, respectively [17-19].  
Histopathology tests of the periprosthetic tissue also constitute valid procedures, and they are 
based on the staining and differential evaluation of granulocytes’ infiltration. However, the tissue 
specimens are highly heterogeneous, thus, sampling of different areas is recommended [4, 16].  
 
Direct methods. Cultures of blood, synovial fluid or peri-prosthetic tissue specimens in enriched 
non-selective media, approach the diagnosis of implant-infection by the direct detection of the 
infective agent. The recovery of the infecting bacteria is followed by standard microbiologic and 
antimicrobial susceptibility assays.  
Synovial fluid or tissue specimens contain a variable and often low number of bacteria, depending 
on the invading microbe and on its detachment from the biofilm. Replicate specimens cultured in 
different media, temperature and aerobic-anaerobic conditions increase the recovery of a vast range of 
organisms in shorter times [18]. Gram stain of synovial fluid or peri-prosthetic tissue specimens gives 
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already important information about the invading microbes and results in high specificity, ranging 
from 92% to 100%, but the sensitivity is usually low (< 26%) [4, 17].  
When removal of the implant is required, the sonication of the explanted device and the sub-
culture of the sonication fluid, have shown a sensitivity of 79%, whereas the conventional cultures of 
periprosthetic tissue have a sensitivity of 60%. Indeed, the sonication induces the partial dislodgment 
of the bacterial biofilm from the device surface, helping their recovery from the implant and their 
growth in culture. As drawback, there is a high risk of contamination of the device during the surgery 
procedure, which could create artifacts in the final culture results [20].  
Microbiology assays have the advantage of giving direct information about the infecting pathogen 
and thus, are essential for the choice of therapy. However, the sensitivity is generally low and could be 
further affected by any antimicrobial therapy started before sampling. 
Molecular methods, such as broad-range PCR (bacterial 16S rDNA), constitute a sensitive and 
innovative procedure for the accurate identification of the invading microorganisms. In addition, the 
characterization of resistance patterns could be accomplished through the identification of specific 
genetic elements encoding for resistance factors (es. methicillin resistance mecA gene). However, the 
high costs, the risk of contamination, and the labour-intensive sample preparation have delayed the 
routine application of molecular methods in the diagnosis of prosthetic joint infections [16]. 
 
1.3.2 Imaging and nuclear medicine  
Imaging techniques can be classified as either structural or functional. Structural imaging 
procedures are used to evaluate macroscopic morphological changes and implant loosening [4, 21, 22]. 
Differently, functional imaging procedures aim to visualize the specific accumulation of an injected 
gamma-emitter radiotracer at the site of infection. The main characteristics of an ideal radiotracer for 
diagnosis of infections are:  
 
• well-understood and characterized chemical structure,  
• high efficiency of labeling,  
• high stability in serum,  
• low toxicity or light side effects, 
• rapid and specific accumulation at the infection site,  
• and fast clearance from all non-infected organs and tissues.  
 
The progresses in positron electron tomography and single photon computed tomography (PET 
and SPECT) for total body scans, together with the experience gathered in the handling and safety of 
short half-lives radioisotopes, stimulated the pre-clinical and clinical research towards novel 
radiolabeled agents. Even if the sensitivity of most radiotracers is high, the main challenge remains the 
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achievement of a satisfying chemical characterization and infection specificity [23].  
 
Indirect methods. Morphological imaging techniques such as conventional X-ray, CT and MRI 
constitute standard procedures to evaluate the structural bone and tissue damage, with loose implants 
or chronically inflamed joints. However, differentiation between aseptic and septic failure cannot 
always be achieved with these techniques. Additional limits are that metallic devices and prosthesis 
can produce artefacts both in CT and MRI [4, 21, 22]. 
The use of radionuclide scintigraphy is more suitable to discriminate between aseptic and septic 
loosening of prosthetic joints. The gamma-emitter isotope gallium-67 was recognized nearly 40 years 
ago to accumulate in infection and inflammation sites and thus, it was widely used to enhance the 
diagnostic accuracy of planar scintigraphy in patients with suspected loose prosthetic joints. However, 
Gallium-67 has many drawbacks, which limited its applications: it is not specific towards infections, it 
has a long decay half-life, and a long persistence in non-target tissues. In addition, a delay of 24 h to 
72 h from the injection of the 67Ga-citrate solution is needed for achieving good contrast in 
scintigraphic scans [17, 21, 22, 24, 25].  
The gold standard for functional imaging of bacterial infections is the labeled host leukocytes. The 
leukocytes isolated from the patient are mainly granulocytes, and they can be labeled ex vivo with 
Indium-111 or technetium-99m. However, the procedure is long and labor-intensive, it involves direct 
handling of blood products, and it requires highly qualified technicians. In addition, for the diagnosis 
of prosthesis infections, the labeled leukocytes have been reported having high sensitivity in acute but 
not in low-grade delayed infections, whereas the specificity was variable or often inconsistent [17, 21, 
24, 26]. Alternatively, radiolabeled monoclonal antibodies or antibody’s fragments of G or M class, 
targeting specific receptors expressed on leukocytes during infection, have been synthesized and 
evaluated. Clinical studies initially reported an accuracy of 95% with Fanolesonab, a murine 
monoclonal immunoglobulin M binding to CD15 receptors on leukocytes. However, the studies were 
withdrawn due to serious, including two fatal, events after administration [27]. Sulesomab, a 
techentium-99m labeled Fab’ fragment of monoclonal IgG, and the murine monoclonal IgG1 BW 
250/183 target the glycoprotein cross-reacting antigen-90 and 95, respectively. They both constitute a 
valid complementary diagnostic tool, showing sensitivity and specificity of about 85% for detecting 
prosthesis infections. Especially, the use of antibody fragments, rather than whole monoclonal 
antibody, has been preferred due to the lower incidence of adverse events [18, 21, 22, 28]. 
An alternative to immunoglobulines has been the use of radiolabeled cytokines and chemokines 
(IL-1, IL-2, IL-8, PF4). These radiotracers were mainly tested in pre-clinical studies, while clinical 
trials were limited by the lack of specificity or the unacceptable side effects [21, 29]. 
Finally, PET/ CT of F-18 fludeoxyglucose has been evaluated as an auxiliary diagnostic tool for 
visualizing loosening prosthetic joints. The tracer is sensitive to local increase in blood flow and 
vascular permeability during inflammation processes, and to the preferential binding to activated 
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leukocytes [18, 24, 27, 30]. However, no discrimination between infection and aseptic inflammation 
can be achieved. 
 
Direct methods. The research in the development of tracers targeting directly the infective 
pathogen, rather than host receptors and physiologic changes, is a novel and challenging issue. A wide 
and heterogeneous class of radiopharmaceuticals, such as radiolabeled antimicrobial peptides (18F- and 
99mTc-UBI 29-41), synthetic antimicrobial agents (99mTc- and 18F-ciprofloxacin, 99mTc-sparfloxacin, 
99mTc-ceftizodime and 99mTc-eperizolid), bacteriophages, and growth factors (99mTc- and 111In-biotin) 
has been described [21, 23, 27, 31]. By binding directly and selectively the infecting organism, such 
radiotracers represent a promising tool for the discrimination of infection from sterile inflammation. 
However, the main issue will be to determine if imaging of infection with bacteria-specific radiotracers 
may represent a feasible procedure. Indeed, the small surface of bacterial cells and their relative low 
number in chronic/subacute infections, are important limiting factors for visualization of in vivo 
radiolabeled bacteria. Pre-clinical and clinical studies are still limited, and have sometimes reported 
conflicting results. Thus, additional optimization is needed, together with the development of standard 
guidelines for radiotracer labeling and scan interpretations [17, 31, 32]. 
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1.4 Calorimetry in Diagnostic Microbiology  
Calorimetry is a sensitive, simple, high reproducible and fast technique in development for clinical 
and experimental microbiology. The principle is that any dividing microorganism produces heat 
proportionally to their metabolism (catabolism) and replication rate. As consequence, bacterial culture 
constitutes a close thermodynamic system, which, at constant pressure and temperature, exchanges 
heat with its surrounding proportionally to the number of replicating organisms. The heat produced can 
be recorded in real time, and plotted as heat flow (Watt) versus time (thermogram). The slope of the 
heat flow curve at each time point depends on the replication rate of the cells, while the area under the 
heat flow curve is the total heat (Joule), which is proportional to the final number of cells (figure 3) 
[33-35]. 
 
  
 
Figure 3. Bacterial cultures in sealed calorimetric ampoules (left) at 37°C are associated to exponential bacterial growth 
(center), which can be measured and plotted as replication-dependent cumulative heat (right): 1 indicates rate of heat 
production at time t, proportional to the number of replicating cells, 2 the change in rate of heat production at time t, and 3 
the total heat produced by time t. 
 
Heat of bacterial cultures at 37°C can be measured with a batch calorimeter. For clinical 
microbiology, the isotherm thermopile heat-conduction microcalorimeter is the most commonly 
reported by experimental studies, due to its high sensitivity and precision.  
The calorimeter continuously measures temperature differential between the sample (bacterial 
culture) and a thermally inert reference (figure 4). A heat sink made of a metal block, connects the 
sample and the reference vessels through a thermopile (“Peltier effect plates” semiconducting 
thermoelectric plates). The heat production rate is proportional to the potential between the 
thermocouple plates generated by the heat flow from the sample vessel through the thermopiles to the 
metal heat sink [33]. The Thermal Activity Monitor (TAM, Model 3102 TAM III, TA Instruments, 
New Castle, DE, USA), displayed in figure 4, is an example of batch isothermal thermopile 
calorimeter, which allows parallel measurements of different samples in 48 channels with a detection 
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limit of ±0.225 µW. 
 
  
Figure 4. Schematic assembly of batch calorimetric unit of the instrument used in our studies, temperature differences 
between the sample (Ts) and a thermally inert reference (Tr) is continuously measured in a heat sink (Ths) (left); and TAM, 
Model 3102 TAM III, TA Instruments, New Castle, DE, USA (right). 
 
In the diagnosis of infections, enriched growth media inoculated with patient specimens (blood, 
synovial fluid or periprosthetic tissue), with catheter or implant sections, or with implant sonication 
fluids, can be incubated in a batch isothermal calorimeter and the heat flow monitored as indicator of 
microbial infection.  
The use of selective growth media may allow the recovery of specific microbes, when present in 
the specimens. In addition, rapid determination of resistance patterns could be performed by 
incubation of the isolated infective pathogen with test antimicrobials at concentrations correspondent 
to their resistance cut-off. Susceptible microorganisms are inhibited in their growth and will not lead to 
any heat measurements; contrarily, resistant bacteria are not inhibited and thus, will produce heat, 
independently on the presence or absence of the antimicrobial agent [33]. Due to the high sensitivity to 
the heat produced during bacterial growth, the detection of resistance by calorimetry may be faster 
than most of culture methods, which are based on the optical evaluation of turbidity associated to the 
bacterial growth (requiring between 24 h and 48 h of incubation).  
Calorimetric methods showed also potentials for early determination of MIC values, or for 
screening sub-inhibitory concentration of antimicrobial agents against the isolated pathogen. The latter 
methods allow the early discrimination of the most effective antimicrobials inhibiting heat, and thus, 
the bacterial catabolism and replication rate [34].  
Calorimetric methods have not entered yet into the routine microbiologic procedures, but several 
studies have been and are conducted to elucidate the benefits and potentials for clinical applications. In 
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addition, calorimetric techniques have a wide application in experimental microbiology for evaluation 
of drug-related antimicrobial inhibitory profiles, dose and time dependency of antimicrobials 
mechanism, antimicrobial post-antibiotic effect on bacterial cultures, potentials of combinations of 
antimicrobial agents in preventing bacterial growth or development of resistance [34].  
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1.5 Prevention and Treatment of Prosthetic Joint-associated Infections  
The treatment of prosthetic joint-associated infections has the main goal of restoring a pain-free, 
functional joint. The frequent relapses of the infection and failure of the implants constitute a main 
cause of morbidity [4]. Within the biofilm, bacteria have shown a 1000-fold higher tolerance, than 
planktonic bacteria, towards many antimicrobial agents. In addition, the spread of resistant strains has 
reduced the choice of possible active agents. Methicillin-resistant S. aureus (MRSA) and coagulase-
negative staphylococci (MRSE) have been associated to increased morbidity and treatment failures, 
especially when combined to tolerance towards glycopeptides, such as vancomycin [5, 13].  
 
1.5.1 Antimicrobial prophylaxis 
Protocols have been developed for the prevention of perioperative infections, which constitute the 
most frequent cause of prosthetic joint-associated infections. As first, the use of sterile instruments, 
ultra-clean conditions and of laminar airflow in the operating room, has become standard practice 
together with the administration of systemic antimicrobial prophylaxis. The antimicrobial agents for 
prophylaxis should be chosen in each health care centre depending on the most commonly species 
isolated from healthcare-acquired infections, and their susceptibility-resistance pattern. In general, 
first- or second-generation cephalosporins, such as cefazolin, cefamandole or cefuroxime, effective 
against staphylococci and streptococci are the first-choice antimicrobials, when the patient is not 
allergic or the risk of MRSA infection is minor. Otherwise, vancomycin and teicoplanin can be used. 
The antimicrobial prophylaxis should be given within 30 and 60 minutes prior to surgery, in order to 
have periprosthetic tissue levels above the minimal inhibitory concentrations (MICs) at the time of 
incision and during the whole time of the surgery [5, 13]. 
In order to reduce the risk of secondary infections, nasal and skin decolonization with mupirocin of 
patients with indwelling devices and positive for MRSA is recommended by some experts, but no 
uniform guidelines are accepted. Otherwise, the benefits of antimicrobial prophylaxis in risk of 
haematogenous infections due to dental surgery, or a secondary localized infection, are unknown. In 
any case, the early diagnosis and administration of antimicrobial therapy when a bacteremia occurs is 
essential for reducing the risk of implant-infection.  
 
1.5.2 Antimicrobial coating of implants 
A combinatory approach to systemic prophylaxis for the prevention of bacterial perioperative 
infection is the use of antimicrobial-coated implants and impregnated cement. Several substances have 
been evaluated, such as: standard antimicrobials (gentamicin, ciprofloxacin, flucloxacillin and 
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vancomycin), antiseptics (chlorexidine or quaternary ammonia compounds), hydrophilic proteins 
(albumin, poly-l-lysine), polysaccharides (hyaluronic acid), lysostaphin or inorganic salts (copper, 
silver ions and silver nitrate, or nitric oxide). Substances having a wide antimicrobial spectrum and a 
low rate of induction of resistance are recommended. For standard antimicrobial agents it is mandatory 
that the concentrations released from the implant remain above the MIC, in order to prevent the 
emergence of resistant strains. Contrarily, inorganic substances active against bacterial adherence are 
usually not associated with mechanisms of development of resistance [7, 11].  
The principle of implant coating would be the local and immediate release of a burst of the 
antimicrobial agent, followed by a gradual and long-term release. The presence of an anti-biofilm 
substance covering the surface of the implant would modify the implant-tissue interface and reduce the 
bacterial adherence mechanisms. In addition, the systemic dose of antimicrobials used for prophylaxis 
could be lowered, when combined to a coated implant, minimizing the systemic toxicity of the first.  
Currently, several research studies about coating procedures (bioactive treatments, simple 
impregnation and covalent bonding), evaluation of innovative substances and their local and systemic 
toxicity, are aiming to develop a coating technology for the active prevention of biofilm formation in 
vivo [4, 7, 11, 36, 37].  
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1.5.3 Treatment algorithm for prosthetic joint-associated infections 
Different treatments of prosthetic joint-infections have been developed and adapted depending on 
the type of infection (early, delayed or late), the severity (local or systemic) of the clinical symptoms, 
the stability of the implant and the condition of the periprosthetic tissue. Debridement with implant 
retention can be used for stable implants, infected by hematogenous route or early after surgery (with 
symptom duration <3 weeks). Figure 5 shows the algorithm developed by Zimmerli et al. as general 
guideline for the management of prosthetic joint-associated infections with implant retention [4, 5, 13]. 
This algorithm was validated in cohort studies of total hip and knee prosthetic infections with an 
overall efficacy rate of 80% [38]. 
 
 
Figure 5. Zimmerli algorithm for the management of patients with prosthetic joint-associated infection qualifying for 
implant retention (adapted from Zimmerli et al. [4]). 
 
In all other cases (figure 6), a one-stage or two-stage prosthesis exchange is recommended. In two-
stage exchanges, a long interval (6-8 weeks) is recommended, if rifampin-resistant staphylococci, 
quinolon-resistant gram-negative bacilli or small-colony variants of bacteria are involved. In addition, 
long-term therapy (3 months) with combinations of bactericidal and anti-biofilm antimicrobial agents 
is mandatory.  
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Especially, the management of patients with prosthetic joint infections associated with multi-
resistant S. aureus strains or SCV, may require a two-stage procedure including implant removal 
without use of spacer [12]. 
 
Figure 6. Zimmerli algorithm for the management of patients with prosthetic joint-associated infection qualifying for 
implant exchange (adapted from Zimmerli et al. [4]) 
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1.6 Antimicrobial Therapy of Prosthetic Joints Infections associated with 
Staphylococci 
1.6.1 Antimicrobial therapy guidelines 
Eradication of prosthetic joint infections requires both, surgical and antimicrobial therapy. The 
eradication of the biofilm constitutes the main challenge. Indeed, in the biofilm, bacteria persist in a 
stationary growth phase, which makes them tolerant towards most antimicrobial agents. In addition, 
the polymeric matrix of the biofilm forms a physical protective barrier, which reduces the 
concentration of antimicrobials reaching the embedded bacterial cells. As consequence, the 
antimicrobial therapy of prosthetic infections requires bactericidal agents, given in combination and 
administered for long-term [4, 5, 13]. Further complications have raised consequently the spread of 
methicillin resistant staphylococci in the hospital setting and in the community [11, 39]. 
The ideal antimicrobial therapy of prosthetic infection would consist of a combination of agents: 
acting synergistically, effective against biofilm, bactericidal against stationary phase bacteria, rarely 
associated to induction of resistance, active at low concentrations, well-tolerated, non-toxic and 
suitable to be given orally.  
The research conducted in the last decades has brought important progresses in the treatment of 
patients with prosthetic infections upon the establishment of antimicrobial therapy guidelines (table 3). 
In pre-clinical and clinical studies rifampin was the only agent, which gave evidence of high 
efficacy against staphylococcal biofilm, and as consequence, it became mandatory component in any 
antimicrobial regimen against staphylococcal prosthetic infection. The high incidence of development 
of rifampin-resistance, when the agent was used in monotherapy, stimulated the development of 
effective and well-tolerated rifampin combinations with other anti-staphylococcal antimicrobials [40-
42].  
Nowadays, rifampin-containing regimens are administered for totally 3 months. The first choice 
for treating methicillin-susceptible staphylococcal infections is the rifampin combination with a beta-
lactam. In case of hypersensitivity to beta-lactams or in case of methicillin-resistant staphylococcal 
infection, rifampin combinations with ciprofloxacin have shown good activity and safety profiles [43]. 
Moreover, newer fluoroquinolone agents (levofloxacin, moxifloxacin) have displayed higher anti-
staphylococcal activity in vitro than ciprofloxacin, and are now under evaluation for long-term safety 
data. Unfortunately, the use of fluoroquinolones against MRSA prosthetic infections has been limited 
by the spread of resistance towards these agents. Thus, in alternative, glycopeptides such as 
vancomycin and teicoplanin could be used, even if associated to frequent adverse events and low 
efficacy rates. Extensive pre-clinical and clinical research have been evaluating the potentials of new 
rifampin combinations with the oxazolidindione linezolid, the lipopeptide daptomycin, the 
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lipoglycopeptide dalbavancin, the streptogamin quinupristin/ dalfopristin and the glycylcycline 
tigecycline. However, systematic studies should be conducted to evaluate their applicability to 
staphylococcal prosthetic joint infections and safety in long-term combination therapies [4, 5, 13] 
 
Table 3. Antimicrobial treatment of staphylococcal prosthetic infections (adapted from Zimmerli et 
al. [5]) 
Microorganism Antibacterial agent Route 
Methicillin-susceptible staphylococci 
 Rifampin plus (flu)cloxacillin for 2 weeks 
followed by 
 
Rifampin plus ciprofloxacin or levofloxacin 
for 10 weeks 
PO/IV 
 
 
PO 
Methicillin-resistant staphylococci 
 Rifampin plus (vancomycin or daptomycin) 
for 2 weeks, followed by 
 
Rifampin plus ciprofloxacin or levofloxacin or 
fusidic acid or cotrimoxazole or minocycline, 
for 10 weeks 
PO/IV 
 
 
 
PO 
PO: per os, oral administration route 
IV: intravenous administration route 
 
 
1.6.2 Rifampin 
Rifampin (figure 7) is a semisynthetic bactericidal antibiotic belonging to the group of ryfamicins. 
The mechanism of antimicrobial action is the binding to the beta-subunit of the bacterial RNA-
polymerase followed by blockage of DNA transcription into messenger RNA, and as consequence, of 
the protein synthesis [44]. 
 
 
Figure 7. Chemical structure of rifampin. 
 
Rifampin is bactericidal against most of gram-positive bacteria, growing both intra- and extra-
cellularly, and is the first choice in the combined therapy of Mycobacterium infections. Especially, 
because of its activity against staphylococcal biofilms, rifampin became an essential component of 
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combined regimens for the treatment of methicillin-susceptible and methicillin-resistant staphylococci 
[43]. The development of rifampin resistance is determined by one-step point-mutations in the rpoB 
gene encoding for the beta-subunit protein binding pocket of the bacterial ribosome. The mutation is 
associate to the complete loss of activity by rifamycins [44]. Thus, monotherapy is not possible, 
whereas antimicrobial combinations able to increase rifampin potency and prevent occurrence of 
resistance, represent the only treatment option for difficult infections [5, 42].  
Rifampin is available as intravenous and oral formulations, the latter having high bioavailability 
(90% to 95%). Peak serum concentrations are achieved in healthy volunteers between 2 and 4 h after 
administration and the serum half-life ranges from 1.5 to 5 h. Binding to serum protein is over 90%. 
The metabolism is hepatic and consists of hydrolysis of the ester functional group and deacetylation, 
followed by elimination through the faeces. The renal elimination of rifampin is lower than 30% of the 
administered dose. 
Rifampin up-regulates the expression and function of hepatic CYP450 and thus, may reduce the 
half-life of any other drug co-administered and metabolized by this enzyme family.  
Most common mild adverse effects are fever, gastrointestinal disturbances, rashes, breathlessness 
feeling and immunological reactions (development of anti-rifampin antibodies). Severe adverse effects 
are rare, but hepatic toxicity, with liver failure has been reported [44]. Moreover, novel rifamycin 
derivatives with reduced activation of the CYP450 and thus, with reduced drug-drug interactions, have 
shown efficacy against staphylococcal infections and biofilms. The derivative ABI-043 was a 
promising candidate with similar treatment efficacy than rifampin in the tissue cage animal model of S. 
aureus prosthetic joint infection [42]. 
 
1.6.3 Fluoroquinolones 
Fluoroquinolones (figure 8) are a family of synthetic broad-spectrum bactericidal antimicrobials, 
which share with their precursor, the 4-quinolone nalidixic acid, the mechanism of action. The 
bacterial target of fluoroquinolone agents is the DNA gyrase, or topoisomerase IV, essential for the 
double-strand supercoiling and relaxation during DNA replication. Binding and inhibition of the DNA-
gyrase results in DNA fragmentation and rapid cell death [45]. A limitation in the use of 
fluoroquinolone in the clinical practice has been the arising emergence of resistance. The main 
resistance mechanism consists of the over-expression of efflux pumps on the bacterial plasmatic 
membranes, encoded within the bacterial genome or in genetic mobile elements. Additional resistance 
mechanisms consist of: plasmid-mediated proteins able to bind the bacterial DNA-gyrase and to 
protect from fluoroquinolones activity, or mutations in the structure of the DNA gyrase resulting in 
decreased fluoroquinolones binding affinity [45, 46].  
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Figure 8. Chemical structure of the 4-quinolone nalidixic acid (A), and the fluoroquinolones ciprofloxacin (B) and S-
levofloxacin (C). 
 
Ciprofloxacin is a broad-spectrum fluoroquinolone and it has been extensively studied for 
treatment of prosthetic staphylococcal infections. Within the new generation of extended-spectrum 
fluoroquinolones, levofloxacin displayed improved bactericidal activity and consistent post-antibiotic 
effect against Gram-positive aerobes including S. aureus and MRSA.  
Novel fluoroquinolones have favourable pharmacokinetic profiles, especially, excellent tissue 
penetration and convenient once-daily dosing [45]. Indeed, levofloxacin is well absorbed after oral 
administration, with 99% bioavailabilty, and it is mainly eliminated unchanged in the urine. Possible 
activity on liver enzymes, including inhibition of CYP450, was exerted from ciprofloxacin and earlier 
fluoroquinolones, but not by levofloxacin. Fluoroquinolones are usually well-tolerated agents, with 
severe adverse event occurring rarely and mainly associated to central nervous system, hepatic and 
tendon toxicity. Safety of long-term therapies has been evaluated for the second- and the third 
generation agents such as ciprofloxacin and levofloxacin (mycobacterium treatment), but it is still 
unknown for newer agents [47, 48]. 
 
1.6.4 Linezolid 
Linezolid (figure 9) is a synthetic antimicrobial belonging to the class of oxazolidinoni, with a 
bacteriostatic or bactericidal dose-dependent antimicrobial mechanism against Gram-positive bacteria.  
 
 
Figure 9. Chemical structure of linezolid. 
 
The antimicrobial mechanism consists of inhibition of the bacterial protein synthesis. 
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Oxazolidinoni bind to the 23S portion of the ribosome 50S subunit, and they prevent the formation of 
the initiation complex between the ribosome, the tRNA and the mRNA. Cross-resistance with other 
protein synthesis inhibitors is rare. Development of resistance to linezolid is uncommon, because the 
protein binding site is in a highly conserved region of the bacterial ribosome [49]. However, the first 
linezolid-resistant isolates of S. aureus and Enterococcus faecalis have been reported between the 
1999 and the 2001, and they were associated to point mutations of the genes coding for the 23S 
ribosomal RNA [39, 50, 51]. In order to avoid the spread of resistance, the main indication of linezolid 
is limited to the treatment of MRSA and multi-resistant Gram-positive bacteria in uncomplicated ad 
complicated infections (skin, soft-tissue, and lower respiratory infections, endocarditis, bone and joint 
infections) [52]. The potentials for treatment of staphylococcal prosthesis infections are uncertain, and 
further evaluation of linezolid in this setting is necessary [53, 54]. 
Linezolid has a good bioavailability (close to 100%) when given orally, a low protein binding 
(31%), high tissue penetration and a half-life between 3 and 5 hours. The hepatic metabolism does not 
involve the CYP 450 microsomial enzymes, and consist of the oxidation of the morpholine ring 
followed by renal and faecal elimination of the inactive metabolites [55]. Even if no evidence of 
CYP450 metabolism has been found, case-report have described a decreased serum concentration of 
linezolid when given in combination with rifampin, and it was potentially associated to the rifampin 
induction of hepatic microsomial enzymes [56, 57].  
Linezolid is well tolerated in short-term antimicrobial therapy, with the most common adverse 
effects being diarrhoea, headache and nausea [39]. In long-term therapies, bone marrow suppression, 
with reversible anaemia, leucopenia, pancytopenia, and thrombocytopenia have been reported and 
associated with mitochondrial toxicity. In ex vivo studies, linezolid showed inhibitory activity towards 
mammalian mitochondrial protein synthesis, due to the similarities between bacterial and mitochondria 
ribosomes [58]. In addition, lactic acidosis, peripheral neuropathy and optic neuropathy have been 
occasionally reported [39, 59, 60]. 
 
1.6.5 Glycopeptides, lipoglycopeptides and lipopeptides 
Vancomycin and teicoplanin are both antibiotics belonging to the class of glycopeptides, time-
dependent bactereostatic agents active against Gram-positive bacteria. Especially, glycopeptides 
became agents of choice for the treatment of methicillin-resistant staphylococci. The mechanism of 
antimicrobial action relies on the inhibition of the bacterial cell wall biosynthesis. The binding to the 
D-Alanyl-D-Alanyl moieties of the NAM/NAG-peptides inhibits the peptidoglycan cross-linking, 
fundamental step guaranteeing the integrity of the cell wall.  
The emergence of glycopeptide-resistant isolates created big concernments in their clinical use. 
Vancomycin-resistant enterococci (VRE), vancomycin -intermediate S. aureus (VISA), vancomycin-
resistant S. aureus (VRSA), and vancomycin-resistant Clostridium difficile represent a growing 
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problem [39]. Indeed, the increase in glycopeptide MIC strictly correlated with the increase of failures 
of vancomycin-containing regimens. Bacterial resistance has been correlated to several mechanisms, 
one of which relies on the substitution of the D-Alanyl-D-Alanyl fragment with a D-Alanyl-D-Lactate 
or D-Alanyl-D-Serine, mediated by the acquisition of transposons coding for enzymes catalyzing the 
elimination of the native precursors. The new substitutes present decreased binding affinity to 
vancomycin. Intermediate resistant isolates have been described having a thicker peptidoglycan, which 
would confer lower susceptibility to cell-wall active drugs.  
Different resistance categories have been identified for vancomycin in S. aureus and enterococci, 
and in most cases no cross-resistance with teicoplanin and dalbavancin (lipoglycopeptide) was 
observed.  
Vancomycin is administered parenterally because of the low bioavailability, it has a low binding to 
plasma proteins and it is excreted unmodified by the kidney, essentially by glomerular filtration [44]. 
Teicoplanin share with vancomycin the mechanism of antibacterial action and the spectrum of activity, 
but due to its longer serum half-life, it can be administered once daily. Adverse events associated with 
vancomycin and teicoplanin therapy are severe thrombocytopenia (due to the induction of platelet 
reactive antibodies), nephrotoxicity, rash and erythema, red man syndrome, dizziness and/or 
ototoxicity. 
 
Dalbavancin belongs to the class of lipoglycopeptides. Similarly to vancomycin, dalbavancin binds 
the D-Alanyl-D-Alanyl peptide fragment and compromise the bacterial cell-wall integrity. In addition, 
a mechanism of polymerization and insertion into Gram-positives plasmatic membranes has been 
reported but not yet completely understood. Dalbavancin displayed higher in vitro antibacterial activity 
than vancomycin and teicoplanin against staphylococci and especially MRSA [61-63]. Due to its high 
lipophylicity, dalbavancin has a serum half-life of 8.5 days in healthy volunteers, allowing once-
weekly i.v. dosing; it is highly bound to plasma proteins (93%), excreted into faeces via bile or 
eliminated via the renal route.  
In pre-clinical and clinical safety studies dalbavancin was well tolerated. Mild and rare adverse 
events were pyrexia, headache and gastrointestinal symptoms, whereas no renal or hepatic toxicity 
were observed. Dalbavancin is not a substrate of CYP450 and thus, could be given in combination 
with rifampin without dose-adjustment [39, 64, 65].  
 
Daptomycin is a cyclic lipopeptide antimicrobial agent, with fast dose-dependent bactericidal 
activity against Gram-positive bacteria. The mechanism of bacterial killing consists of Ca2+-dependent 
polymerization and insertion in the bacterial plasmatic membranes resulting in the disruption of its 
functionality, and in the cell death without lyses. The formation of pores into the plasmatic membrane 
cause loss of potassium, and thus, rapid membrane depolarization with following inhibition of protein, 
DNA and RNA synthesis [39]. Development of resistance is a rare event both in vitro and in vivo, but 
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resistant MRSA have been isolated from patients who received long-term daptomycin treatment.  
After intravenous administration, daptomycin binding to plasma protein is 90%-96%, the serum 
half-life is about 8 h and is mostly eliminated into the urine [44]. The main severe adverse event 
observed in pre-clinical and clinical studies is the dose-dependent neuropathy resulting in skeletal-
muscle toxicity, which could constitute a limitation for long-term therapies at high doses [66]. Due to 
its rapid killing and the efficacy displayed in preclinical studies, daptomycin may become a first-
choice agent, in combination with rifampin, against MRSA prosthetic joint infections [67, 68].  
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1.7 Experimental Models of Prosthetic Joint-associated Infections 
In the last 30 years, experimental research has been addressed towards the development of in vitro 
and in vivo models able to mimic the pathogenesis of prosthetic infections. The main characteristics of 
implant associated infections are: i) localized and persistent infection, ii) infection inducible with as 
much as 100 CFU bacterial inocula, iii) bacteria adhering to an inert body and forming biofilms and 
iv) absence of spontaneous clearance of the infection. Within the most studied animal models, the 
tissue cage animal model of foreign-body infection has contributed consistently to the development of 
standard guidelines for the management of patients with implanted prosthesis [69].  
 
1.7.1 Tissue cage infection model 
The tissue cage infection model has been widely studied with the purposes of investigating the 
pathogenesis of foreign-body infections, and of screening antimicrobial agents for therapy 
optimization. The model was evaluated in several animal species, such as: mice, guinea pigs, rats, 
rabbits, dogs and caves. The guinea pig tissue cage model perfectly respected the main features 
characterizing prosthesis infections in humans.  The only limitation was that guinea pigs do not 
tolerate long-term antimicrobial therapies or the antimicrobial agents clindamicin and beta-lactams [6, 
40-42, 67, 69-72]. Differently, mice and rats showed a good tolerance to beta-lactams and to long-term 
antimicrobial therapy, and thus, they may be the best choice when testing the latter conditions. 
However, the disadvantages of the mice and rat tissue cage models were a higher rate of spontaneous 
clearance of the cage infection than in guinea pigs, and a higher bacterial inoculum required for the 
establishment of the infection process [73-77].  
The tissue cage infection model relies on the subcutaneous and aseptic implantation into the flank 
of the animals of Teflon cylinder cave tubes (tissue cages), regularly perforated with 130 holes 
throughout their whole surface (figure 10).  
During the two weeks after surgery, the implanted cages become surrounded by a richly 
vascularized granulation tissue (lymphocytes, fibroblasts and collagen fibers) and filled with 
interstitial fluid. The composition of the tissue cage interstitial fluid in guinea pigs, in comparison to 
serum or heart-puncture collected blood, showed a lower pH, a higher pO2 and pCO2, and nearly half 
of protein (g/l) content [69].  
A localized tissue cage infection could be induced with S. aureus Wood 46 by percutaneous 
inoculation of ≥ 100 CFU directly into the cage. In alternative, systemic intravenous inoculation of 
bacteria was attempted in order to simulate a haematogenous infection. In the latter infection route, an 
inoculum of 5×107 CFU injected i.v. resulted in a transient bacteremia of 102-103 CFU/ml at 5 min 
after injection, and it was successful in establishing a selective infection in 50% of the tissue cages, 
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with no microbial evidence of infection elsewhere [40].  
 
A
 
B 
 
Figure 10. (A) Implantation of the Teflon cages in the flanks of a guinea pig (left), and the percutaneous cage puncture 
(right), which is used to inoculate bacteria or to sample cage fluid. (B) SPECT/CT scan of a tissue cage implanted C57Bl/6 
mouse, after injection of the unspecific Technetium-99m radionuclide (radioactivity detected in the kidneys and in the 
bladder). 
 
Being the tissue cage fluid easy-to-sample by subcutaneous aspiration, many parameters can be 
continuously and simultaneously investigated, such as: the number and the ex-vivo activity of cage 
fluid granulocytes, the kinetic of bacterial growth during the cage infection, the pharmacokinetic of 
antimicrobial agents into the cage fluids, and the number of planktonic viable bacteria during 
antimicrobial treatment.  
The studies conducted with the guinea pig tissue cage model were initially addressed to determine 
the fitness of the host inflammatory cells in the tissue cage fluids. The median granulocyte content into 
aspirated cage fluid was about 8×105 PMNs/ml before inducing an infection, and it was shown to 
increase upon S. aureus infection proportionally to the injected bacterial inoculum [71]. 
The bactericidal activity, ingestion rate, oxidative methabolism, and enzyme content of primary 
and secondary granules of the cage fluid PMNs were evaluated ex vivo. All tests showed reduced 
antibacterial activity of isolated cage fluid PMN, when compared to blood or peritoneal exudate PMN. 
On the contrary, the antibacterial activities of tissue cage PMN were comparable to the ones measured 
in both: ex vivo PMN of an experimental system reproducing chronic exudates, and the ex vivo 
exudates PMN pre-incubated in plasma with Teflon fibers. As consequence, it has been postulated that 
the foreign non-phagocytosable body induces a chronic and protracted stimuli of the local PMN 
resulting in their loss of activity. Contrarily, the opsonization activity of tissue cage fluid was proven 
to be intact within the first ours of infections. Thus, the reduced killing activity of the cage fluid PMN 
could be addressed as one of the driving reasons for the enhanced virulence displayed by bacteria in 
the presence of a foreign-body [6, 71]. 
 
Systematic studies were conducted for the optimization of antimicrobial therapies against implant 
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infections. Antimicrobials agents, administered either alone or in combination, were tested against 
established S. aureus, S. epidermidis and E. coli tissue cage infections, in one or twice-daily four-day 
regimens. The treatment efficacies against planktonic bacteria were evaluated on the last day of 
treatment (before administration of the last antimicrobial dose), and five days after the end of 
treatment. The cure rates against biofilm bacteria were evaluated by aseptic explantation of the cages 
and their subcultures in growth medium. Evidence of bacterial growth from the cage subcultures 
indicated the treatment failures.  
The main findings were that most of the tested antimicrobials (glycopeptides, lipopeptides and 
fluoroquinolones) had low in vivo activity against biofilm infections, whereas rifampin resulted to be 
the only agent highly effective against staphylococcal biofilms. Especially, when rifampin was 
administered in combination either with glycopeptides (vancomycin or teicoplanin) or with 
fluoroquinolones (ciprofloxacin), higher cure rates of tissue cage infections were achieved, due to 
either in vivo synergism mechanisms or to prevention of development of rifampin resistance [41, 69, 
72, 78]. Following, clinical studies have confirmed rifampin-containing regimens to be the optimal 
antimicrobial therapies against staphylococcal prosthetic infections [13, 43]. 
 
1.7.2 In vitro tests predicting for in vivo efficacy against prosthetic joint infections 
The minimal inhibitory concentration (MIC) and the minimal bactericidal concentration (MBC) of 
an antimicrobial agent against bacterial isolates are generally good predictors for treatment outcomes 
when dealing with skin and soft-tissue infections. Especially, pharmacokinetic/ pharmacodynamic 
(PK/PD) parameters such as: the peak level of the agent at the site of infection versus the MIC 
(Cmax/MIC), the area under the concentration-time curve of the agent versus the MIC (AUC/MIC), and 
the time-length of the agent concentration at the site of infection above the MIC (t>MIC), can be good 
predictors for treatment efficacies. Indeed, the evaluation of PK/ PD parameters helps to define the 
dose- or time-dependency of in vivo antimicrobial mechanisms, which is important for choosing the 
correct antimicrobial and the dose regimens [79-81]. 
Antimicrobial therapies of patients diagnosed with device-associated infections reported several 
failures, even when the infecting bacteria were susceptible to the antimicrobial agents in standard 
microbiology tests. As mentioned before, biofilms have enhanced tolerance towards many 
antimicrobial agents, due to both the stationary metabolic phase of the bacterial cells, and the physic 
barrier created by the extracellular matrix in which bacterial cells are embedded. Standard 
microbiology susceptibility parameters, such as MIC and MBC, are evaluated against bacteria in a 
logarithmic replication phase, and thus, these assays do not constitute good predictors for the treatment 
of implant infection.  
In order to be effective against biofilm infections, an antimicrobial agent should be able to diffuse 
through the biofilm extracellular matrix, and it should be bactericidal against stationary phase bacteria 
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at concentrations achievable within the biofilm. As consequence, experimental microbiology assays 
were developed for testing the bactericidal activity of antimicrobial agents against bacteria in a 
stationary growth phase, or against in vitro pre-formed biofilms. These tests comprehend: minimal 
bactericidal concentrations (MBCstat) and kill curve studies of stationary phase bacteria, bactericidal 
activity against biofilms pre-formed on sinter-glass beads, or slides, and the Calgary device biofilm 
method for determination of minimal biofilm inhibitory concentrations (MBIC) [41, 82]. Zimmerli et 
al. demonstrated that, in vitro bactericidal activity against biofilm and stationary phase bacteria, 
generally, well-correlates to the cure rates achieved by antimicrobial therapies in the guinea pig model 
of tissue cage infection [41, 72, 78, 83, 84].  
As consequence, the evaluation of PK/ PD parameters, based on in vitro susceptibility assays 
conducted against adherent and stationary phase bacteria, may represent an essential step to predict the 
potentials of new antimicrobial regimens against prosthetic-associated infections. 
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1.8 AIM OF THE STUDY 
The aim of the present study was to develop and evaluate in vitro and in vivo innovative methods 
for the diagnosis and treatment of bacterial implant associated infections.  
 
1) Nuclear medicine studies aimed to evaluate novel radiopharmaceuticals, testing their in vitro 
binding and in vivo accumulation at sites of infection, for targeting implant associated infections. The 
potentials to target bacterial cells of 99mTc-UBI 29-41, 99mTc-Ciprofloxacin, 99mTc-bis-ciprofloxacin 
and 111In-Biotin were evaluated in vitro and in the mouse tissue cage model of infection, using a S. 
aureus and an E. coli bacterial strain (Chapter 2).  
 
2) The vitamin B12 derivative 99mTc-PAMA4-Cbl had been previously developed from Waibel et 
al. [85] and displayed improved biodistribution parameters (shorter serum half-life, low accumulation 
in non-target tissues, fast clearance) than the native Cobalt-57 radiolabeled vitamin B12. We aimed to 
test the potentials of the 99mTc-PAMA4-Cbl derivative for targeting infections in vitro and in the 
mouse tissue cage model of infection, using as controls the Co-57 Vitamin B12, 67Ga-citrate (positive 
control) and 99mTc-DTPA (negative control) (Chapter 3).  
 
3) The ex vivo, fast recognition of MRSA constitutes a key issue for the management of implant 
infections. Calorimetric measurements of bacterial growth-related heat could constitute an innovative 
method for early detection of resistance patterns. The aim of the project was to develop an assay able 
to correlate the S. aureus methicillin resistance, with the heat production of cultures in the absence and 
in the presence of a beta-lactam, using laboratory stains and clinical isolates (Chapter 4). 
 
4) The introduction of non-conventional antimicrobials, for the prophylaxis, implant coating or 
treatment of implant infections, may bring enormous advantages for limiting emergence of resistance 
and infection relapses. The aim of this work was to test the activity of gallium, a semi-metallic element 
competing with iron, against methicillin susceptible and resistant S. aureus and S. epidermidis. The in 
vitro susceptibility of laboratory strains and clinical isolates was characterized towards gallium 
maltolate (GaM), a gallium formulation highly stable, soluble and suitable for oral administration 
(Chapter 5).  
 
5) Linezolid is a promising antmicrobial with ant-staphylococcal activity, used for the treatment of 
MRSA infections. However, limited studies have been reported regarding the efficacy of linzolid 
against MRSA implant associated infections. Thus, we aimed to describe the antimicrobial activity of 
linezolid, alone or combined with rifampin, against a laboratory strain of MRSA in vitro and in the 
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guinea pig tissue cage model of foreign-body infection (Chapter 6).  
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2.1 Abstract 
Diagnosis of implant-associated infection is challenging. Several radiopharmaceuticals have been 
described but direct comparisons are limited. Here we compared in vitro and in an animal model 
99mTc-UBI, 99mTc-ciprofloxacin, 99mTcN-ciproCS2 and 111In-DTPA-biotin for targeting E. coli (ATCC 
25922) and S. aureus (ATCC 43335). 
Methods: Stability controls were performed with the labeled tracers during 6 h in saline and 
serum. The in vitro binding to viable or killed bacteria was evaluated at 37° C and 4° C. For in vivo 
studies, Teflon cages were subcutaneously implanted in mice, followed by percutaneous infection. 
Bioistribution of i.v. injected radiolabeled tracers were evaluated during 24 h in cages and dissected 
tissues.  
Results: Radiochemical purity of the labeled agents ranged between 94 % and 98 %, with high 
stability both in saline and in human serum. In vitro binding assays displayed a rapid but poor bacterial 
binding for all tested agents. However, results are difficult to interpret because similar binding kinetic 
occurred also with heat-killed and ethanol-killed bacteria. In the tissue cage model, infection was 
detected at 4 h p.i.: 99mTc-ciprofloxacin and 111In-DTPA-biotin accumulation was higher in both E. coli 
and S. aureus infected than in sterile cages, whereas 99mTcN-ciproCS2 and 99mTc-UBI only 
distinguished for E. coli infected cages. However, cage fluid or tissue cage to blood (T/NT) ratios did 
not achieve values >2. All tested radiotracers were mostly cleared from non-target tissues between 12 
h and 24 h p.i.  
Conclusion: 99mTc-UBI, 99mTc-ciprofloxacin, 99mTcN-ciproCS2 and 111In-DTPA-biotin are 
promising agents for in vivo targeting of living bacteria. 99mTc-ciprofloxacin and 111In-DTPA-biotin 
showed high sensitivity and accumulated in both E. coli and S. aureus infected cages. The low T/NT 
ratios may constitute a limiting factor for the application of the tested tracers in patients. 
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2.2 Introduction 
Implanted devices are increasingly used in modern medicine to alleviate pain or improve 
compromised function. Implant associated infections constitute a major complication leading to high 
morbidity, extensive patient care and costs [4]. The early discrimination between infective and aseptic 
implant failures is essential for choosing the appropriate therapy procedures. However, standard 
laboratory methods such as tissue cultures and direct microscopy are either slow or have low 
sensitivity [17, 86]. Thus, the development of a sensitive and specific diagnostic tool for detection of 
foreign body infections remains an important and challenging issue.  
Imaging techniques for visualization of an injected radiopharmaceutical have been increasingly 
used for evaluation of loosening prostheses. The gold standard consisted of ex-vivo radiolabeled 
autologous leukocytes [87]. In alternative, an indirect approach is the injection of radiolabeled 
monoclonal antibodies or antibody fragments targeting specific leukocytes antigens or receptors. 
However, these methods are characterized by a long and labor-intensive in vitro labeling procedure the 
first, and the frequent emergence of toxicity episodes the second. In addition, sensitivity and 
specificity reported in pre-clinical and clinical studies have been often contradictory or not satisfying 
[17, 22, 88].  
In the last years, diverse and novel agents able to target directly the infecting pathogens, rather 
than inflammatory cells, have been widely investigated. The antimicrobial peptide UBI 29-41 was 
labeled with technetium-99m and showed preferential accumulation at sites of experimental soft-tissue 
or foreign body associated infections. In clinical studies radiolabeled UBI 29-41 was investigated as an 
infection-specific agent allowing imaging of infectious foci in humans already 30 min after 
administration [89-94]. In addition, synthetic antimicrobials have been evaluated and proposed as 
potential infection-specific radiotracers. 99mTc-ciprofloxacin, belonging to the fluoroquinolone class of 
antibacterials, was pioneering this field and is the most extensively investigated. Promising in the pre-
clinical setting, in clinical studies 99mTc-ciprofloxacin reported controversial frequency of false-
positive cases, with specificity ranging between 41% and 83%. However, an increased specificity has 
been described when imaging was delayed from 1 h to 4 h or 24 h after administration of the tracer. 
Indeed, the delayed imaging would allow the clearance of aseptic inflamed lesions, whereas the 
radioactivity is retained in infection sites [22, 23, 95-101].  
The suboptimal radiochemical yield and the little understanding in the chemical structure of 99mTc 
complexes of ciprofloxacin stimulated the research towards better chemically defined derivatives. 
Recently, a promising candidate, ciprofloxacin dithiocarbamate (ciproCS2), has shown a fast and 
effective labeling, occurring by binding of two ciproCS2 molecules to a nitrido technetium-99m and 
resulting in a highly stable compound. Pre-clinical studies conducted with the 99mTcN-ciproCS2 
displayed in vitro bacterial binding and accumulation into infections sites higher than the precursor 
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ciprofloxacin [102]. Further evaluation would be recommended for a better characterization of this 
new tracer both in the pre-clinical and in the clinical settings. 
Radiolabeled growth factors may also behave as specific agents accumulated by bacteria due to 
their high replication rate. Recently, indium-111 labeled biotin displayed high potentials for the 
diagnosis of vertebral osteomyelitis infections. When compared to clinical, radiological or laboratory 
tests, the SPECT/CT imaging of administered 111In-DTPA-biotin achieved a sensitivity of 84-100% 
and specificity of 84-98% [103]. However, confirmatory clinical studies are required for confirming 
the diagnostic potentials of this radiotracer. 
The aim of our study was to compare the performance of 99mTc-UBI, 99mTcciprofloxacin, 99mTcN-
ciproCS2 and 111In-DTPA-biotin for targeting experimental S. aureus and E. coli infection in a tissue-
cage mouse model of foreign body infection. The tissue-cage model is a well-studied and well-
understood model of reproducible, localized and persistent infection [71, 77, 104]. After subcutaneous 
aseptic implantation on the back of the mice, perforated Teflon cages fill with a vascularized 
granulation tissue and exudate, originating from an unspecific local inflammation process around the 
foreign body. Percutaneous injection of bacteria into cages causes a persistent infection, in which 
bacteria grow in adherent and planktonic growth phases. The advantage of this model is the easy 
sampling of cage fluid, performed in successive time points without harming the animals, allowing an 
accurate determination of planktonic bacterial load or concentration of administered radiotracers.    
   
 
CHAPTER 2 
 51 
2.3 Materials and Methods 
Labeling procedures. 
99mTc-UBI 29-41 
Lyophilized kits were reconstituted under aseptic conditions with Na99mTcO4, as previously 
described [90]. Briefly, the kits consisted of two vials: vial n°1 contained 40 µl of NaOH and vial n°2 
contained 25 µg of UBI 29-41 and 12 µg of SnCl2. One ml of a 555 MBq/ml 0.9 % saline solution 
ofNa99mTcO4, eluted from a 99Mo/99mTc generator, was transferred to vial 1. Thus, the content of vial 1 
was resuspended and transferred to vial 2. After 15 min at room temperature, 5 ml of 0.9 % saline 
solution were added to vial 2 (stock solution, SS) and radiochemical purity analyzed with a Sep-Pak C-
18 Cartridge (Waters Instruments, USA). The column was preconditioned with 5 ml ethanol, 0.1 ml of 
the tracer solution was loaded and, first the free 99mTcO4 was eluted 5 ml HCl 1 mM, then the 99mTc-
UBI 29-41 was eluted with 3 ml of ethanol/saline (1:1) followed by 3 ml of HCl 0.1 M/methanol 
(15:85). The colloidal forms remained on the column. 
High-performance liquid chromatography (HPLC) was carried out with a Jupiter 4 n column (250 
× 4.6 mm2, 4 µm, Phenomenex, USA), connected to both radioactivity and UV-photodiode detectors. 
As mobile phases 0.1% TFA/water (solvent A) and 0.1 % TFA/acetonitrile (solvent B) were used at a 
flow rate of 0.75 ml/min starting with a mixture of solvent A/B of 95/5 % for 3 minutes. Following, a 
mobile phase gradient started during 10 min to a final ratio solvent A/B of 50/50 %. The latter mobile 
phase was kept for further 10 min, when the ratio was changed to solvent A/B of 30/70 % during 3 min 
and to the starting ratio solvent A/B of 95/5 % during the last 3 min. Instant thin layer chromatography 
(ITLC, Pall Life Sciences, USA) silica gel strips were used with saline or with mobile phase ethanol/ 
water/ ammonium (2:5:1) as eluent, for measuring the free pertechnetate or colloids, respectively. 
Stability of the 99mTc-UBI 29-41 was evaluated by resuspending 100 µl of the SS in saline and 
performing ITLC at different time points during 6 h.  
 
99mTc-ciprofloxacin 
99mTc-ciprofloxacin (1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid) 
was prepared using a lyophilized kit, as previously described [105, 106]. The kit consisted of 3 vials: 
vial n°1 contained 20 mg of ciprofloxacin, vial n°2 30 mg of L-tartarat acid and vial n°3 50 mg of 
SnCl2. First, vial 1 was reconstituted with 5 ml of sterile saline solution 0.9 %, vial 2 with 10 ml of 
water for injection and vial 3 with 10 ml of HCl 0.1M. Vial 2 and 3 were further diluted 1:20 with 
water for injection in oxygen free vials. Labeling was performed in a fourth oxygen free vial (reaction 
vial), in which were transferred 250 µl from vial 1 and 50 µl from 1:20 dilutions of vial 2 and 3, and 
finally 500 µl of a Na99mTcO4 solution with activity of 740 MBq were transferred to the reaction vial. 
After 20 min at room temperature the solution in reaction vial was filtered trough a 0.22 µm Millipore 
CHAPTER 2 
 52 
and diluted 1:10 in saline (stock solution, SS) to obtain a ciprofloxacin concentration of 125 µg/ml and 
an activity of 87 MBq/ml. The latter was further processed for quality controls. Radiochemical purity 
was evaluated by ITLC using as solvents aceton or ethanol/water/ammonium 25% (20:50:10) for free 
pertechnate or colloids, respectively. Stability of the 99mTc-ciprofloxacin was evaluated by 
resuspending 100 µl of the SS in 900 µl saline or serum and performing ITLC at different time points 
during 6 h. 
 
99mTcN-ciproCS2 
The kit was obtained from A. Duatti et al. (University of Ferrara, Italy) and consisted of 3 vials: 
vial n°1 contained 5 mg of succinic acid dihydrazide (SDH), 5 mg of ethylenediamine tetraacetic acid 
(EDTA), 0.1 mg of SnCl2 and phosphate buffer 0.1 M; vial n°2 contained 12 mg of 1-cyclopropyl-6-
fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl-N-dithiocarbamate)-3-quinolinecarboxylic acid sodium salt, 
(abbreviated as ciprofloxacin dithiocarbamate or ciproCS2); vial n°3 contained 15 mg of γ-
cyclodextrin. 
Briefly, 1 ml of 99mTcO4- (740 MBq) was added to vial 1 and after 30 minutes of incubation at 
room temperature, 100 µl of a 0.5 M carbonate buffer (pH=9.5) were added. Then, 15 ml of normal 
saline were added to vial 3 and 12 ml of the obtained solution were added to vial 2 and finally 1 ml 
was transferred to vial 1. The mixture was incubated at room temperature for 20 minutes. The final 
solution had a concentration of 0.5 mg/ml of 99mTcN-ciproCS2. The final stock solution (SS) was 
prepared by diluting 1:5 of the labeling solution with normal saline obtaining a final concentration of 
100 µg/ml and a specific activity of 74 MBq/ml. Quality controls were performed by both instant thin 
layer chromatography (ITLC), thin layer chromatography (TLC) and reverse phase high-performance 
liquid chromatography (HPLC). ITLC silica gel strips and TLC silica gel strips (Baker-flex®, J.T. 
Baker, USA) were used as stationary phase. Regarding the former the mobile phase consisted in 
normal saline, while for the latter a methanol/0.5 M ammonium acetate (80:20 v/v) solution was used 
to determine the amount of free 99mTcO4- and unreacted 99mTc-nitrido intermediate. The amount of 
colloids was determined using ITLC albumin absorbed strips as stationary phase and an 
ethanol/water/ammonium (2:5:1) solution as mobile phase. High-performance liquid chromatography 
(HPLC) was carried out using a method previously described [103]. Radiochemical purity was 
determined by HPLC using a Phenomenex Jupiter 4 n column and 0.1% TFA/water (solvent A) and 
0.1 % TFA/acetonitrile (solvent B) as mobile phases at a flow rate of 0.75 ml/min, starting with a 
solvent ratio of  A/B = 95/5  for 10 minutes. Then, a gradient started over 15 min to a final ratio A/B = 
5/95 and held constant for 3 minutes then back to 95/5 during the last 2 min. Stability of the 99mTcN-
ciproCS2was evaluated by resuspending 100 µl of the SS in 900 µl saline or serum and performing 
TLC analyses at different time points during 6 h. 
 
 
CHAPTER 2 
 53 
111In-biotin 
A Diethylenetriaminepentaacetic acid α,ω-bis-biocytinamide (DTPA-biotin) (SIGMA-ALDRICH, 
USA) solution of 500 µg/ml was prepared in Acetate buffer 0.05 M, pH 5.5 and sterile filtered with 
Millipore 0.2 µm filters. Labeling was performed as previously described [103]. Briefly 1 ml of 
DTPA-biotin sterile solution (500 µg) was mixed to 110 MBq of Indium-111 Chloride at room 
temperature for 15 minutes (stock solution, SS). Radiochemical purity was determined by high-
performance liquid chromatography (HPLC). HPLC was carried out using a Phenomenex Jupiter 4 n 
column. As mobile phases 0.1% TFA/water (solvent A) and 0.1 % TFA/acetonitrile (solvent B) were 
used at a flow rate of 0.75 ml/min starting with a mixture of solvent A/B of 95/5 % to a final ratio 
solvent A/B of 70/30 % during 25 minutes. Stability of the 111In-Biotin was evaluated by resuspending 
100 µl of the SS in 900 µl saline or serum and performing quality controls at different time points 
during 6 h. 
 
Microorganisms. The laboratory strains E. coli (ATCC 25922) and S. aureus (ATCC 35556, 
methicillin-susceptible) were used. Bacteria were stored at -70°C using a cryovial bead preservation 
system (Microbank, Pro-Lab Diagnostics, Richmond Hill, ON, Canada). Single cryovial beads were 
cultured overnight on Columbia sheep blood agar plates (Becton Dickinson, Heidelberg, Germany). 
Bacterial cultures were prepared by resuspending two to three colony forming units (CFUs) in 5 ml of 
Tryptic soy broth (TSB) and incubating overnight for 18-20 h at 37°C. For in vitro studies, overnight 
cultures were diluted 1:100 in TSB and further incubated at 37°C to mid-logarithmic phase. Following, 
when an optical density (OD600) between 0.3 and 0.4 was achieved, cultures were centrifuged and 
bacterial pellets concentrated 10× in the appropriate volume of phosphate buffer solution (PBS) or a 
0.1% acetic acid and 0.05 % Tween 80 supplemented PBS (incubation buffer solution, IBS) for testing 
99mTc-UBI 29-41. Hundred µl of resuspended bacterial cultures were mixed with 900 µl of tracer 
solution, reaching a final load of ≈ 1×108 CFU/ml. 
For in vivo studies, overnight cultures were washed three times and re-suspended in 5 ml of sterile 
saline 0.9%. Appropriate dilutions (inocula of 5×105 CFU and 1×107 CFU injected per mouse-cage of 
S. aureus and E. coli, respectively) of the washed overnight cultures were prepared and used for mice 
inoculation. 
 
In vitro binding studies. Binding of the test radiotracers to E. coli and S. aureus was investigated 
in vitro. Mid-logarithmic phase bacterial cultures were 10× concentrated and aliquoted into Eppendorf 
vials, together with the test tracers. Vials were incubated for 1 h at 37°C, in the presence and in the 
absence a 100-fold excess of unlabelled tracer. Temperature dependency was evaluated by adapting 
bacterial aliquots for 1 h at 4°C before addition of the tracers, followed by further incubation for 1 h at 
4°C. Bacterial colony forming units were evaluated before and after 1 h incubation in the presence of 
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tracer. For this purpose, 50 µl were 10-fold serial diluted in sterile saline and spread on Columbia agar 
plates. After overnight incubation at 37°C, plates were counted and the exact log10CFU/ml calculated.  
For measuring tracers’ binding to non-viable bacteria, cultures were exposed to 70 % ethanol 
solution at 4°C or in the buffer solution to 99°C for 30 min (E. coli) or 1 h (S. aureus). Ethanol 
exposed cultures where washed before performing the binding tests. To confirm the non-viability of 
the resuspended heat-killed or ethanol-killed bacteria, 100 µl were spread on Columbia blood agar 
plates and the CFU enumerated after 24 h of incubation at 37°C. Colony counts <10 CFU/ml were 
considered valid for further binding evaluation.  
For testing 99mTc-UBI 29-41, freshly prepared stock solutions (SS) were diluted 1:20 with the 
incubation buffer solution (IBS, phosphate buffer solution 0.02 M supplemented with 0.1 % acetic acid 
and 0.05 % Tween 80), to a final concentration of 210 ng/ml, 2.3 MBq/ml. Following, Eppendorf vials 
were filled with 800 µl of IBS, 100 µl of bacterial suspension and 100 µl of diluted tracer.  
The SS of 99mTc-Ciprofloxacin and 99mTcN-ciproCS2 were diluted in PBS 1:10 and 1:40, 
respectively, from which 100 µl were transferred to Eppendorf vials containing 800 µl of PBS and 100 
µl of bacterial suspensions. 
In the 111In-DTPA-biotin binding assay, the labeled SS was diluted 1:1000 (0.45 µg/ml DTPA-
Biotin, 0.1 MBq/ml) in PBS, and 500 µl transferred to vials pre-filled with 500 µl of bacterial cultures 
resuspended in PBS or a biotin depleted minimal medium. 
The % radiotracer bound to bacterial cells was calculated by incubating the different 
radiopharmaceuticals with the bacteria suspensions for different time points between 5 min 
and 1 h. Probes were then centrifuged for 5 minutes at 13,500 rpm at 4°C. Pellets were 
washed with 500 µl of cooled buffer solution. Supernatants and re-suspended pellets were 
counted in a multi-well NaI γ-counter (Cobra; Packard) and the counts per minutes (CPM) 
recorded. The percentage of radiolabeled agents in the pellets was calculated as percentage of 
the CPMp/CPM0-ratio per 8.0 log10CFU/ml, where CPMp were the CPM associated to pellets 
and CPM0 the total CPM of the radiolabeled agent added per vial. 
 
       Tissue-cage infection model in mice. C57Bl/6 mice from in-house breeding or purchased from 
Charles River (CR, Germany) were housed in the Animal Facility of the Department of Biomedicine, 
University Hospital Basel, Switzerland, at a mean temperature of 23 ± 2°C, 50-55% relative humidity, 
and 12-h light/dark cycle. Drinking water and standard laboratory food pellets (CR) were provided ad 
libitum. At the age of 12 weeks, one sterile polytetrafluoroetylene (Teflon) cage (32 × 10 mm), 
perforated by 130 regularly spaced holes of 1 mm diameter, was aseptically implanted into the back 
of each mouse, as previously described [74, 104] (figure 11). Each cage was weighted and numbered 
before implantation, in order to normalize the final cage-associated CPM measurements with the 
weight of the cage tissue only. Two weeks after surgery, clips were removed from healed wounds and 
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sterility of the cage was confirmed by plating of percutaneously aspirated cage fluid on Columbia 
blood agar plates. On the following day, 5 × 105 CFU of E. coli or 5 × 106 CFU of S. aureus 
resuspended in 200 µL of 0.9% NaCl, were injected into the cages. Cages in control animas were 
injected with sterile 0.9% NaCl. Experiments were performed in accordance to the regulations of 
Swiss veterinary law. The Institutional Animal Care and Use Committee approved the study protocol. 
 
 
 
Figure 11. CT picture of a C57Bl/6 mouse with subcutaneous implanted tissue cage. 
 
Biodistribution studies. In biodistribution studies, 100 µl of test radiopharmaceuticals were 
administered i.v. into the mice lateral tail vein, 24 h and 48 h after induction of E. coli and S. aureus 
infection, respectively. In particular, the injected stock solutions were: 99mTc-UBI 29-41 (9.3 MBq, 
0.40 µg per mouse), 99mTc-ciprofloxacin (7.4 MBq, 13 µg per mouse), 99mTcN-ciproCS2 (7.4 MBq, 10 
µg per mouse) and 111In-biotin (0.6 MBq, 0.5 µg per mouse). Each tracer was injected in at least 10 to 
12 mice per sterile/ infected testing group. 
Bacterial counts into cage fluids were evaluated by plating 10-fold serial dilutions of fluids 
collected on the day of tracer injection and plates were incubated for 24 h at 37°C and the CFU 
counted.  
Distribution of tracers into the infected/sterile cage fluids was determined at 30 min, 1 h, 2 h, 4 h, 8 
h, 12 h and 24 h p.i. of the radiopharmaceuticals. Hundred µl of aspirated fluids were resuspended in 1 
ml PBS and counted in a gamma counter. The percentage of injected dose (% IDTCF/ml) was calculated 
as measured CPM normalized per 1 ml cage fluid and divided by the CPM0 of the injected dose. 
Distribution into organs, tissues and explanted cages was measured at 30 min, 4 h and 24 h p.i. Mice 
were sacrificed with an intra-peritoneal injection of 50-80 µl saline solution of pentothal (100 mg/ml). 
Blood was collected by cardiac puncture and animals were perfused with 0.9% NaCl solution for 
around 5 min. Following, tissues were dissected, weighted and collected into test tubes for γ-counter 
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(blood, heart, liver, spleen, stomach, kidneys, lungs, intestine, muscle, bone and cage). The percentage 
of injected dose (% IDtissue/g) was calculated as CPM associated to each organ divided by its weight in 
grams and by the CPM0 of the injected dose.  
 
Statistical analysis. Comparisons of in vitro binding results and in vivo biodistribution data were 
performed using the Student t test for continuous variables. All results were given as mean values ± 
SEM, unless otherwise indicated. Differences were considered significant when P values were <0.05. 
All calculations were performed using Prism 4.0a (GraphPad Software, La Jolla, CA, USA).  
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2.4 Results 
        Quality controls and stability assays (table 4) 
99mTc-UBI 29-41 
The labeling efficiency of 99mTc-UBI 29-41 determined by ITLC and HPLC was 97 %, while the 
radioactivity associated with colloid or hydrolyzed 99mTc species was less than 1.6 %. The compound 
was stable in saline up to 6 h, but its stability decreased to 12 % after 6 h in serum. 
 
99mTc-ciprofloxacin 
The labeling efficiency of 99mTc-ciprofloxacin determined by ITLC and HPLC was 93 %, with an 
amount of colloids not greater than 5 %. The compound was stable in serum up to 6 h, whereas in 
saline its radiochemical purity decreased up to 58 % after 6 h. 
 
99mTc-ciproCS2 
The labeling efficiency of 99mTcN-ciproCS2 determined by HPLC and TLC was approximately 97 %, 
with an amount of unreacted 99mTc-nitrido intermediate not greater than 3%. The compound was 
stable in saline and serum up to 6 h, without any decrease of the radiochemical purity. 
 
111In-DTPA-biotin 
111In-DTPA-biotin presented a labeling efficiency of 96% determined by HPLC and was highly stable 
in saline and serum up to 6 h, without any decrease of the radiochemical purity. 
 
Table 4. Radiochemical purity of 99mTc-UBI 29-41, 99mTc-Ciprofloxacin, 99mTcN-CiproCS2 and 111In-
DTPA-biotin immediately after labeling, and during 6 h incubation in saline or serum of a 1:10 
dilution of the labeling solution. 
 Stability Control (Saline) 
Stability Control 
(Serum) 
 
Labeling 
Efficiency 1 h 3 h 6 h 1 h 3 h 6 h 
99mTc-UBI 29-41 97% 96% 97% 94% 34% 18% 12% 
99mTc-Ciprofloxacin 94% 83% 71% 58% 94% 92% 92% 
99mTcN-CiproCS2 98% 96% 97% 97% 96% 97% 97% 
111In-DTPA-biotin 96% 96% 95% 95% 96% 96% 95% 
 
        In vitro binding studies. The in vitro binding of 99mTc-UBI 29-41, 99mTc-ciprofloxacin, 99mTcN-
CiproCS2 and 111In-DTPA-biotin to the E. coli and S. aureus test strains was independent on 
temperature or bacterial viability. No competition occurred when binding was measured in the 
presence of 100-fold excess of unlabelled compounds. In addition, for the 99mTc-UBI 29-41 and 
99mTc-ciprofloxacin, trends of higher binding to ethanol or heat killed than viable bacteria were 
CHAPTER 2 
 58 
observed, with the exception of 99mTc-ciprofloxacin binding to S. aureus which remained constant in 
all tested conditions. The highest in vitro bacterial binding was observed with 99mTcN-CiproCS2. 
Percentages of binding per 8.0 log10 CFU/ml were calculated and are reported in Table 5.   
Bacterial viability was tested for the cultures exposed to the tracer solutions during 1 h. Both S. 
aureus and E. coli cultures were not affected by the presence of any of the tracers and bacterial counts 
remained equal to control vials during 1 h of incubation. Whereas, in competition experiments, E. coli 
counts at 1 h incubation decreased when exposed to the 100-fold excesses of unlabeled ciprofloxacin 
and CiproCS2 by ≈0.8 and ≈3.5 log10CFU/ml, respectively.  
 
Table 5. In vitro binding assay reported as % CPM/CPM0 (means ± SD) measured after 1 h 
incubation of the tracers with the S. aureus or E. coli bacterial strain. 
 
 
        Biodistribution studies. The E. coli and S. aureus mean ± SD load into cage fluids was 9.4 ± 
0.82 log CFU/ml and 6.3 ± 0.62 log CFU/ml, respectively. No clinical or pathological signs of 
systemic infection (hematogenous dissemination) were observed during organ dissection. Thus, the 
cage fluid infections were considered persistent and localized.  
Accumulation of the radiolabeled agents into cage fluids was measured at 30 min, 2 h, 4 h, 8 h, 12 
h and 24 h p.i., the % IDTCF/ml calculated were plotted versus time and the kinetic profiles are reported 
in figure 12. 99mTc-UBI 29-41 and 111In-DTPA-biotin (figure 12A and 12D) displayed a similar kinetic 
into cage fluids, with peak values measured at 30 min p.i. of 3.26 ± 1.45 and 3.55 ± 0.92, respectively, 
followed by fast clearance and already at 12 h p.i. %ID/ml became <0.1. Similarly, 99mTc-
ciprofloxacin (figure 12B) peaks of 2.94 ± 1.01 %ID were achieved in cage fluids at 30 min p.i. 
 
 
 
37°C 4°C EtOH Killed Heat Killed 
100x Cold 
37°C 
99mTc-UBI 29-41 
E. coli 0.94 ± 0.082 0.61 ± 0.15 3.34 ± 0.35 12.02 ± 0.52 1.01 ± 0.079 
S. aureus 0.36 ± 0.045 0.28 ± 0.050 15.90 ± 0.87 10.20 ± 2.53 1.02 ± 0.13 
99mTc-Ciprofloxacin 
E. coli 2.60 ± 0.032 1.6 ± 0.16 4.35 ± 0.20 4.81 ± 0.22 1.18 ± 0.052 
S. aureus 1.43 ± 0.073 1.11 ± 0.047 2.12 ± 0.25 0.52 ± 0.040 1.038 ±0.11 
99mTcN-CiproCS2 
E. coli 32.51 ± 3.47 55.46 ± 4.98 48.34 ± 6.14 53.11 ± 6.47 95.41 ± 2.39 
S. aureus 91.10 ± 3.67 95.14 ± 4.15 93.14 ± 4.03 92.56 ± 7.97 98.86 ± 3.19 
99mTc-DTPA-Biotin 
E. coli 0.23 ± 0.058 0.10 ± 0.032 0.088 ± 0.037 0.10 ± 0.038 0.21 ± 0.088 
S. aureus 0.14 ± 0.024 0.25 ± 0.022 0.069 ± 0.024 0.050 ± 0.015 0.063 ± 0.037 
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Differently, the penetration of 99mTcN-ciproCS2 (figure 12C) into cage fluids was lower than the other 
tested agents, with a slow kinetic and peak values in sterile fluids between 8 and 12 h of 0.23 ± 0.01.    
 
A 
 
B 
 
C 
 
D 
 
Figure 12. Distribution profiles of 99mTc-UBI 29-41 (A), 99mTc-ciprofloxacin (B),99mTcN-CiproCS2 (C) and 111In-DTPA-
Biotin (D) at 30 min, 2, 4, 8, 12 and 24 h p.i. into cage fluids sterile (black diamonds and dotted lines), S.aureus (empty 
circles and dashed lines) or E. coli (close circles and continuous lines) infected. Data represent % ID/ ml of tissue fluid, 
expressed as means ± 1 SEM of three to five mice per testing group. Significant differences between infected and control 
cage fluids are indicated as follow: * P < 0.05, ** P < 0.005, ***P < 0.0005 
 
Radiopharmaceutical accumulation into dissected tissues, organs and cage tissues was evaluated at 4 
h and 24 h p.i. %ID/ g measured from total body biodistribution are reported in table 6a, and plots of 
the cage associated %ID/ g are displayed in figure 13. Distributions of the radiotracers into cage 
tissues well correlated to the one measured in the cage fluids. In table 6b are reported the cage-fluid 
and the cage-tissue to blood %ID ratios for all tracers at 4 h and 24 h p.i.. 
Preferential accumulation of 99mTc-UBI 29-41 in E. coli infected than in sterile cages was measured 
between 12 h (P=0.045) and 24 h p.i. (P=0.0069) (figure 13A). The agent was fast cleared from blood 
and calculated cage fluid or tissue cages to blood ratios ranged between 1.60 - 6.00 % in sterile 
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animals and 4.50 – 18.35 % in infected animals (table 6b). At 24 h p.i. cage-fluid to blood ratios were 
significantly lower in non-infected than in both E. coli (P=0.0008) and S. aureus (P=0.035) infected 
animals (table 6).  
The uptake of 99mTc-ciprofloxacin in both S. aureus and E. coli infected cage fluids and tissues (figure 
12B and 13B) were higher than in sterile ones at any time point between 4 h and 24 h p.i. (P<0.05). 
Both cage and cage fluids to blood ratios were highly discriminative for infections already from 4 h 
p.i. (table 6b).  
99mTcN-ciproCS2 did not differentiate between sterile and S. aureus infection (figure 12C and 13C), 
whereas %ID, cage-fluid to blood and tissue-cage to blood ratios became significantly higher in E. 
coli infected animals from 4 h p.i. (P=0.028) to 24 h p.i. (P=0.0003).  
 
A 
 
B 
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D 
 
Figure 13. Distribution of 99mTc-UBI 29-41 (A), 99mTc-ciprofloxacin (B),99mTcN-CiproCS2 (C) and 111In-DTPA-biotin 
(D) at  4 and 24 h p.i. into explanted cages sterile (dashed bars), E.coli (close bars) or S. aureus (open bars) infected. Data 
represent % ID/g of tissue, expressed as means ± 1 SEM of three to five mice per testing group. Significant differences 
between infected and control cages are indicated as follow: * P < 0.05, ** P < 0.005, ***P < 0.0005 
 
111In-biotin accumulated in S. aureus infected cages more than in sterile animals at any time after 4 h 
(P=0.0089) p.i. (figure 12D and 13D). %IDs were significantly higher in E. coli infected than in 
explanted cages at 4 h p.i. (P=0.028) but not at 24 h p.i., while the accumulation in E. coli infected 
cage fluids was equal than the one in sterile animals. On the other hand, the ratios of cage-fluid and 
tissue-cage to blood were discriminative for both E. coli and S. aureus infections from 4 h to 24 h p.i.
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(table 6b).  
As previously described, in biodistribution studies both 99mTc-UBI 29-41 and 99mTc-ciprofloxacin 
accumulated in the kidneys, which constitute the main elimination route. In addition, 99mTc-
ciprofloxacin showed liver uptake, probably due to hepatic metabolism [89, 91, 92]. In accordance to 
J. Zhang et al. [102] 99mTcN-CiproCS2 distributed mainly in liver and intestine, secondarily in spleen, 
lungs and kidneys. 111In-biotin showed a low accumulation in all organs and tissues, as it was cleared 
from blood already at 4 h p.i. A slight accumulation into kidneys indicated the latter being involved in 
the tracer elimination. 
All tested radiopharmaceuticals were cleared from most organs and tissues at 24 h p.i. (table 6a). 
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Table 6. a Biodistribution after i.v. injection of 99mTc-UBI 29-41, 99mTc-ciprofloxacin,99mTcN- 
CiproCS2 and 111In-DTPA-biotin expressed as means (±SD) %ID/g of tissue and target-to-non target 
cage ratios (T/NT). 
99mTc-UBI 29-41 99mTc-ciprofloxacin 99mTcN-CiproCS2 111In-DTPA-biotin 
 
4 h 24 h 4 h 24 h 4 h 24 h 4 h 24 h 
Blood 0.06(±0.01) 0.02(±0.00) 0.71(±0.17) 0.55(±0.05) 3.35(±0.31) 0.75(±0.03) 0.03(±0.00) 0.02(±0.00) 
Heart 0.14(±0.01) 0.02(±0.01) 2.16(±0.63) 1.01(±0.04) 0.64(±0.09) 0.20(±0.02) 0.06(±0.01) 0.01(±0.00) 
Liver 0.77(±0.02) 0.17(±0.07) 7.34(±3.76) 3.14(±0.27) 21.13(±0.93) 8.51(±1.29) 0.08(±0.01) 0.07(±0.02) 
Stomach 1.09(±0.18) 0.23(±0.16) 2.11(±0.74) 1.26(±0.14) 0.67(±0.36) 0.31(±0.12) 0.06(±0.04) 0.03(±0.01) 
Spleen 0.38(±0.10) 0.09(±0.03) 1.94(±0.85) 1.35(±0.05) 7.76(±0.96) 2.48(±0.75) 0.09(±0.02) 0.07(±0.01) 
Kidneys 40.18(±1.88) 5.80(±2.90) 15.42(±1.95) 9.94(±0.40) 3.78(±0.65) 0.87(±0.17) 1.48(±0.31) 1.00(±0.21) 
Lungs 0.62(±0.06) 0.05(±0.03) 1.61(±0.36) 1.09(±0.14) 5.62(±2.99) 0.51(±0.18) 0.04(±0.01) 0.38(±0.70) 
Intestine 0.71(±0.07) 0.13(±0.07) 2.71(±1.03) 0.84(±0.14) 14.50(±3.87) 1.12(±0.13) 0.18(±0.06) 0.08(±0.04) 
Bone  0.09(±0.01) 0.03(±0.01) 3.15(±0.46) 3.64(±0.25) 1.58(±0.27) 0.68(±0.05) 0.06(±0.00) 0.04(±0.00) 
Muscle 0.05(±0.02) 0.01(±0.00) 0.62(±0.17) 0.38(±0.06) 0.82(±0.09) 0.22(±0.03) 0.03(±0.01) 0.01(±0.01) 
aE. coli/ 
sterile TC 1.01(±0.12) 2.83(±1.28) 1.86(±0.14) 2.93(±0.91) 2.35(±0.48) 2.29(±0.36) 1.76(±0.19) 1.47(±0.21) 
aS. aureus/ 
sterile TC 1.31(±0.65) 2.17(±1.42) 2.16(±0.53) 1.63(±0.14) 0.71(±0.30) 1.22 (±0.19) 1.91(±0.27) 1.89(±0.36) 
aRatios between %ID/g measured in infected and sterile cages. TC = tissue cage. 
 
 
 
 
Table 6.b 99mTc-UBI 29-41, 99mTc-ciprofloxacin,99mTcN-ciproCS2 and 111In-DTPA-biotin cage 
fluids or explanted cages to blood %ID ratios expressed as means (±SD). 
Sterile TC E. coli TC S. aureus TC 
 
Fluids Cages Fluids Cages Fluids Cages 
4 h 4.39(±1.07) 6.00(±1.35) 5.68(±2.21) 6.03(±0.70) 4.50(±1.92) 7.83(±3.91) 99mTc-UBI 29-41 
24 h 1.90(±1.11) 4.00(±1.73) 18.35(±2.91) 11.33(±5.13) 4.82(±1.87) 8.67(±5.69) 
4 h 0.26(±0.06) 0.35 (0.08) 0.44(±0.06) 0.65(±0.05) 0.53(±0.03) 0.76(±0.18) 99mTc-
ciprofloxacin 24 h 0.52(±0.03) 0.81(±0.09) 1.66(±0.65) 2.38(±0.74) 0.80(±0.05) 1.33(±0.11) 
4 h 0.22(±0.02) 0.31(±0.04) 0.35(±0.06) 0.74(±0.15) 0.14(±0.09) 0.22(±0.09) 
99mTcN-ciproCS2 
24 h 0.82(±0.04) 1.25(±0.07) 1.59(±0.08) 2.87(±0.45) 0.85(±0.17) 1.52(±0.24) 
4 h 4.69(±1.42) 4.72(±0.86) 7.44(±1.31) 8.89(±0.95) 9.51(±0.29) 9.61(±1.36) 
111In-Biotin 
24 h 2.26(±0.38) 5.33(±0.58) 3.82(±0.85) 7.00(±1.00) 6.24(±1.17) 9.00(±1.73) 
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2.5 Discussion 
Several classes of radiopharmaceutical have been developed, with the common aim of targeting 
either host or bacterial cells specifically involved in the infective process. We compared four well-
known and promising radiotracers for targeting bacterial infections in a tissue-cage mouse model of 
implant-associated infection. First, we evaluated the radiotracers in vitro in a competitive binding 
assay with laboratory strains of E. coli and S. aureus, followed by study of their biodistribution in 
sterile and infected animals.  
The labeling kits demonstrated a high labeling efficiency and high stability both in saline and 
serum, with exception of 99mTc-ciprofloxacin, whose radiochemical purity decreased in saline to ≈ 60 
% during 6 h. In serum, the stability of 99mTc-UBI cannot be assessed by ITLC, but in previous studies 
the tracer was reported to maintain a radiochemical purity of 85 % to 90 % during 24 h incubation in 
human serum [107]. 
The correlation of the in vitro binding results with the binding to bacteria in vivo is unclear. The 
different uptake mechanism and kinetics of radiopharmaceuticals to bacteria may result being highly 
affected by the conditions adopted in the in vitro tests. In our studies, the in vitro binding of the four 
radiotracers to E. coli and S. aureus was poorly satisfactory. All radiopharmaceuticals showed strain 
differences and generally similar capacity to bind to both alive and dead bacteria. Furthermore, not 
always we were able to displace the bound radiopharmaceutical by an excess of unlabelled compound, 
due to the lack of a receptor-mediated binding mechanism and to the killing induced by the high 
concentration of unlabelled compound to be added in excess.  
Indeed, the initial interaction of antimicrobial peptides, as UBI 29-41, to microbial plasmatic 
membranes is only guided by electrostatic interaction between the positively charged peptide and the 
negatively charged lipid bacterial membranes. Following, the amphipathic nature of antimicrobial 
peptides induces hydrophobic interactions, and insertion through the membranes with formations of 
pores. Then, the pores mediate internalization and accumulation of antimicrobial peptides in the 
bacterial cytoplasm, where they presumably specifically bind to intracellular targets [89, 108].  
Similarly, ciprofloxacin, a fluoroquinolone antimicrobial targeting bacterial DNA-gyrase, has been 
described to be taken up by Gram positive and Gram negative bacteria in a non-saturable mode, as 
simple diffusion through non specific protein channels or directly through the phospholipids bilayer. 
Bacterial uptake of ciprofloxacin is reduced at lower temperatures, which is in accordance with our 
results. The ciprofloxacin binding to bacteria may be affected by the phase of bacterial growth, the 
culture medium or the degree of aeration during growth. In addition, the active efflux system across 
the cytoplasmic membrane and the washing step performed after exposure of the bacterial cultures to 
the radiolabeled ciprofloxacin may play key roles in the final binding percentage [109]. Previously, by 
using the same 99mTc-ciprofloxacin kit preparation applied in our study, Sierra et al. reported an in 
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vitro binding to S. aureus of 22-23%, which is 10-fold higher than what we could measure [105]. 
However, Sierra et al. tested a bacterial density of OD600 = 1.5, which is three times higher than the 
one we used in the in vitro binding studies. In our in vitro studies, we chose a bacterial density with 
OD600 0.5 because corresponding to ≈ 8 log10CFU/ml, which is the highest bacterial counts achieved in 
vivo in the mouse cage fluid. Indeed, bacterial densities like ours have been used in in vitro assays in 
previous studies and led to a binding percentage similar to the one we report [110, 111].  
Differently from the other tested agents, biotin is a vitamin and was reported to have a specific, 
temperature and energy dependent receptor-mediated binding to E. coli [112]. However, our results 
showed that the binding of 111In-DTPA-biotin was not dependent on bacterial viability. A possible 
explanation for this discrepancy is the different concentration of biotin and bacteria that we used in our 
experiments. 
The distribution studies of 99mTc-UBI 29-41, 99mTc-ciprofloxacin and 111In-DTPA-biotin performed 
in the mouse tissue cage model showed a rapid penetration into the cage tissues and fluids followed by 
an exponential clearance.  The peak concentrations were higher in sterile than infected cages, but 
clearance of sterile cages occurred earlier than infected, thus giving the possibility to discriminate 
between sterile inflammation and infection with late acquired images. Differently, the penetration of 
99mTcN-ciproCS2 into cage fluids followed a slow kinetic and peak concentrations were achieved 
between 8 h and 12 h p.i..  
In contrast with the low binding obtained in vitro, a significantly higher accumulation of the tracers 
into infected tissue cages was achieved between 4 h and 12 h p.i.. 99mTc-ciprofloxacin and 111In-DTPA-
biotin were discriminative for both E. coli and S. aureus infections. In previous pre-clinical and 
clinical studies, 99mTc-UBI 29-41 was reported to be accumulated preferentially at infection sites 
between 30 min and 4 h p.i. [89, 94, 113-115]. However, the tissue cage model did not support early 
time points due to delayed clearance of the non-infected cages. Indeed, at 30 min p.i., the radiotracers 
showed comparable concentrations in sterile and infected cages and became discriminative for E. coli 
infected cages between 12 h and 24 h p.i..99mTcN-ciproCS2 displayed low penetration into all cages, 
with peak values between 7- and 20-fols lower than the ones measured with the other tested 
radiotracers. Contrarily to the in vitro binding results, which led to higher binding affinity to S. aureus 
then to E. coli, 99mTcN-ciproCS2 was able to discriminate only for E. coli and not for S. aureus infected 
cages.  
The T/NT (cage fluids, or tissue cage to blood) ratios of 99mTc-ciprofloxacin and 111In-DTPA-biotin 
at 4 h were higher than for 99mTc-UBI 29-41 and 99mTcN-CiproCS2. At 24 h T/NT ratios > 2 where 
observed with 99mTc-UBI 29-41, 99mTc-ciprofloxacin and 99mTcN-CiproCS2 in E. coli infected cages, 
whereas in S. aureus cages and in all 111In-DTPA-biotin injected mice the radioactivity was mainly 
cleared. T/NT ratio >3 were not achieved at any time and with any bacteria, a finding that in our 
opinion may constitute a limiting factor for their use in human to detect residual infection during or 
after therapy. 
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Conclusions  
We report here for the first time, a comparison between four different radiopharmaceuticals 
developed for imaging of bacterial infections. We compare in vitro labeling stability of published 
formulated kits, in vitro binding to different strains of bacteria, in vivo biodistribution in a reliable and 
reproducible animal model of foreign body infection.  
All compounds showed in vivo discrimination for infected sites, and thus, they constitute 
promising option for diagnosis occult implant infections. While 99mTc-ciprofloxacin and 111In-DTPA-
biotin accumulated in both E. coli and S. aureus infected cages, 99mTc-UBI 29-41 and 99mTcN-ciproCS2 
preferentially discriminated for E. coli infected cages.  
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3.1 Abstract 
Vitamin B12 (Cbl) is accumulated by rapidly replicating prokaryotic and eukaryotic cells. We 
investigated the potential of a 99mTc-labeled Cbl derivative (99mTc-PAMA(4)-Cbl) for targeting 
infections caused by Escherichia coli and Staphylococcus aureus. In vitro binding assays were 
followed by biodistribution studies in a mouse model of foreign body infection.  
Methods: E. coli (ATCC 25922) and S. aureus (ATCC 43335) were used as test strains. 57Co-Cbl, 
67Ga-citrate and 99mTc-DTPA served as reference compounds. The in vitro competitive binding of 
57Co-Cbl or 99mTc-PAMA(4)-Cbl, and unlabeled Cbl, to viable or killed bacteria, was evaluated at 
37°C and 4°C. A cage mouse model of infection was used for biodistribution of intravenous 57Co-Cbl, 
99mTc-PAMA(4)-Cbl and reference compounds in cage and dissected tissues of infected and non-
infected mice.  
Results: Maximum binding (mean ± SD) of 57Co-Cbl to viable E. coli was 81.7 ± 2.6% and to S. 
aureus 34.0 ± 6.7%, at 37°C; no binding occurred to heat-killed bacteria. Binding to both test strains 
was displaced by 100- to 1000-fold excess of unlabeled Cbl. The in vitro binding of 99mTc-PAMA(4)-
Cbl was 100-fold lower than of 57Co-Cbl for E. coli, whereas was equal to the one of 57Co-Cbl for S. 
aureus. In vivo, 99mTc-PAMA(4)-Cbl showed peak %ID values between 1.33 and 2.3, at 30 min p.i. 
Significantly higher retention occurred in cage fluids infected with S. aureus at 4 h and with E. coli at 
8 h p.i. than in non-infected animals. Accumulation into infected cages was also higher than the one of 
99mTc-DTPA, which showed similar biodistribution in infected and sterile mice.  
 57Co-Cbl gradually accumulated in cages with peaks %ID between 3.58% and 4.83% achieved 
from 24 h to 48 h. Discrimination for infection occurred only in E. coli infected mice, at 72 h p.i.  
67Ga-citrate, which showed a gradual accumulation into cage fluids during 12 h, was discriminative 
for infection from 48 to 72 h p.i. (P<0.05).  
Conclusion: Cbl displayed rapid and specific in vitro binding of the test strains. 99mTc-PAMA(4)-
Cbl was rapidly cleared from most tissues and discriminated between sterile and infected cages, being 
a promising candidate for imaging infections in humans. 
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3.2 Introduction 
Bacterial infections are an important cause of morbidity and mortality worldwide. The accurate 
diagnosis of infection (or its exclusion) is the first crucial step in the management of these patients. 
Imaging techniques constitute a non-invasive and attractive approach that, in the last decades, has 
gained on importance by combining visualization of radiopharmaceuticals and morphological imaging, 
with PET/CT and SPECT/CT imaging [24, 32]. In various types of infections, including prosthetic 
joint infections, radionuclide imaging techniques become essential when the diagnosis remains unclear 
[4]. The current standard method is based on labeling white blood cells isolated from patients [87, 116-
118]. Other agents have been developed in the past decade, such as radiolabeled antimicrobials 
(ciprofloxacin, sparfloxacin, ceftizoxime, isoniazid, ethambutol, fluconazole), antimicrobial peptides 
(29-31 UBI, human beta-defensin-3), cytokines (IL-8), 18F-FDG, growth factors and bacteriophages 
[24, 30, 93, 97, 119-121]. However, in pre-clinical and clinical studies these agents showed several 
limitations, in particular insufficient specificity for diagnosing infection, making them unsuitable in 
the clinical practice [22, 31, 32].  
Vitamins are essential growth factors, which are required in fast replicating cells, such as bacteria 
or fungi and may be used in a labeled form for specific targeting infection. Vitamin B12 or cobalamin 
(Cbl) is an important hydrophilic enzyme cofactor. In bacteria, Cbl catalyzes transmethylation and 
rearrangement reactions by binding to Cbl-dependent enzyme isoforms, directly or indirectly 
responsible for the synthesis of ATP, amino acids and nucleotides [122] Comparative genomic 
analysis revealed a wide distribution of genetic elements involved in the regulation or uptake of Cbl 
derivatives [122]. Cbl transport systems were studied mainly in enteric bacteria, where the best 
structurally characterized was in E. coli. The E. coli Cbl uptake is mediated by an external membrane 
transporter (BtuB, TonB-dependent), which transfer Cbl to a periplasmatic protein (BtuF) and finally 
across the inner membrane (BtuCD, ABC ATP-dependent) [123-125]. Gram-positive bacteria, as S. 
aureus, do not have an outer membrane, and thus completely lack the BtuB carrier. However, elements 
analogue to the E. coli BtuCD inner-membrane transporter system were reported in S. aureus and S. 
epidermidis strains, and described as less specific carriers of Cbl and closely related molecules as 
heme and siderophores [122]. The latter findings supported previous in vitro studies of 57Co-Cbl 
uptake mechanism, which reported high avidity of binding to several pathogen bacteria in different 
culture conditions [126, 127].  
The distinctive uptake mechanism in bacterial and animal cells may represent the basis for 
development of radiolabeled Cbl derivatives for specific targeting bacterial infections and for reduced 
systemic accumulation in vivo. Cbl distributes through the blood circulation upon binding to the 
transport protein transcobalamin II (TC II). The Cbl-TC II complex is rapidly internalized through 
binding to the transcobalamin II receptor (RTC II) and megalin receptor, mainly expressed in humans 
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in the kidneys, liver, intestine lumen, glands and absorptive epithelia [128, 129]. A second family of 
proteins, transcobalamin I (TC I or haptocorrins, or R-type Cbl-binders), bind free Cbl and 
cobinamides in the blood. The TC I protein family was mainly found in secondary granules of 
granulocytes and in salivary glands, and its release has a protective function of reducing pathogen 
colonization and growth [130, 131].  
A 57Co-Cbl oral formulation was initially developed and used in humans for diagnosis of vitamin 
B12 malabsorption syndromes [132]. A similar intravenous formulation showed potential targeting of 
tumor cells [133]. However, the long half-life of the isotope 57Co-Cbl, together with its systemic non-
specific accumulation and persistence in several organs, limited the maximal injectable dose to 1 µCi. 
This dose limit prohibits the use of 57Co-Cbl for imaging purposes. Therefore, vitamin B12 analogues 
were synthesized and labeled with isotopes such as 111In and 99mTc. An 111In-labeled Cbl derivative, 
diethylentriamine-pentaacetat adenosylcobolamin (111In-DAC), showed promising results for the 
diagnosis of various malignancies. Interestingly, in the same study, 111In-DAC derivative accumulated 
in the right wrist of one patient, who was diagnosed a staphylococcal septic arthritis [134]. However 
the high unspecific accumulation of the 111In-DAC in non-target tissues made this tracer inappropriate 
for routine clinical application.  
The Cbl derivative 99mTc-PAMA(4)-Cbl has been recently developed and tested for imaging of 
malignancies (figure 14) [85, 135]. This conjugate carries mono-anionic ligands with a NNO donor set 
and can be efficiently labelled with [99mTc(OH2)3(CO)3]+ at yields > 95% under mild conditions (50°C, 
60 min) [135]. Importantly, 99mTc-PAMA(4)-Cbl has abolished binding to the major Cbl-transport 
protein TC II. As a consequence, significantly lower uptake in non-targeted tissue and organs was 
demonstrated in mice bearing different tumour types.  
In this study we evaluated the potential of 99mTc-PAMA(4)-Cbl for specific targeting E. coli and S. 
aureus in vitro and in a cage model of foreign body infection in mice [71]. The results were compared 
with the TCII binding molecule 57Co-Cbl.  
The infection model of subcutaneously implanted cages has been used in mice for investigating 
pathophysiology and treatment efficacy of implant-associated infection [74, 77, 104]. The kinetic and 
histology of the infected cage closely resemble a human infection of prosthesis with bacteria adherent 
to the foreign body, infiltration of granulocytes and pus. The model allows the induction of a localized 
persistent infection, characterized by a high and reproducible bacterial density of 107-109 colony 
forming units (CFU) per ml cage fluid. Cages fill with inflammatory fluid (exudate) surrounded by a 
highly vascularized tissue. To determine appropriateness of the animal model for testing radiotracers, 
the distribution of 67Ga-citrate, an agent accumulating unspecifically at the site of aseptic inflammation 
and infection, was used as control. In addition, biodistribution studies with 99mTc-DTPA were 
performed to evaluate the local vascularization of infected and non-infected cages.  
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Figure 14. Chemical structure of 99mTc-PAMA(4)-Cbl 
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3.3 Material and Methods 
       Radiolabeled tracers. 99mTc-PAMA(4)-cyanocobalamin (99mTc-PAMA(4)-Cbl) was synthesized 
and labeled as described elsewhere [85]. Five GBq of pertechnetate (1.2 ml) were added to the kit and 
heated for 20 min. The alkaline solution was neutralized with a 1 M HCl solution and additionally 
buffered 1 M MES. This solution was added to 30 µg of the lyophilized Cbl-b-(butyl)-PAMA-OEt. 
The reaction mixture was kept at 75°C for 75 min. The product was purified over a RP-8 column (X-
Terra RP8 5µm 30x150 mm) using a gradient of solvent A (10 % Ethanol, 90 % 0.1 M Acetate buffer) 
and B (70% Ethanol/water). The collected fraction of about 1 ml was diluted with phosphate buffer pH 
7.4 up to 10 ml. Aliquots of the product were distributed according to the needs. Briefly, DTPA 
(Pentacis®, IBA Molecular, Switzerland) was labeled in 10 ml of sterile 0.9% saline with 3.05 GBq of 
sodium-99mTc-pertechnetat, according to the manufacturer instructions, with a labeling efficiency of 
98.6%. 57Co-cyanocobalamin (57Co-Cbl) 0.39 MBq/50 ng/ml was purchased by MP Biomedicals 
(Diagnostic Division, Orangeburg, NY, USA). 67Gallium citrate solution for injection was purchased at 
a radiochemical concentration of 17.17 MBq/ml (Mallinckodt Schweiz AG, Radiopharma, Wollerau, 
Switzerland). 
 
       Test microorganisms. Laboratory strains E. coli (ATCC 25922) and S. aureus (ATCC 35556, 
methicillin-susceptible) were used. Bacteria were stored at -70°C using a cryovial bead preservation 
system (Microbank, Pro-Lab Diagnostics, Richmond Hill, ON, Canada). Single cryovial beads were 
cultured overnight on Columbia sheep blood agar plates (Becton Dickinson, Heidelberg, Germany).  
For in vitro binding studies, overnight cultures were prepared in snap-lid tubes from two to three 
CFU in 5 ml of a synthetic minimal medium depleted of vitamin B12. After 18-20 h incubation at 37°C 
and 200 rpm, the cultures were diluted 1:100 in the same medium and further incubated at 37°C to 
mid-logarithmic phase in sealed tubes, without shaking.  
For in vivo studies, overnight cultures were prepared in 5 ml tryptic soy broth (TSB), incubated at 
37°C without shaking for 18-20 h. Bacterial suspensions were then washed three times, re-suspended 
in 5 ml of sterile 0.9% saline and diluted. 
 
       In vitro binding studies. The in vitro binding and internalization profiles of 57Co-Cbl and 99mTc-
PAMA(4)-Cbl to E. coli and S. aureus were characterized. Stock solutions of the radiotracers were 
prepared at concentration of 0.004 MBq/ml (0.350 – 0.700 ng/ml, 0.3 – 0.5 pmol/ml) for 57Co-Cbl and 
≈1 MBq/ml (≈ 0.5 ng/ml, ≈ 0.3 pmol/ml) for 99mTc-PAMA(4)-Cbl in phosphate buffer solution (PBS). 
In competition studies, 10-fold dilutions between 3 µg/ml and 0.003 µg/ml of unlabeled Cbl (Sigma-
Aldrich, Steinheim, Germany) were added to the stock radiotracer solutions.  
Bacterial cultures in the logarithmic phase at OD600 between 0.4 and 0.6 were centrifuged and re-
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suspended in equal volume of sterile PBS. Five hundred µl of re-suspended cultures were transferred 
to Eppendorf tubes and used for the measurement of binding to viable bacteria at 37°C. For testing 
binding at 4°C, bacterial suspension in PBS were let equilibrate for 1 h at 4°C before adding of the 
tracers. In order to evaluate the binding to killed bacteria, bacterial cultures were either exposed to heat 
at 99°C or to 70% ethanol at 4°C for 30 min (E. coli) or 60 min (S. aureus). The bacterial suspensions 
were then centrifuged, re-suspended in PBS and used for further studies. The PBS resuspended heat-
killed or ethanol-killed bacteria were sampled on Columbia blood agar plates and the CFU enumerated 
after 24 h of incubation at 37°C. Colony counts remained <10 CFU/ml.  
Five hundred µl of each tracer solution was added to the 500 µl of bacterial suspensions. Binding 
assays were performed in quadruplicate vials per testing conditions. Afterwards, vials were centrifuged 
for 5 minutes at 13,500 rpm and 4°C, and pellets washed with 500 µl of cooled PBS. Supernatants and 
re-suspended pellets were counted in a multi-well NaI γ-counter (Cobra; Packard, USA) and the counts 
per minutes (CPM) recorded. The percentage of radiolabeled Cbl in the pellets was calculated as 
percentage of the CPMp/CPM0-ratio per log10 8.0 CFU/ml, where CPMp were the CPM associated to 
pellets and CPM0 the total CPM of the radiolabeled Cbl added per vial.  
In vitro binding of the radiotracers was measured after 5, 30, 60, 120 min (E. coli and S. aureus) 
and 180 min (S. aureus) of incubation at 37°C and 4°C.  
Competition binding studies were measured for cultures incubated for 1 h (E. coli) and 3 h (S. 
aureus), at 37°C and 4°C, simultaneously with 10-fold serial dilution of unlabeled Cbl and either  
57Co-Cbl or 99mTc-PAMA(4)-Cbl. In addition, competition with unlabeled Cbl was studied on bacterial 
cultures previously incubated with 57Co-Cbl or 99mTc-PAMA(4)-Cbl for 20 min (E. coli) or 2 h (S. 
aureus), and further exposed to the unlabelled-labeled Cbl mixtures for 10 min (E. coli) or 1 h (S. 
aureus). 
 
       Tissue-cage infection model in mice. C57Bl/6 mice from in-house breeding or purchased from 
Charles River Laboratories GmbH (Sulzfeld, Germany) were housed in the Animal Facility of the 
Department of Biomedicine, University Hospital, Basel, Switzerland. Experiments were performed in 
accordance to the regulations of Swiss veterinary law. The Institutional Animal Care and Use 
Committee approved the study protocol. Drinking water and standard laboratory food pellets (CR) 
were provided ad libitum. To reduce interference of high vitamin B12 level in mice, animals 
randomized for Cbl biodistribution studies were fed with a vitamin B12-reduced diet (Provimi Kliba 
AG, Kaiseraugst, Switzerland) beginning at the age of 10 weeks. At the age of 12 weeks, one sterile 
polytetrafluoroetylene (Teflon) tube (32 x 10 mm), perforated by 130 regularly spaced holes of 1 mm 
diameter, was aseptically implanted into the back of each mouse, as previously described [71, 77]. 
Each cage was weighted and numbered before implantation. Two weeks after surgery, clips were 
removed from healed wounds and sterility of the cage was confirmed by culture of aspirated cage 
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fluid. On the following day, 5 × 105 CFU of E. coli or 5 × 106 CFU of S. aureus, resuspended in 200 
µL of 0.9% saline, were injected into cages. Sterile 0.9% saline was injected in cages in animals used 
as negative controls.  
 
       Biodistribution studies. Biodistribution studies were performed in control and infected mice, 24 
h (for E. coli) or 48 h (for S. aureus) after infection. The bacterial counts in cage fluid were 
enumerated by plating 10-fold serial dilutions of cage fluid, collected on the day of tracer injection, 
and incubated for 24 h at 37°C. 
Hundred µl of isotonic saline solution containing ≈10 MBq of 99mTc-PAMA(4)-Cbl and 0.25 mg/ 
≈10 MBq of 99mTc-DTPA were injected into the lateral tail vein of each mouse, randomized for a 
minimum of nine mice per infection group (E. coli, S. aureus or sterile mice) per tracer. Distribution of 
tracers into the cage fluids was determined at 30 min, 1 h, 2 h, 4 h, 8 h, 12 h and 24 h. Distribution into 
organs, tissues and explanted cages was measured at 30 min, 4 h and 24 h after injection.  
One hundred µl of isotonic saline solution containing 1.2 - 2.3 ng/ 0.014 MBq 57Co-Cbl or 0.83 pg/ 
0.172 MBq of 67Gallium citrate were injected into the lateral tail vein of each mouse, randomized for a 
minimum of four mice per infection group (E. coli, S. aureus or control mice) per tracer. Cage fluids 
were measured at 1 h, 6 h, 24 h, 48 h and 72 h after injection. Animals were sacrificed at 72 h and the 
total-body biodistribution was determined. 
The two different experimental sets up of biodistribution were adapted to the known tracer 
binding/ non-binding to plasma protein, long persistence in organs and tissues and half-life of the 
labeling radioisotope. 
Accumulation of tracers in the cage fluid was measured by re-suspending 100 µl of aspirated fluid 
in 1 ml PBS and counted in gamma counter. The percentage of injected dose (% IDTCF/ml) was 
calculated as measured CPM normalized per 1 ml cage fluid and divided by the CPM0 of the injected 
dose. For determination of tracer biodistribution, mice were sacrificed with an intraperitoneal injection 
of 50-80 µl saline solution of pentothal (100 mg/ml). Blood was collected by cardiac puncture and 
mice were perfuse with 0.9% saline for around 5 min. Following, tissues were dissected, weighted and 
collected into test tubes for γ-counter (blood, heart, liver, spleen, stomach, kidneys, lungs, intestine, 
muscle, bone and cage). The percentage of injected dose (% IDtissue/g) was calculated as CPM 
associated to each organ divided by its weight in grams and by the CPM0 of the injected dose. 
 
       Statistical Analysis. Comparisons of in vitro binding results and in vivo biodistribution data were 
performed using the Student’s t test for continuous variables. All results were given as mean values ± 
SEM, unless otherwise indicated. P values of <0.05 were considered significant. All calculations were 
performed using Prism 4.0a (GraphPad Software, La Jolla, CA, USA).  
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3.4 Results 
 In vitro binding studies. Binding of 57Co-Cbl to viable E. coli and S. aureus was time-dependent. 
E. coli showed a rapid binding with plateau reached already 10 minutes after incubation in a 
temperature independent fashion (figure 15A). With S. aureus, 57Co-Cbl displayed a slower binding 
kinetic and no plateau was reached even after 3 h of incubation (figure 15B). In addition, the binding 
of S. aureus to 57Co-Cbl was temperature-dependent (approximately 3-fold higher at 37°C than at 
4°C). The maximum binding (mean ± SD) was measured at 37°C and was 81.7 ± 2.6% for E. coli and 
34.0 ± 6.7% for S. aureus. Binding of 57Co-Cbl to ethanol-killed E. coli was lower than the one 
observed in viable bacteria, while no binding was measured with heat-killed E. coli. In contrast, 57Co-
Cbl did not show any binding to both ethanol-killed and heat-killed S. aureus.  
Binding of 99mTc-PAMA(4)-Cbl to E. coli was low, and ranged between 0.1 and 0.3% in all the 
tested conditions (living bacteria as well as ethanol- and heat-killed bacteria, data not shown). In 
contrast, 99mTc-PAMA(4)-Cbl binding to viable S. aureus at 37°C and 3 h incubation was 11.43 ± 
1.7%, and, similarly to the one obtained with the 57Co-Cbl, it was characterized by a slow temperature-
depe ndent kinetic of binding to viable cultures and no binding to both ethanol-killed and heat-killed 
bacteria (figure 15C). 
   A 
 
   B 
 
    C 
 
Figure 15. Kinetic of vitro binding (mean CPM/CPM0% ± SD) of 57Co-cyanocobalamin to E. coli (A) and S. aureus (B) 
at different incubation times. Kinetic of vitro binding (mean CPM/CPM0% ± SD) of 99mTc-PAMA(4)-Cbl to S. aureus (C) at 
different incubation times. At 37°C (open circles, continuous line), 4°C (closed circles, dashed line), ethanol-killed bacteria 
(closed triangles, dotted line) and heat killed bacteria (closed diamonds, dashed-dotted line). Note, X- and Y- axis are scaled 
depending on the bacterium or tracer tested. 
 
57Co-Cbl could be displaced by non-radioactive Cbl in a concentration-dependent manner. A 1000-
fold concentration of unlabeled Cbl was required to show an inhibition of binding to E. coli at 37°C, 
while at 4°C and in ethanol-killed bacteria, a 10-fold cold vitamin B12 excess was sufficient to reduce 
the maximal binding to 50% (figure 16A). The S. aureus binding to 57Co-Cbl was reduced already by 
10-fold excess of unlabeled Cbl at both 37°C and 4°C; with 1000-fold excess of unlabeled Cbl, 
binding of the 57Co-Cbl was completely blocked (figure 16B). Similarly, already 1-fold of unlabeled 
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Cbl decreased the binding of 99mTc-PAMA(4)-Cbl to S. aureus (figure 16C). 
 
   A 
 
   B 
 
   C 
 
Figure 16. In vitro displacement of binding of 57Co-Cbl to viable and non-viable E. coli (A) and to S. aureus (B); in vitro 
displacement of binding of 99mTc-PAMA(4)-Cbl to S. aureus (C); viable bacteria at 37°C (empty bar) or 4°C (filled bar) and 
non-viable bacteria after ethanol fixation (diagonal hatched bars, E. coli only). Significant differences between binding in the 
absence and in the presence of cold Cbl (at different concentrations) are indicated as follow: * P < 0.05, ** P < 0.005, ***P 
< 0.0005. Note, X- and Y- axis are scaled depending on the bacterium or tracer tested. 
 
The rate of internalization of 57Co-Cbl and 99mTc-PAMA(4)-Cbl by the test microorganisms was 
measured in an in vitro competition assay (figure 17).  
 
   A 
 
   B 
 
   C 
 
Figure 17. In vitro displacement of binding by non-labeled Cbl added after pre-incubation of 57Co-Cbl and E. coli (A), 
57Co-Cbl and S. aureus (B) and of 99mTc-PAMA(4)-Cbl and S.aureus (C). Viable bacteria at 37°C (empty bars), at 4°C 
(filled bars) and non-viable bacteria after ethanol fixation (diagonal hatched bars, E. coli only). Significant differences 
between binding in the absence and in the presence of cold Cbl (at different concentrations) are indicated as follow: * P < 
0.05, ** P < 0.005, ***P < 0.0005. Note, X- and Y- axis are scaled depending on the bacterium or tracer tested. 
 
At 37°C, the binding of 57Co-Cbl to E. coli achieved after 20 minutes incubation was unchanged 
upon following addition of the unlabeled Cbl. Differently, at 4°C the binding showed a slight decrease 
when challenged with 1000-fold excess of unlabeled Cbl. Binding of 57Co-Cbl to ethanol-killed E. coli 
could be reversed by the excess of unlabeled Cbl, independently on the pre-incubation with the labeled 
Cbl (figure 17A). Similar mechanisms were also observed when S. aureus was pre-exposed to 57Co-
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Cbl or 99mTc-PAMA(4)-Cbl: the measured binding was only slightly reduced upon later challenge with 
excess of unlabeled vitamin, both at 37°C and 4°C (figure 17B and 17C). 
 
 Biodistribution studies. On the day of tracer injection, the mean ± SD bacterial counts were 9.4 ± 
0.82 log10 CFU/ml for E. coli and 6.3 ± 0.62 log10 CFU/ml for S. aureus. Three days after injection 
bacterial counts were 8.6 ± 0.2 log10 CFU/ml for E. coli and 7.8 ± 0.1 log10 CFU/ml for S. aureus. 
Spontaneous cure was not observed in any infected cage. No clinical or pathological signs of systemic 
infection were observed during organ dissection.  
The results of biodistribution studies of 99mTc-PAMA(4)-Cbl, 99mTc-DTPA, 57Co-Cbl and 67Ga-
citrate are reported in figure 18 and table 7. The highest concentration of 99mTc-PAMA(4)-Cbl was 
measured in sterile cage fluid samples at early time points after injection (figure 18A). The maximum 
99mTc-PAMA(4)-Cbl % IDTCF/ml at 30 min was 2.3 ± 0.39% for sterile cages, 1.33 ± 0.26% for 
infected cages with E. coli and 2.06 ± 0.79% for infected cages with S. aureus. Clearance from sterile 
cages was faster than in infected cages and the % IDTCF/ml was significantly lower in controls than in 
infected mice with S. aureus at 4 h (P = 0.042), and with E. coli at 8 h (P = 0.0035). 99mTc-PAMA(4)-
Cbl cage fluid/blood ratios discriminated between non-infected mice (1.53 ± 0.30) and infected mice, 
both with S. aureus (13.48 ± 2.75, P = 0.0036) or E. coli (6.31 ± 2.92, P <0.0001), at 24 h p.i. The 
tracer was rapidly cleared from blood, whereas retention of radioactivity was observed in kidneys up 
to 24 h after injection. The tracer accumulation measured in explanted cages did not significantly differ 
in infected and sterile conditions up to 4 h, but it was discriminative at 24 h for E. coli infected cages 
(P = 0.0375), with % ID/g nearly 10-fold higher than in sterile cages (table 7).  
99mTc-DTPA was used in vivo to evaluate the vascularization of sterile and infected cage fluids. 
The tracer showed an early peak in all sterile and infected cage fluids and cage tissues, ranging 
between 1.5 and 3%. Following, clearance was fast from all, sterile and infected cages and tissues 
(figure 18B).  
The distribution profile of 57Co-Cbl is shown in figure 18C. 57Co-Cbl displayed a slow penetration 
into cage fluids, with peaks achieved between 24 and 48 h in sterile and S. aureus infected cages. A 
plateau % IDTCF/ml of 57Co-Cbl into E. coli infected cages was not achieved up to 72 h. Clearance 
from cage fluids was also slow, and was similar in sterile and S. aureus infected mice up to 72 h after 
injection. Only cages infected with E. coli at 72 h showed significantly higher tracer retention in the 
cage fluid, when compared to control mice (P = 0.0032). The cage fluid/blood-ratios in control mice 
(1.40 ± 0.19) were slightly discriminative for infected cages with E. coli (1.72 ± 0.07, P=0.04), but not 
with S. aureus (1.52 ± 0.10, P >0.05). At 72 h 57Co-Cbl remained in high percentage in blood, liver 
and kidneys.  
Similarly to 57Co-Cbl, 67Ga-citrate penetration into cages was slow and peak values were achieved 
at 12 h. Clearance was faster in sterile compared to infected cages and tissues (figure 18D). The 67Ga-
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citrate retention in cage fluid samples became significantly higher in infected than in non-infected 
animals at 48 h (P=0.029) and 72 h (P=0.0006). At 72 h, accumulation became also significantly 
higher in explanted cages of infected mice with both, S. aureus (P <0.0001) and E. coli (P = 0.0019). 
The cage fluid/blood-ratio of 67Ga-citrate in non-infected animals was 1.14 ± 0.21, which was lower 
than the one measured in infected cages with E. coli (5.41 ± 0.52, P <0.0001) or S. aureus (3.56 ± 
0.87, P = 0.0003). The distribution in tissues and organs at 72 h after injection showed the highest 67Ga 
uptake into liver, kidneys and bone, while it was mostly cleared from the remaining tissues.  
 
 
A 
 
B 
 
C 
 
D 
 
Figure 18. Distribution of: (A) 99mTc-PAMA(4)-Cbl, (B) 99mTc-DTPA, (C) 57Co-caynocobalamin and (D) 67Ga-citrate 
into tissue cage fluids of sterile (dotted line), S. aureus (dashed line) and E. coli (continuous line) infected cages. Data 
represent % ID/ml of tissue fluid, expressed as means ± 1 SEM of three to five different mice. 
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Table 7. Tissue distribution after i.v. injection of 99mTc-PAMA(4)-cyanocobalamin, 99mTc-DTPA, 
57Co-cyanocobalamin and 67Ga-citrate, expressed as means (±SD) of %ID/g of tissue. 
99mTc-PAMA(4)-Cbl 99mTc-DTPA 
57Co- 
vitamin B12 
67Ga- 
citrate Organ  or tissue 
30 min 4 h 24 h 30 min 4 h 24 h 72 h 72 h 
Blood 1.79 (±0.05) 0.15 (±0.02) 0.02 (±0.10) 1.46 (±1.10) 0.02 (±0.10) 0.01 (±0.00) 2.55 (±0.35) 0.46 (±0.20) 
Heart 0.90 (±0.07) 0.33 (±0.07) 0.11 (±0.01) 0.15 (±1.10) 0.05 (±0.00) 0.01 (±0.00) 3.60 (±0.68) 1.26 (±0.10) 
Liver 5.75 (±0.86) 2.98 (±0.45) 0.92 (±0.90) 0.33 (±0.20) 0.09 (±0.00) 0.02 (±0.00) 15.78 (±1.49) 7.44 (±0.90) 
Stomach 1.73 (±0.30) 0.49 (±0.23) 0.44 (±0.14) 1.67 (±1.70) 0.05 (±1.10) 0.02 (±0.00) 4.83 (±0.85) 3.73 (±1.50) 
Spleen 1.48 (±0.18) 0.60 (±0.07) 0.22 (±0.03) 0.19 (±0.00) 0.06 (±0.00) 0.02 (±0.00) 9.07 (±1.44) 6.09 (±0.70) 
Kidneys 15.66 (±1.88) 13.47 (±1.79) 11.19 (±1.35) 3.92 (±0.80) 0.93 (±0.80) 0.15 (±0.00) 25.91 (±4.64) 10.73 (±1.30) 
Lungs 2.81 (±0.51) 1.09 (±0.26) 0.29 (±0.10) 0.40 (±0.20) 0.06 (±0.10) 0.01 (±0.00) 3.72 (±1.75) 2.11 (±0.30) 
Intestine 1.81 (±0.14) 1.52 (±0.51) 0.59 (±0.05) 0.90 (±0.50) 0.66 (±0.20) 0.02 (±0.00) 3.63 (±0.89) 2.00 (±0.40) 
Bone 0.74 (±0.05) 0.22 (±0.01) 0.08 (±0.01) 0.47 (±0.30) 0.05 (±1.50) 0.01 (±0.00) 3.93 (±0.96) 10.99 (±2.40) 
Muscle 0.38 (±0.03) 0.09 (±0.01) 0.03 (±0.01) 0.34 (±0.30) 0.06 (±1.10) 0.00 (±0.00) 1.42 (±0.20) 0.69 (±0.20) 
Cage - 
sterile 2.37 (±0.16) 0.87 (±0.25) 0.04 (±0.01) 2.88 (±0.50) 0.34 (±0.40) 0.01 (±0.00) 4.60 (±0.41) 1.45 (±0.50) 
Cage –  
S. aureus 1.80 (±0.91) 1.47 (±0.38) 0.14 (±0.06) n.d. 0.40 (±0.10) 0.05 (±0.10) 4.88 (±0.55) 9.45 (±2.30) 
Cage –  
E. coli 0.76 (±0.21) 0.84 (±0.23) 0.37 (±0.18) n.d. 0.91 (±0.15) 0.15 (±0.10) 6.52 (±0.17) 3.99 (±1.10) 
n.d. = not determined 
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3.5 Discussion 
In vitro studies demonstrated that the bacterial binding of 57Co-Cbl is specific and displaceable by 
excess of unlabelled Cbl. Higher binding avidity was measured for the E. coli strain, which also 
presented a rapid binding kinetic. On the other hand, 57Co-Cbl binding to S. aureus was slow and 
occurred exclusively with viable bacteria. When E. coli and S. aureus cultures were pre-exposed to 
57Co-Cbl only small fractions of the bound agent could be displaced by unlabeled Cbl, indicating fast 
internalization mechanisms. In agreement with an energy-dependent uptake mechanism, the 
internalized fractions were higher at 37°C than at 4°C and they were exclusively measured in viable 
bacteria.  
The in vitro binding of 99mTc-PAMA(4)-Cbl derivative to E. coli was significantly lower than for 
57Co-Cbl. Indeed, the techentium chelator of 99mTc-PAMA(4)-Cbl is linked to the b-acid of the corrin 
ring A, a functional group previously described as directly involved in the recognition by the E. coli 
outer membrane transporter BtuB [122]. Especially, the amidic and the carboxyl oxygen of the corrin 
ring A side chains are involved in an hydrogen bond with the amine groups of the residues Leucin 63 
and Alanin 231, respectively, in the BtuB binding pocket. In contrast, binding of 99mTc-PAMA(4)-Cbl 
to S. aureus was specific and only slightly lower than 57Co-Cbl. The S. aureus receptor mediating Cbl 
uptake is evidently less affected by Cbl modifications than the E. coli outer membrane transporter 
BtuB. 
In animal studies, 99mTc-PAMA(4)-Cbl showed a fast penetration into all cages, followed by a 
slower release in infected cages than in sterile ones. The tracer retention into infected fluids became 
significantly higher at 4 h p.i. for S. aureus infected mice and at 8 h p.i. for E. coli infected mice, 
which is in accordance with a lower receptor affinity of PAMA(4)-Cbl for E. coli BtuB receptors. The 
uptake measured in cage fluid of infected animals was also significantly higher for 99mTc-PAMA(4)-
Cbl than for the non-specific tracer 99mTc-DTPA. This finding supports a specific interaction with the 
colonizing bacteria, rather than a non-specific retention due to the morphological differences between 
infected and sterile cage-fluids.  
Differently, 57Co-Cbl and 67Ga-citrate had a slow kinetic of penetration into both infected and 
sterile cages, explained by their high plasma protein binding and long persistence in blood and organs 
[136, 137]. 57Co-Cbl was only partially cleared from sterile cages even after 72 h p.i. Significantly 
higher retention than in sterile mice could be observed in cages infected with E. coli at 72 h. The latter 
result is in accordance to the higher 57Co-Cbl binding measured in vitro to E. coli than to S. aureus.  
The mechanism of the 67Ga-citrate accumulation at infection/inflammation site is associated to the 
Ga (III) binding to transferrin, lactoferrin and other inflammatory proteins in inflamed sites, 
internalization into the cells with active metabolic pathway as citrate for citric acid cycle and 
presumable binding to bacterial siderophores [136, 138]. In our studies 67Ga-citrate discriminated 
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between infected and sterile cages from 48 h after injection. The retention of the tracer observed in 
bone, kidneys, liver and spleen is in accordance with data from previous publications [139].  
In our cage infection studies, the tracer accumulation was several times higher in the cage fluid 
than in the tissue surrounding explanted cages. While explanted cages contain residues of low 
vascularized tissue and adherent bacteria in a stationary-growth phase, the cage fluid represent the 
active infection site with replicating bacteria in the planktonic growth-phase and exchange with the 
blood [71]. Sterile cage fluids are characterized by a non-specific low-grade inflammatory response, 
which is induced by the presence of the foreign body [97].  
 
Conclusion 
 We demonstrated that the tissue cage mice model of infection is a valid alternative to other 
experimental models for screening radiotracers targeting infection, such as osteomyelitis, infectious 
endocarditis and infection of thigh muscles [140]. The model has also the advantage that cage fluid can 
be sampled several times during the experiment thereby avoiding sacrificing animals for each time-
point.  
Furthermore, we showed that radiolabeled Cbl has a specific, receptor-mediated binding to E. coli 
and S. aureus. In vivo, the 99mTc-PAMA(4)-Cbl derivative discriminated between infected and non-
infected cages in the mouse model within 4 to 8 h after tracer injection, and thus may become a 
selective tracer for targeting infections in humans. 
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4.1 Abstract 
Early and accurate detection of methicillin-resistant Staphylococcus aureus (MRSA) is essential in 
the hospital and the outpatient setting. Growing bacterial cultures produce an increasing heat signal 
that can be measured by isothermal microcalorimetry. We established an assay for discrimination of 
MRSA from methicillin susceptible S. aureus (MSSA) by paired incubation of batch cultures at 37°C 
in pure medium and in medium supplied with 4 µg/ml cefoxitin. Relative heat was calculated as ratio 
between the total heat measured in the presence and absence of cefoxitin after 3 h, 4 h and 5 h of 
incubation in the microcalorimeter. Twenty repeated heat measurements of the two laboratory strains 
MSSA (ATCC 29213) and MRSA (COL) served to define an optimal cutoff value of relative heat. 
Subsequently the performance of the assay was evaluated on genetically distinct clinical isolates of S. 
aureus, previously classified with an oxacillin resistance test and PBP2a latex test into MRSA (20 
isolates) and MSSA (10 isolates). Using a relative heat cutoff of 0.4, 19 of 20 MRSA (95%) and 10 of 
10 MSSA (100%) isolates were correctly identified within 5 h. The relative heat values for correctly 
identified clinical isolates of MSSA (0.35 - 0.25) and MRSA (0.74 - 0.84) did not overlap. In 
summary, we developed an assay for the detection of MRSA within 5 hours with high sensitivity, 
specificity and repeatability. With optimization of the calorimetric assay, the accuracy and speed of 
MRSA detection could be further increased and potentially extended to other organisms and 
antimicrobial substances. 
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4.2 Introduction 
Methicillin-resistant Staphylococcus aureus (MRSA) is a frequent cause of healthcare- and 
community-associated infections. Its prevalence continues to increase in hospitals as well as in the 
outpatient setting, causing a growing problem worldwide. Infection control guidelines combine active 
surveillance with elaborate patient management, including screening for MRSA, contact isolation and 
decolonization [141]. Therefore, a rapid and accurate detection of MRSA is essential for both, efficient 
prevention of spread of resistant bacteria and early-targeted treatment of infections.  
Methicillin-resistance in S. aureus is mediated by the expression of a low-affinity penicillin-
binding protein (PBP2a) encoded by the mecA gene, and conferring resistance towards most β-lactam 
antibiotics. The mecA gene is inserted in a mobile genetic element, designated staphylococcal 
chromosomal cassette mec (SCCmec) and is present in the chromosome of all MRSA isolates [142, 
143]. Thus, MRSA has been traditionally defined as S. aureus having the mecA gene and an oxacillin 
MIC >4 µg/ml [144]. Various approaches are used to discriminate between MSSA and MRSA [145-
148]. Resistance to oxacillin in staphylococci is usually screened by phenotypic tests, as recommended 
by the Clinical and Laboratory Standards Institute. In most clinical laboratories, culture methods using 
selective broth, disc diffusion or chromogenic agar are widely used. In general, a combination of 
several tests is recommended, as no single test has a 100% sensitivity and specificity for detection of 
MRSA [145]. The gold standard for the detection of MRSA when screening includes the use of 
overnight enrichment in salt-containing TSB followed by plating. However, PCR amplification of the 
mecA gene from isolated colonies is largely regarded as one of the most accurate methods to 
differentiate MRSA from MSSA. Nevertheless, PCR is more expensive. 
Calorimetry is a highly sensitive and useful technique that allows measurement of heat generated 
by biological processes in the living cell [149]. Most of medically relevant microorganisms replicate 
fast in an appropriate culture medium at 37°C, resulting in an exponential increase of heat that can be 
recorded in real-time (i.e. heat-flow curve). The time at which the growth-related heat becomes 
detectable depends on the initial number or organisms, their replication rate and the heat production 
per cell. Since bacterial growth can be inhibited by exposure to antimicrobials, isothermal calorimetry 
of bacterial culture can be used to determine antimicrobial susceptibility [150]. This principle for 
discrimination between an MRSA and MSSA has been recently demonstrated with two laboratory 
strains of S. aureus (ATCC 25923 and ATCC 43300), cultured in the presence of oxacillin or cefoxitin 
[151]. However, the performance, validity and robustness of this test system have not yet been 
evaluated with clinical isolates of S. aureus. Moreover, genetically diverse strains from various types 
of patient specimens, existing in different growth and metabolic state may have different thermogenic 
characteristics than laboratory strains. 
       Therefore, the aim of this study was to develop a calorimetric assay and optimize it for accurate 
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detection of methicillin-resistance in clinical isolates of S. aureus within few hours. First, we 
evaluated the assay repeatability in 20 consecutive measurements of two well characterized MSSA 
and MRSA reference laboratory strains. Subsequently we screened and classified, in a blinded 
manner, 30 genetically distinct clinical isolates of S. aureus (10 MSSA and 20 MRSA strains). 
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4.3 Materials and Methods 
Reference strains and clinical isolates of S. aureus. Two laboratory strains of S. aureus, ATCC 
29213 (MSSA) and COL (MRSA), were used as reference strains [152]. Ten MSSA and 20 MRSA 
clinical isolates were obtained from the clinical microbiology laboratory at our institution and used for 
testing the assay performance. The clinical strains were collected from non-related patients between 
January 2005 and December 2007, without evidence of transmission in the hospital or the community. 
These strains were isolated from intraoperative tissue specimens (n = 16), blood (n = 6), urine (n = 5) 
or respiratory aspirates (n = 3). In addition, the commonly used standard laboratory strain ATCC 
43300 (MRSA), characterized by delayed expression of methicillin resistance [153], was evaluated by 
the calorimetric assay.  
 
Susceptibility tests and PFGE-pattern analysis. The clinical isolates were screened for 
susceptibility to oxacillin using a microdilution broth procedure (Merlin Diagnostika, Bornheim-
Hersel, Germany) and interpreted in accordance with the Clinical and Laboratory Standards Institute 
[144]. Isolates showing an oxacillin MIC >4 µg/ml were confirmed by the presence of PBP2a with a 
slide latex agglutination test (Denka Seiken, Tokyo, Japan). All clinical isolates were characterized by 
PFGE-pattern analysis with Pearson correlation, using the Chef DR III system (BioRad) for separating 
SmaI-digested genomic DNA, as previously described [154]. 
The S. aureus reference strains were tested with a macrodilution broth assay to determine the MIC 
of cefoxitin in TSB, since this growth medium was used in the calorimetric assay. Two-fold dilutions 
of cefoxitin ranging from 32 to 0.5 µg/ml were prepared in TSB in glass tubes and inoculated with a 
suspension of the test strain corresponding to 1 × 105 CFU/ml. After static incubation at 37°C for 24 h, 
samples were checked for turbidity and the lowest concentration of cefoxitin which prevented visible 
growth was determined as the MIC.   
 
Calorimetry sample preparation. Every strain was tested in parallel in the presence and absence 
of cefoxitin. Discrete colonies of S. aureus freshly grown overnight on Columbia 5% sheep blood agar 
were resuspended in 0.85% sterile saline to a McFarland turbidity of 5 (corresponding to 
approximately 1 × 109 CFU/ml). Aliquots of 300 µl were inoculated into sterile calorimetry ampoules 
prefilled with 2.7 ml tryptic soy broth (TSB) with and without cefoxitin (Sigma, Buchs, Switzerland). 
A cefoxitin 100× concentrated stock solution, aliquoted and stored at -20°C, served for all the repeats 
performed. Two-fold dilutions of cefoxitin between 32 and 0.5 µg/ml were tested on both the MSSA 
and MRSA laboratory strains. The lowest concentration of cefoxitin that inhibited heat production of 
MSSA was 4 µg/ml (data not shown), which was used for subsequent calorimetric studies.  
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Calorimetric equipment and measurements. A 48-channel batch calorimeter (Thermal Activity 
Monitor, Model 3102 TAM III, TA Instruments, New Castle, DE) was used to measure the heat flow 
at 37°C controlled at ± 0.0001°C and a sensitivity of ± 0.2 µW. Heat generated by each individual 
sample was measured in an air-tightly sealed 4-ml glass ampoule and plotted over time as a heat-flow 
curve. The 1-ml gas phase in the ampoule consisted of ambient air. Ampoules were sequentially 
introduced into the calorimetry channels and remained 15 minutes in the thermal equilibration position 
before lowering to the measurement position. Heat was then measured in 10 s intervals for up to 24 h 
and plotted over time as a heat-flow (in Watts [W]). Total heat (in Joules [J]) was defined as heat 
generated until a time point and was determined by integration of the area below the heat flow-time 
curve. After measurement was completed, the content of each calorimetry ampoule was assessed for 
turbidity.  
 
Measurement of relative heat. The relative heat was defined as ratio between the total heat 
measured in the presence and absence (growth control) of cefoxitin at 3 h, 4 h and 5 h of incubation in 
the calorimeter. For reference strains, the calorimetric measurement was performed in 20 replicates on 
consecutive days in order to calculate the inter-day variation of the relative heat, expressed as mean ± 
standard deviation (SD). Based on these results, a cutoff value of relative heat was set for 
discrimination of the MSSA and MRSA reference strains. This cutoff value was then applied for the 
classification of the S. aureus clinical isolates. The relative heat of the clinical strains was measured in 
duplicates. The sensitivity, specificity, positive and negative predictive values and their 95% 
confidence intervals of the calorimetric assay for detection of methicillin resistance were calculated 
based on the results of the standard tests. The variability of the relative heat of clinical MSSA or 
MRSA isolates, reflecting the genetic diversity of these strains, was expressed as mean ± SD.  
In addition, the relative heat of the MRSA laboratory strain ATCC 43300 was measured in 20 
consecutive repeats. 
 Data analysis was accomplished using the manufacturer's software (TAM Assistant, TA 
Instruments) and Prism 4.0a (GraphPad Software, La Jolla, CA). 
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4.4 Results 
Susceptibility tests and PFGE-pattern analysis. The cefoxitin MICs in TSB of the MSSA ATCC 
29213, MRSA COL and the ATCC 43300, assessed with a macrodilution method, were 2 µg/ml, 16 
µg/ml and 8 µg/ml, respectively. Clinical isolates displayed a Pearson correlation <75% in the PFGE, 
except for two MRSA isolates (S1771 and T4545) that showed a correlation of 98.2% (figure 19).  
 
 
 
Figure 19. Pulsed-field gel electrophoresis (PFGE) pattern analysis of 10 MSSA (A) and 20 MRSA (B) clinical isolates. 
The numbers on horizontal lines indicate the percentage of homology by Pearson correlation. 
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The oxacillin MIC of all 20 MRSA clinical isolates was ≥4 µg/ml, whereas the MIC of all 10 
MSSA isolates was ≤1 µg/ml. All clinical MRSA isolates were positive for PBP2a. 
 
Relative heat of reference strains. The lowest concentration of cefoxitin that abrogated heat 
production of the MSSA was 4 µg/ml. Figure 20 shows the heat-flow (A) and total heat (B) curves in 
the presence and absence of cefoxitin 4 µg/ml of a representative measurement using both MSSA and 
MRSA COL strains. In the absence of cefoxitin, the heat-flow curve of the MSSA laboratory strain 
reached a peak earlier than the one of the MRSA, indicating faster replication of the former. However, 
the total heat signal from 8 h to 24 h of incubation was higher for the MRSA (independently on the 
presence or absence of cefoxitin) compared to the MSSA, indicating higher cumulative growth and/or 
metabolism. Cefoxitin inhibited the heat production of the MSSA during 24 h, whereas only 
insignificantly affected the heat production of the MRSA strain.  
 
  
Figure 20. Heat-flow (A) and total heat (B) of reference MSSA (ATCC 29213) and MRSA (COL) strains cultured in the 
presence of cefoxitin at 4 µg/ml (continued line) or without antibiotic (discontinued line).  
 
We then assessed the repeatability of the reference strains relative heat. Figure 21 shows 20 
repeated measurements of relative heat at 3 h, 4 h and 5 h. The standard deviation of the relative heat 
decreased with prolonged incubation time from 3 h to 5 h. The mean relative heat remained constant 
for MRSA during 5 h (1.0 – 0.97), while it decreased for MSSA from 0.28 (at 3 h) to 0.22 (at 5 h) 
(table 9). The 5 h mean relative heat (± SD) for the MSSA and MRSA reference strains was 0.22 (± 
0.05) and 1.00 (± 0.09), respectively (p <0.001). Subsequently, based on the distribution of the relative 
heat values at 5 h, a cutoff of 0.4 was chosen and used for the classification of the clinical isolates.  
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Figure 21. Relative heat distribution in 20 repeated measurements of the reference strains MSSA ATCC 29213 (open 
circles), MRSA COL (closed circles) and MRSA ATCC 43300 (closed rhombs). Relative heat is calculated as ratio between 
the total heat in the presence and the absence of 4 µg/ml cefoxitin after 3 h, 4 h and 5 h of incubation. The horizontal line 
indicates the cutoff value (0.4) of relative heat for discrimination of MSSA and MRSA. 
 
The calorimetric measurements of the MRSA strain ATCC 43300 were characterized by a delay in 
the peak heat-flow of the cultures in the presence of cefoxitin compared to the growth control. The 
magnitude of delay varied in the 20 replicates performed on different days, which affected the relative 
heat distributions around the chosen cutoff. Therefore, the calorimetric measurement for this strain was 
prolonged. The relative heat (mean ± SD) increased from 0.48 ± 0.14 (at 5 h) to 0.60 ± 0.18 (at 6 h) 
and 0.80 ± 0.15 (at 8 h) (p for trend <0.05). Of 20 MRSA ATCC 43300 replicates, the relative heat of 
≥0.4 was measured in 15, 17 and 20 replicates after 5 h, 6 h and 8 h of incubation, respectively. Thus, 
prolonged incubation time of 8 h was necessary to detect the MRSA strain ATCC 43300 with 100% 
accuracy. 
 
Relative heat of clinical isolates. Figure 22 shows the relative heat of 30 clinical isolates at 3 h, 4 
h and 5 h of incubation. Cefoxitin at 4 µg/ml inhibited the heat production and the growth of all MSSA 
clinical isolates cultures in the tested conditions, whereas no inhibition of growth occurred for any of 
the MRSA isolates. After 24 h, all MSSA and MRSA growth controls and MRSA cultures with 
cefoxitin showed turbidity, while all of the MSSA cultures with cefoxitin were clear.  
Based on the preselected relative heat cutoff of 0.4 for MSSA and MRSA discrimination, 17 of 20 
(85%) MRSA clinical isolates were correctly identified after 3 h of incubation. When the incubation 
was prolonged to 4 h and 5 h, 19 of 20 MRSA isolates (95%) were correctly identified. All MSSA 
strains had a relative heat <0.4 and were correctly identified after 4 h and 5 h of incubation. At 5 h of 
incubation, the sensitivity, specificity, positive and negative predictive values (and their 95% 
confidence intervals) for detection of methicillin resistance were 95% (89%-100%), 100% (92%-
100%), 100% (91%-100%) and 91% (85%-97%), respectively.   
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Figure 22. Relative heat distribution of 30 clinical isolates, 10 different MSSA and 20 different MRSA strains. Relative 
heat is calculated as ratio between the total heat in the presence and the absence of 4 µg/ml cefoxitin after 3 h, 4 h and 5 h of 
incubation. Open circles indicate MSSA, closed circles MRSA; the horizontal line indicated the cutoff (0.4) value of relative 
heat for discrimination of MSSA and MRSA. 
 
The mean relative heat after 3 h, 4 h and 5 h ranged between 0.35 and 0.25 for the MSSA isolates, 
whereas the ones for the MRSA ranged from 0.74 and 0.84 after 3 h and 5 h, respectively. Table 8 
summarizes the relative heat means (± SD) of correctly identified clinical isolates. 
One of the MRSA clinical isolates (T3011) showed a discrepant result. The relative heat was <0.4 
during all 5 h of incubation and the heat-flow curve showed no peak during 24 h of incubation. This 
clinical isolate was resistant to methicillin by conventional tests (oxacillin MIC ≥4 µg/ml, positive 
PBP 2a), and had a cefoxitin MIC in TSB of 4 µg/ml when tested with the macrodilution broth 
method. One MSSA isolate (T 448-1) displayed a relative heat between 0.4 and 0.5 after 3 h of 
incubation, which decreased below 0.4 thereafter. The unusually high relative heat at 3 h was due to a 
prolonged lag-phase of the isolates in the growth control. 
 
Table 8. Relative heat of two reference strains (1 MSSA and 1 MRSA) and 30 clinical isolates of S. 
aureus (10 MSSA and 20 MRSA) measured after 3 h, 4 h and 5 h of incubation. Values are means ± 
SD of 20 repeated measurements (for reference strains) and of 30 clinical isolates (10 MSSA and 20 
MRSA).  
Relative heat at different incubation time, mean (± SD) 
Strains 
3 h 4 h 5 h 
Reference strains    
MSSA (ATCC 29213) 0.29 (± 0.06) 0.23 (± 0.05) 0.22 (± 0.05) 
MRSA (COL) 1.00 (± 0.08) 0.97 (± 0.08) 0.97 (± 0.05) 
Clinical isolates    
MSSA (n = 10) 0.35 (± 0.06) 0.27 (± 0.04) 0.25 (± 0.05) 
MRSA (n = 20) 0.76 (± 0.15) 0.80 (± 0.16) 0.84 (± 0.11) 
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4.5 Discussion 
The principle of calorimetric detection of MRSA is based on paired heat measurements of S. 
aureus cultures in the presence and absence of inhibitory concentrations of β-lactam antibiotics in a 
batch calorimeter. We have chosen cefoxitin since it is a strong inducer of mecA expression in both, 
high-level and low-level methicillin-resistant staphylococci [146, 155]. Cefoxitin is less susceptible to 
penicillinases than oxacillin and other β-lactams, and is thus more appropriate for correct classification 
of MRSA, excluding the penicillinase-hyperproducing strains known as borderline oxacillin-resistant 
S. aureus (BORSA) [145]. In our calorimetric MRSA assay, we used cefoxitin at 4 µg/ml since this 
was the lowest concentration that completely inhibited heat production of the MSSA reference strain 
and showed only a slight delay of the heat signal of both MRSA reference strains (COL and ATCC 
43300). Thus, cefoxitin 4 µg/ml was used in subsequent studies for discrimination of S. aureus clinical 
isolates.  
The heat measurements were used to calculate the relative heat, which takes into consideration the 
strain specific differences in replication rate and minimize the inter-day variability. The assay was 
highly repeatable when evaluated on 20 consecutive measurements of the reference strains MSSA 
ATCC 29213 and MRSA COL. In the subsequent testing using clinical isolates, we evaluated the 
effect of genetic variability on the relative heat. The variability of relative heat for MSSA was similar 
to the one of the MSSA laboratory strain (SD of relative heat was 0.04 – 0.06), indicating high 
robustness of the method towards the susceptible strains. On the contrary, the SD of the relative heat of 
the MRSA clinical isolates ranged between 0.11 – 0.16, reflecting the different phenotypic expression 
of methicillin-resistance in the 20 MRSA clinical isolates. In a previous study, the majority of MRSA 
isolates showed a heterogeneous expression of methicillin-resistance, which were categorized into 4 
phenotypic expression classes; class 1 was the most hetero-resistant (≤1 in 108 cells expressing high-
level resistance) and class 4 was homogeneous (≥1 in 102 resistant cells) [156]. Therefore, 
susceptibility results may be misinterpreted, making detection by phenotypic tests challenging [155, 
157, 158]. In our assay, high-density bacterial inocula were used to allow early heat measurements and 
to increase the chances of including highly resistant cells in the detection of heterogeneous MRSA 
populations [145, 159].  
Using the relative heat cutoff of 0.4, clinical isolates showed a sensitivity of 95% (19 of 20 
correctly identified MRSA) and a specificity of 100% (10 of 10 correctly identified MSSA) after 5 h of 
incubation. One MRSA isolate (T 3011) with a relative heat <0.4 had a low growth rate in the presence 
of cefoxitin during 24 h. This isolate had a cefoxitin MIC in TSB of 4 µg/ml, while the MIC of the 
MRSA reference strains, was 1- or 2- fold higher. The lower cefoxitin MIC value could be explanatory 
for the growth inhibition occurred in the cefoxitin cultures of the clinical isoate T 3011. The MRSA 
ATCC 43300, known to express a heterogeneous methicillin resistance, displayed high variance of 
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relative heat up to 6 h, with heat ratios <0.4 in 3 of 20 repeated measurements. All measurements led 
to correct classification of MRSA if the incubation was prolonged to 8 h.  
In conclusion, in this report we described a calorimetric assay for rapid and accurate discrimination 
of clinical MSSA and MRSA isolates, which is highly repeatable, easy to set up, suitable for 
automation and computer-generated results. The hands-on preparation time is around 15 min and the 
consumables are inexpensive (two disposable 4 ml glass ampoules with rubber-aluminum lids and 6 
ml standard culture medium per test isolate). A prerequisite for a valid test result is normal growth of 
the isolate in the absence of antibiotic (growth control). With optimization of the calorimetric assay, 
the accuracy and speed of MRSA detection could be further increased and potentially extended to 
other organisms and antimicrobial substances. However, a validation study with additional clinical 
strains from different body sites is needed before introduction in the clinical routine.  
CHAPTER 5 
 95 
 
Chapter 5  
 
In Vitro Activity of Gallium Maltolate against Staphylococci in 
Logarithmic, Stationary and Biofilm Growth-Phase: Comparison 
of Conventional and Calorimetric Susceptibility Testing 
Chapter 5 
 
Daniela Baldoni1, Andrea Steinhuber1, Werner Zimmerli2, Andrej Trampuz1,3 
 
1Infectious Diseases, Department of Biomedicine, University Hospital, Basel, Switzerland 
2University Medical Clinic, Kantonsspital, Liestal, Switzerland 
3Infectious Diseases Service, Department of Internal Medicine, University Hospital and University 
of Lausanne, Lausanne, Switzerland 
 
 
Running title: Antimicrobial activity of gallium maltolate 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: Antimicrobial Agents and Chemotherapy, 2010 Jan 
Received 25 May 2009/Returned for modification 7 September 2009/Accepted 29 September 
2009. 
CHAPTER 5 
 96 
5.1 Abstract  
Ga3+ is a semi-metal element competing for iron-binding sites of transporters and enzymes. We 
investigated the activity of gallium maltolate (GaM), an organic gallium salt with high solubility, 
against laboratory and clinical strains of methicillin-susceptible and methicillin-resistant S. aureus 
(MSSA, MRSA) and S. epidermidis (MSSE, MRSE) in logarithmic or stationary phase and in biofilm. 
The MICs of GaM were higher for S. aureus (375-2000 µg/ml) than S. epidermidis (94-200 µg/ml). 
Minimal biofilm inhibitory concentrations (MBIC) were 3000-≥6000 (S. aureus) and 94-3000 µg/ml 
(S. epidermidis). In time-kill studies, GaM exhibited a slow and dose-dependent killing mechanism, 
with maximal killing at 24 h against S. aureus of 1.9 (MSSA) and 3.3 log10CFU/ml (MRSA) at 3× 
MIC, and 2.9 (MSSE) and 4.0 log10CFU/ml (MRSE) against S. epidermidis at 10× MIC. In 
calorimetric studies, growth-related heat production was inhibited by GaM sub-inhibitory 
concentrations and minimal heat inhibitory concentrations (MHIC) were 188-4500 (MSSA), 94-1500 
(MRSA), and 94-375 µg/ml (MSSE and MRSE), correlating well with the MIC values. Thus, 
calorimetry was a fast, accurate and simple method, useful to investigate antimicrobial activity at sub-
inhibitory concentrations. In conclusion, GaM exhibited activity against staphylococci in different 
growth phases, including in stationary phase and biofilms, but high concentrations were required.       
These data supports the potential use of GaM for topical use, including treatment of wound infections, 
MRSA decolonization and implant coating. In addition, GaM at sub-inhibitory concentrations may 
show efficacy against staphylococcal infections, alone or probably tested in combinations to standard 
antimicrobials.  
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5.2 Introduction 
Staphylococcus aureus continues to represent the major cause of infection in the outpatient and 
healthcare settings. The therapeutic options for multiresistant strains, including methicillin-resistant S. 
aureus (MRSA) strains, are limited [160, 161]. In addition, coagulase-negative staphylococci often 
cause chronic low-grade infections associated with implanted devices, on which they can grow 
embedded in a protective extracellular matrix, known as a biofilm [14]. In the biofilm, bacteria can 
persist in a low metabolic, stationary growth-phase, in which they resist the killing by the host immune 
system and antimicrobials [38, 162]. Both the spread of multi-resistant staphylococci and the increased 
use of temporary implants (vascular catheters, pins from external fixation devices) and permanent 
implants (e.g. joint prosthesis, breast implants, cardiac or brain pacemakers), drive the need for new 
antimicrobial agents for innovative therapeutic strategies [39, 160, 163, 164].  
The antimicrobial activity of different inorganic salts, such as sodium metabisulfite and copper 
silicate, was demonstrated in vitro against planktonic and adherent staphylococci [165, 166]. Gallium 
(Ga3+) is a semi-metal element. The proposed mechanism of action is its competition for Fe3+ in the 
binding to proteins and chelators. Ga3+ is virtually irreducible under physiological conditions, while 
Fe3+ participates to redox reaction in which is readily reduced to Fe2+. Thus, when replacing Fe3+, Ga3+ 
could interfere with bacterial DNA and protein synthetic pathways by blocking redox reactions 
depending on iron electron acquisition [136].  
Staphylococci are known to be avid of iron. Previously, several mechanisms of iron recruitment 
have been studied and described as essential virulence factors [167-171], as consequence, iron uptake 
and metabolism may constitute a potential target to combat staphylococcal infections.  
 
In the form of nitrate salt, gallium demonstrated bactericidal in-vitro activity against planktonic 
and adherent Pseudomonas aeruginosa and Burkholderia cepacia [172, 173]. Gallium maltolate 
(GaM), a high soluble gallium formulation [174], was effective in vivo against P. aeruginosa and S. 
aureus infection after topical subcutaneous injection in thermally injured mice [175]. However, to our 
knowledge, the in-vitro activity of gallium against staphylococci has not yet been characterized. 
Gallium was chosen among elements with antibacterial properties due to its theoretical mechanism of 
action (i.e. competition for Fe3+), selective against bacteria (with low predicted tissue toxicity), in-vitro 
data on other gram-negative bacilli and previous experience in humans by using it for diagnostic 
purposes in nuclear medicine. 
 
We investigated the in vitro activity of GaM against staphylococci in the logarithmic, stationary 
phase and biofilms. Standard in vitro tests for determination of MIC, minimal bactericidal 
concentration (MBC) in the logarithmic and stationary growth phase [176] and activity against biofilm 
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were used. To better investigate the activity of GaM at sub-inhibitory concentrations, we studied its 
effect on bacterial heat production in cultures exposed to GaM using a newly developed calorimetric 
assay. Antimicrobial assays were performed in a synthetic iron-limited medium. The aim of the study 
was to investigate the potential use of GaM for systemic or topical application against staphylococci, 
including treatment of wound infections, MRSA decolonization and the coating of implants. 
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5.3 Materials and methods 
Laboratory bacterial strains. S. aureus ATCC 29213 (MSSA), S. aureus ATCC 43300 (MRSA), 
S. epidermidis 1457 (MSSE) and S. epidermidis B3972 (MRSE) were used. Bacteria were stored at -
70°C using a cryovial bead preservation system (Microbank, Pro-Lab Diagnostics, Richmond Hill, 
ON, Canada). Single cryovial beads were cultured overnight on Columbia sheep blood agar plates 
(Becton Dickinson, Heidelberg, Germany). Inocula were prepared from the sub-culture of two to three 
colonies resuspended in trypticase soy broth (TSB) and incubated overnight at 37°C without shaking. 
The overnight cultures were diluted with the appropriate medium to an inoculum of ≈1 × 106 CFU/ml. 
 
Clinical isolates. For susceptibility screening, 20 genotypically distinct clinical isolates, 5 per 
bacterial susceptibility group, were used. The clinical strains were collected from non-related patients 
admitted to our hospital (University Hospital, Basel) between January 2005 and December 2008, 
isolated from intraoperative tissue specimens (n = 3), blood (n = 6), urine (n = 8) or synovial fluid (n = 
3). The S. aureus isolates were characterized by PFGE-pattern analysis with Pearson correlation using 
the Chef DR III system (BioRad) for separating SmaI-digested genomic DNA, as previously described 
[154], displaying a Pearson correlation <75% [177]. The clinical isolates were screened for 
susceptibility to methicillin using a microdilution broth procedure (Merlin Diagnostika, Bornheim-
Hersel, Germany), interpreted in accordance with the Clinical and Laboratory Standards Institute. 
Inocula of clinical isolates were prepared from bacterial overnight cultures on Columbia sheep blood 
agar plates resuspended to a McF of 0.5, and further diluted in the appropriate medium to inocula of 
≈1 × 106 CFU/ml. 
 
Chemicals. Susceptibility assays were performed in iron-limited media, including RPMI 1640 
(Invitrogen, Basel, Switzerland) supplemented with 5% pyruvate and 5% glutamate (RPMI), or 0.01 M 
phosphate-buffered saline (PBS), pH 7.4. GaM was kindly provided by Titan Pharmaceuticals (South 
San Francisco, CA, USA). Stock solutions were freshly prepared and sterile filtered on the day of the 
assays. 
 
Doubling time. Bacterial doubling time of laboratory strains in Mueller-Hinton broth (MHB) and 
RPMI were investigated. 1:100 diluted overnight cultures were further grown in MHB and in RPMI 
until mid-logarithmic phase. From the mid-phase each culture was diluted 1:100 (S. aureus) or 1:10 (S. 
epidermidis) in either MHB or RPMI and incubated at 37°C at 180 rpm (for MSSA, MRSA, MRSE) 
or without shaking (for MSSE to avoid clot formation induced by shaking). OD600 was measured every 
30 minutes during 10 h (MSSA, MRSA, MRSE) or every 60 minutes during 12 h (MSSE). The log2 of 
OD600 values were plotted versus time and the linear regression equation determined for the 
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logarithmic growth phase. The inverse of the slope was defined as the bacterial doubling time (in 
minutes). Experiments were performed in triplicate and results expressed as mean ± SD. Comparisons 
in doubling time were performed using the Student’s t-test. Differences were considered significant 
when P values were <0.05.  
 
Antimicrobial susceptibility of planktonic bacteria. The MIC and MBC in the logarithmic 
growth phase (MBClog) were evaluated in RPMI with a broth macrodilution method according to the 
Clinical Laboratory Standards Institute (CLSI) (formerly the NCCLS) guidelines [176]. The MBC in 
the stationary growth phase (MBCstat) was assayed in PBS, as previously described [41]. In this 
medium, bacterial counts remained within ± 15% of the initial inoculum within 24 h. Ten 2-fold serial 
dilutions were prepared from GaM stock solution of 6000 µg/ml. The MIC was defined as the lowest 
GaM concentration that prevented visible bacterial growth and the MBC as the lowest GaM 
concentration that reduced the CFU/ml by ≥ 99.9% of the initial inoculum. MIC and MBC of 
laboratory strains were repeated three times and results were expressed as medians. Following, the 
MIC values of GaM against the clinical isolates were determined. 
 
Antimicrobial susceptibility of biofilm bacteria. The activity of GaM against staphylococcal 
biofilms was tested with a broth microdilution assay, as previously described [178, 179] and modified 
by Sandoe et al. [82]. Briefly, 200 µl of overnight cultures diluted in 1% glucose supplemented RPMI 
(inoculum ≈1 × 106 CFU/ml) were distributed into 96-wells microtiter plates (Nuclon Delta, Nunc). 
Frame wells were filled with medium only, serving as negative growth control. Biofilms were formed 
on pegs of modified polystyrene microtiter lids (TSP system, Nunc, Roskilde, Denmark), immersed 
into the wells and cultured for 20 h at 37°C. Following, pegged lids were rinsed with PBS and 
transferred to a second microtiter plate (antimicrobial susceptibility plate) containing 2-fold serial 
dilutions of GaM between 6000 µg/ml and 10 µg/ml, six wells were filled with medium only and 
served as positive growth control. Plates were incubated for further 20 h at 37°C. On the third day, 
peg-lids were rinsed again with PBS and transferred to recovery plates, where 200 µl of RPMI had 
been distributed to all wells. Plates were shaken for 5 minutes at 250 rpm to enhance bacterial re-
growth from biofilms and incubated at 37°C without shaking. After 48 h of incubation bacterial 
growth occurring on the recovery plates was measured as turbidity using an ELISA-reader at OD600. 
The lowest concentration of GaM, which prevented biofilm re-growth in the recovery plate, was 
defined as the minimal biofilm inhibitory concentration (MBIC). Experiments were performed in 
triplicate, four times in different days and results were reported as median values. Screening of clinical 
isolates was performed in triplicate and MBIC medians reported.  
 
As control, strain-dependent biofilm formation was evaluated as previously described [180, 181]. 
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Briefly, 200 µl of bacterial inocula, prepared as described above, were distributed in six replicates in 
polystyrene, 96-well, flat-bottomed tissue culture plates (Becton Dickinson, Falcon, France). Plates 
were incubated for 20 h at 37°C. Following, medium was gently aspirated from each well. Bacteria 
adhering on the plate bottoms were washed with 200 µl PBS and air dried for around 2 h. Biofilms 
were stained for 15 minutes with a solution of 0.5% crystal violet in 70% methanol. Then, the stain 
was removed and wells were rinsed twice with 300 µl of PBS. Stained adherent bacteria were re-
suspended from each well with 200 µl of 70% methanol and transferred to a new plate. OD490 of the 
latter was measured, each value was subtracted by the mean absorbance of the blank wells (negative 
control) and the mean of 6 well per each strain was calculated. The value derived from three standard 
deviations above the mean OD490 of the blank was used as breakpoint for classifying the strain as able 
or not able to form biofilms in the in vitro tested conditions [180]. 
 
Time-kill studies. Killing profile of four GaM concentrations were assessed in parallel with 
growth controls against laboratory strains. Samples were incubated at 37°C without shaking during 24 
h (for S. aureus) and 48 h (for S. epidermidis). Bacterial concentrations (CFU/ml) were determined by 
plating aliquots of appropriate dilutions on Muller-Hinton agar plates at 0 h, 2 h, 4 h, 6 h, 8 h, 24 h and 
48 h (the 48 h time points was tested only with the S. epidermidis strains). Bacterial colonies were 
enumerated after 24 h incubation at 37°C. Each strain was tested three times on different days and 
results were analyzed using GraphPad Prism 4.0 (GraphPad Software, La Jolla, CA). Results were 
plotted as means ± SD of reduction of log10 CFU/ml, defined as log10 (CFU/ml)t - log10 (CFU/ml)0, 
over time (t). 
 
Inhibition of growth-related heat production by GaM. Viable and growing microorganisms 
produce heat, which can be measured in a calorimeter [182, 183]. This property allows measuring the 
antimicrobial potency against bacterial growth [183]. We evaluated the inhibition of bacterial heat 
production at different concentrations of GaM during 24 h. From a GaM stock solution of 6000 µg/l, 
nine 2-fold serial dilutions were performed in RPMI and 2 ml were transferred into sterile 4-ml glass 
ampoules. Ampoules were then inoculated under meniscus with the adjusted bacterial cultures, air-
tightly sealed and sequentially introduced into the calorimetry channels.  
 
A 48-channel batch calorimeter (Thermal Activity Monitor, Model 3102 TAM III, TA Instruments, 
New Castle, DE) was used to measure the heat flow at 37°C controlled at ± 0.0001°C and an analytical 
sensitivity of ± 0.2 µW. Heat-flow (in µWatts) was measured for 24 h in 10 s intervals. The curve of 
total heat (in Joules) versus time was determined by integration of the area below the heat flow-time 
curve. After the heat measurement was completed, the content of each ampoule was assessed for visual 
growth. The minimal heat inhibitory concentrations (MHIC) was defined as the lowest GaM 
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concentration leading to a growth-related heat production < 0.25 Joule after 24 h. Bacterial cultures 
without GaM were used as positive (growth) controls. Experiments were performed in duplicates, for 
two times in different days, for the laboratory strains. Following, the clinical isolates were screened 
and the MHIC values collected. 
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5.4 Results 
Doubling time in iron-limited medium. The replication of S. epidermidis was slower than of S. 
aureus laboratory strains, with doubling times in RPMI (mean ± SD) of 46 ± 10 min (MSSA) and 55 ± 
8 min (MRSA) versus 114 ± 27 min (MSSE) and 108 ± 17 min (MRSE). No significant differences in 
doubling time were observed between strains cultured in RPMI or MHB (P > 0.05). 
 
Antimicrobial susceptibility of planktonic bacteria. Table 9 summarizes the in vitro 
susceptibility of GaM against laboratory strains. Against the laboratory S. aureus strains, MIC values 
were about 10-fold higher than the S. epidermidis strains. GaM in concentrations up to 6000 µg/ml 
was not bactericidal against MSSA, whereas a 3-log10 CFU reduction was reached against the other 
strains. MBClog values were between 6× and 20× the respective MICs. In the stationary phase GaM 
exhibited bactericidal activity only against S. epidermidis; the MBCstat was 60× the MIC for the MSSE 
and 7.5× the MIC for the MRSE. Table 10 shows the results for clinical isolates. GaM inhibited 
growth of all tested strains. Clinical isolates of MSSA and S. epidermidis exhibited similar MIC values 
to the correspondent laboratory strain, whereas MRSA isolates had median MIC values about 4-times 
lower than the correspondent laboratory strain.  
 
Antimicrobial susceptibility of biofilm bacteria. In biofilm susceptibility studies, GaM MBIC 
values for laboratory strains were 3× MIC for MSSA, 6× MIC for MRSA and 2.8× MIC for MSSE and 
MRSE (table 9). The biofilm formation on pegged lids was confirmed by growth of positive control 
biofilm cultures in the recovery plates. Three of the five MSSA clinical isolates screened for MBIC 
(table 10) resulted in MBIC >6000 µg/ml. The MRSA isolates displayed better susceptibility, with 2 
strains only having MBIC >6000 µg/ml. The median MBICs for the MSSE and MRSE isolates were 
respectively 375 and 750 µg/ml, with all isolates displaying biofilm susceptibility to GaM. The strain 
DJ192 did not grow in the recovery plate during the 48 h of incubation both in wells with and without 
GaM. Therefore, for this strain, MBIC value could not be measured.  
 
Both laboratory strains and clinical isolates resulted positive for biofilm formation after crystal 
violet staining of bacteria adhering on the bottom of polystyrene 96-well tissue culture plates. The 
OD490 breakpoint was 0.08, calculated as three standard deviations (3× 0.009) above the mean OD490 
(0.053) of the blank wells. The OD490 means ± SD (laboratory strain and clinical isolates) were 0.104 ± 
0.044 (MSSA), 0.184 ± 0.074 (MRSA), 0.244 ± 0.077 (MSSE) and 0.187 ± 0.070 (MRSE).  
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 Time-kill studies. Figure 23 shows the reduction log10 CFU/ml of the laboratory strains in the 
presence of GaM over 24 h (S. aureus) or 48 h (S. epidermidis) of incubation.  
 
 
Figure 23. Time-kill curves of GaM in RPMI against MSSA (A), MRSA (B), MSSE (C) and MRSE (D). Values are 
mean CFU/ml ± SD of three measurements. GC indicates growth controls performed in RPMI without GaM. Horizontal 
dotted line indicates the 3-log10 CFU/m reductions. Note that the X- and Y-axis scales are adapted for S. aureus and S. 
epidermidis. 
 
For all tested strains, GaM inhibited bacterial growth in a time-dependent and dose-dependent 
manner. At sub-inhibitory concentrations, only a slight reduction and a delay in net bacterial counts 
were detected when compared to growth controls. Against MSSA and MRSA the highest killing after 
24 h, achieved with GaM at 3× MIC, was by 1.9 and 3.3 log10 CFU/ml, respectively. Against the 
MSSE GaM at 10× MIC reduced bacterial viability by 2.9 and 4.4 log10 CFU/ml after 24 h and 48 h, 
respectively, while MRSE was reduced by 4.0 log10 CFU/ml already at 24 h. A bactericidal activity 
was demonstrated against the MRSA, MSSE and MRSE, and was time-dependent. 
 
Inhibition of growth-related heat production. Figure 24 shows representative calorimetry curves 
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of total heat generated by each of the laboratory strains cultured at 37°C in RPMI over 24 h. The 
inhibition of growth-related total heat produced by the strains in the presence and absence of GaM was 
measured. The total heat generated over 24 h without GaM was similar for all strains and ranged 
between 4 and 5 Joules. The curves of laboratory strains were analyzed and followed a two-phase 
course: an initial rapid increase of heat, corresponding to the logarithmic growth phase, occurred in 
MSSA between 0 and 4 h, in MRSA and MSSE between 3 and 7 h, and in MRSE between 4 and 9 h of 
incubation. In the second phase, the increase of heat production was slower but continuous up to 24 h 
(except for MSSA, which reached a plateau at ≈16 h of incubation).  
 
  
  
Figure 24. Calorimetry curves representing the total heat generated by MSSA (A), MRSA (B), MSSE (C) and MRSE (D) 
at 37°C for 24 h in presence of 2-fold dilutions of GaM in RPMI. Dashed lines represent growth controls without GaM, 
continuous lines indicate GaM concentrations below the MIC and dashed-dot lines indicate GaM concentrations above the 
MIC of the corresponding test strain. NOTE: GC = growth control;  = 23 µg/ml,  = 46 µg/ml,  = 94 µg/ml,  = 188 
µg/ml,  = 375 µg/ml,  = 750 µg/ml,  = 1500 µg/ml,  = 3000 µg/ml,  = 6000 µg/ml GaM. Note Y-axis scales are 
adapted for S. aureus and S. epidermidis. 
 
At sub-inhibitory concentrations, GaM reduced the production of heat in a dose-dependent manner, 
in comparison to the growth controls. Cultures associated to a 24 h total heat <0.25 Joule did not 
display any visual turbidity and thus 0.25 Joule was used as total heat breakpoint for MHIC evaluation. 
The MHICs of laboratory and clinical isolates (table 9 and 10) correlated with the MICs for all strains, 
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with values ± 4× the respective MICs, except for one MSSE isolate (DJ134) where the MHIC was 6× 
higher than the MIC value.  
 
Table 9. In-vitro susceptibility of 4 laboratory strains of staphylococci against GaM (in the 
logarithmic, stationary and biofilm growth phase) with corresponding calorimetry parameters. 
Organism (strain) 
MIC 
(µg/ml) 
MBCloga 
(µg/ml) 
MBCstatb 
(µg/ml) 
MBICc 
(µg/ml) 
MHICd 
(µg/ml) 
MSSA (ATCC 29213) 2000 >6000 >6000 6000 4500 
MRSA (ATCC 43300) 1000 6000 >6000 6000 1500 
MSSE (1457) 100 2000 6000 280 375 
MRSE (B3972) 200 1500 1500 560 375 
aMBClog, minimal bactericidal concentration in the logarithmic growth phase. 
bMBCstat, minimal bactericidal concentration in the stationary growth phase. 
cMBIC, minimal biofilm inhibitory concentration. 
dMHIC, minimal heat inhibitory concentration. 
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Table 10.  In-vitro susceptibility of 20 clinical isolates of staphylococci against GaM (in the 
logarithmic and biofilm growth phase) with corresponding calorimetry parameters. 
Organism 
MIC 
(µg/ml) 
MBICa 
(µg/ml) 
MHICb 
(µg/ml) 
MSSA    
 B14097/07 750 >6000 375 
 T6477/05 1500 6000 750 
 S2626/07 1500 >6000 375 
 T642/05 750 >6000 188 
 B10984/07 750 3000 188 
MRSA    
 T3011 375 >6000 94 
 U8927-1/07 375 3000 94 
 M1082/07 375 3000 94 
 S1771.07 375 6000 375 
 B12570/07 375 >6000 375 
MSSE    
 DJ 67 188 1500 188 
 DJ 134 188 3000 1500 
 DJ 169 188 750 94 
 DJ 198 94 3000 94 
 DJ 254 94 3000 188 
MRSE    
 DJ 146 94 3000 188 
 DJ 192 94 -c 375 
 B 102285 94 94 375 
 B 102534 188 750 375 
 B 103110 94 750 188 
aMBIC, minimal biofilm inhibitory concentration. 
bMHIC, minimal heat inhibitory concentration. 
cBiofilm susceptibility not available due to absent growth in the growth control. 
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5.5 Discussion 
Gallium exhibits its antimicrobial action by targeting iron metabolism and interfering thereby with 
an important virulence factor for infection and persistence of staphylococci [170, 171]. We evaluated 
the antimicrobial activity of gallium in the form of GaM against four staphylococci laboratory strains 
and twenty distinct clinical isolates. Assays were performed in a defined synthetic iron-limited 
medium (RPMI). By determination of bacterial doubling time, we could assume the appropriateness of 
the iron-restricted medium RPMI to be used instead of the standard medium (MHB) for susceptibility 
testing. Indeed, in our assay RPMI supported staphylococcal growth as well as MHB. 
 
Against laboratory strains and using the criteria applied for conventional antimicrobial substances, 
S. epidermidis was more susceptible to GaM than S. aureus. Moreover, bactericidal activity was 
detected against staphylococci in logarithmic phase, except for MSSA, and also against S. epidermidis 
in the stationary growth-phase. The time-kill studies demonstrated that the killing mechanism of GaM 
occur in a time-dependent and dose-dependent fashion. Since S. epidermidis strains had longer 
doubling times than S. aureus (both in RPMI and MHB), time-kill studies were prolonged to 48 h for 
MSSE and MRSE. Indeed, killing of MSSE was improved at 48 h compared to 24 h. A higher killing 
was achieved with GaM in time-kill curves than with the MIC/MBC macrodilution assay. This 
discrepancy was mainly observed with the MRSA strain, where a 3-log reduction was achieved in the 
time-kill curves already at the MIC value. The reason of the better killing action may be correlated to 
the different conditions in which bacteria are cultured for the MBC test and for the kill curves. The 
MBC assay requires incubation in static conditions, whereas killing curves are performed with 
repetitive shaking at each sampling time point. By shaking, bacteria get access to more oxygen in the 
growth medium and thus, they may maintain a better metabolic activity also at late times of 
incubation. Since GaM displayed a better efficacy against replicating bacteria, in killing curves the 3-
log reduction may occur already at concentrations lower than the MBC.  
 
The activity of GaM against biofilm embedded bacteria was measured by determining the MBIC 
for laboratory strains and 20 clinical isolates. All isolates were classified as able to form biofilms by 
the crystal violet staining assay. However, one of the MRSE isolates could not be further evaluated for 
biofilm susceptibility to GaM because of the lack of re-growth from sub-cultured pegged lids. For the 
remaining strains, GaM exhibited inhibitory activity against biofilms with MBIC values between 3000 
and 6000 µg/ml (for S. aureus) and between 280 and 3000 µg/ml (for S. epidermidis). In 5 of 10 tested 
clinical S. aureus isolates no inhibition of biofilms were observed up to 6000 µg/ml.  
 
By measurement of bacterial heat production, we compared this novel calorimetric method with 
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conventional susceptibility tests and we evaluated the effect on bacterial metabolism and growth of 
GaM at sub-inhibitory concentrations. The concentrations of GaM for heat inhibition correlated well 
with MICs, confirming the direct link between heat measurement and bacterial growth. Eventual 
discrepancies in absolute values of MHIC and MIC could possibly have occurred because of the 
culture conditions. Indeed, for heat measurement, bacteria were cultured in sealed ampoules with 
limited oxygen availability, while broth macrodilution assays were performed in snap-lid tubes with 
sufficient oxygen availability. However, differences of 2 to 4-fold may still represent good correlation 
of the two parameters. Thus, we suggest the potential use of calorimetry as a fast, accurate and simple 
method to investigate antimicrobial activity of new substances at sub-inhibitory concentrations. The 
major finding was that, in accordance to the results of the kill studies performed, also the GaM 
mechanism of inhibition of heat production was dose-dependent and time- dependent, and a reduction 
in heat production comparing to controls was measured up to 23 µg/ml of GaM.  
 
The in vitro activity of GaM against laboratory and clinical strains of staphylococci occurred at 
MICs ranging from 100 to 2000 µg/ml. After a single oral dose of 500 mg of GaM in three healthy 
volunteers, the median peak concentration of gallium in serum was 1 µg/ml, which is 100- to 2000-
fold lower than the measured MICs [174]. These data suggest that, systemic application of GaM will 
probably not achieve therapeutic concentrations in humans. However, a subcutaneous injection of 
GaM (25 mg/kg) was highly protective against a wound infection induced with P. aeruginosa and S. 
aureus in a thermally injured infection mouse model [175]. The latter study would support, together 
with our in vitro results, the potentials of GaM for local administration in the prevention and treatment 
of wound infections. Moreover, due to its activity at sub-inhibitory concentrations, low doses of GaM 
may be investigated in combination with standard antimicrobials to elucidate potential synergistic 
effects or prevention of resistance development. Also, GaM is a promising candidate for topical use, 
where high local concentrations can be achieved. In the view of the increasing resistance of S. aureus 
to oxacillin and mupirocin, GaM may become an option (alone or in combination with other agents) 
for skin and mucosal decolonization. Finally, the displayed anti-biofilm activity may suggest the 
gallium use in coating of implants as preventive strategy against staphylococcal adherence. Animal 
and clinical studies are needed to further characterize the therapeutic and preventive potentials of 
gallium, followed by toxicity studies. A safe and efficacious Ga-containing formulation to treat a 
broad spectrum of biofilm-forming or multi-resistant microbes would be highly desirable.  
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6.1 Abstract 
We investigated the activity of linezolid, alone and in combination with rifampin (rifampicin), 
against a methicillin-resistant Staphylococcus aureus (MRSA) strain in vitro and in a guinea pig model 
of foreign-body infection. The MIC, minimal bactericidal concentration (MBC) in logarithmic phase 
and MBC in stationary growth phase for linezolid, rifampin and levofloxacin were 2.5, >20 and >20 
µg/ml, respectively, for linezolid; 0.01, 0.08 and 2.5 µg/ml, respectively, for rifampin; and 0.16, 0.63 
and >20 µg/ml, respectively, for levofloxacin. In time-kill studies, bacterial re-growth and 
development of rifampin resistance were observed after 24 h with rifampin alone at 1× or 4× MIC, and 
were prevented by the addition of linezolid. After the administration of single intraperitoneal doses of  
25, 50 and 75 mg/kg of body weight, linezolid peak concentrations of 6.8, 12.7 and 18.1 µg/ml, 
respectively, were achieved in sterile cage fluid at ≈3 h. The linezolid concentration remained above 
the MIC of the test organism during 12 h with all doses. Antimicrobial treatments of animals with cage 
implant infections were given twice daily for 4 days. Linezolid alone at 25, 50 and 75 mg/kg reduced 
the planktonic bacteria in cage fluid during treatment by 1.2-1.7 log10 CFU/ml; only linezolid at 75 
mg/kg prevented bacterial re-growth 5 days after end of treatment. Linezolid used in combination with 
rifampin (12.5 mg/kg) was more effective than linezolid used as monotherapy, reducing the planktonic 
bacteria by ≥3 log10 CFU (P <0.05). Efficacy in eradication of cage-associated infection was achieved 
only when linezolid was combined with rifampin, with cure rates being between 50% and 60%, 
whereas the levofloxacin-rifampin combination demonstrated the highest cure rate (91%) against the 
strain tested. The linezolid-rifampin combination is a treatment option for implant-associated 
infections caused by quinolone-resistant MRSA. 
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6.2 Introduction 
Implanted devices are increasingly used in modern medicine to alleviate pain or improve a 
compromised function. Implant-associated infections represent an emerging complication, caused by 
organisms which adhere to the implant surface and grow embedded in a protective extracellular 
polymeric matrix, known as a biofilm [4, 9, 184]. In addition, the microorganisms in biofilms enter a 
stationary growth phase and become phenotypically resistant to most antimicrobials, frequently 
causing treatment failure. In such cases, surgical removal of the implant is often required, causing high 
morbidity and substantial healthcare costs [38, 185, 186].  
Staphylococcus aureus is the most common pathogen causing implant-associated infections [184, 
185]. Successful treatment of these infections includes early surgical intervention and antimicrobial 
treatment with bactericidal drugs that also act on surface-adhering microorganisms. Rifampin 
(rifampicin) is bactericidal against stationary-growth-phase staphylococci, as demonstrated in vitro, in 
experimental animal models, and in clinical studies [43, 187]. However, when it is used as single 
agent, the rapid emergence of rifampin resistance occurs [83, 188]. Therefore, the use of antimicrobial 
combinations to prevent the development of rifampin resistance during treatment has been investigated 
[41, 72, 83]. Rifampin in combination with quinolones has successfully been used for the treatment of 
orthopedic implant-related infections [189-191]. However, the increasing prevalence of quinolone-
resistant staphylococci has urged investigations for alternative drugs to use in combination with 
rifampin [192, 193]. In particular, methicillin-resistant staphylococci represent an increasing challenge 
due to their resistance to a broad variety of antimicrobials [194, 195].  
The oxazolidinone linezolid is active against gram-positive cocci, including methicillin-resistant 
Staphylococcus aureus (MRSA) [196-199]. Limited data on the use of the linezolid-rifampin 
combination for the treatment of MRSA implant-associated infections are available. In vitro time-kill 
experiments showed a potential additive effect between linezolid and rifampin against MRSA [200]. 
However, only case reports or small case series describing the treatment of implant-associated 
infections with linezolid and rifampin exist [52, 54, 201, 202].  
 
In the study described here, we investigated the activity of linezolid, alone and in combination with 
rifampin, against one reference MRSA strain in vitro and in an established foreign-body infection 
model. The cage-associated infection model in guinea pigs has been validated for testing the activities 
of antimicrobial agents and their combinations against implant-associated infections in pre-clinical 
studies [71, 203].  
(Part of the results of this study was presented at the 47th Interscience Conference of 
Antimicrobiaal Agents and Chemotherapy, Chicago, IL, 17th to 20th September 2007, abstr. B-811) 
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6.3 Materials and Methods 
 
Study organism. MRSA strain ATCC 43300, which is susceptible to levofloxacin and rifampin, 
was used for in vitro and in vivo antimicrobial testing. Methicillin-susceptible S. aureus strain ATCC 
29213 was used as the indicator organism for the agar diffusion bioassay. The strains were stored at  
-70°C by use of a cryovial bead preservation system (Microbank, Pro-Lab Diagnostics, Richmond 
Hill, ON, Canada). One cryovial bead was cultured overnight on Columbia sheep blood agar plates 
(Becton Dickinson, Heidelberg, Germany). Inocula were prepared from the sub-culture of two to three 
colonies, which were resuspended in 5 ml of trypticase soy broth (TSB) and incubated overnight at 
37°C without shaking.  
 
Antimicrobial agents. Linezolid was provided as purified powder by the manufacturer (Pfizer 
AG, Zurich, Switzerland); stock solutions of 2.5 mg/ml were prepared in sterile pyrogen-free water. 
Levofloxacin hemihydrate injectable solution (5 mg/ml; Aventis Pharma AG, Zurich, Switzerland) and 
rifampin (Sandoz AG, Steinhausen, Switzerland) were purchased from the respective manufacturers.  
 
In vitro antimicrobial susceptibility. The in vitro susceptibility of the MRSA strain to linezolid, 
levofloxacin and rifampin was determined in triplicate by using a standard inoculum of 1-5 × 105 
CFU/ml, adjusted from overnight cultures. The MIC was determined in Mueller-Hinton broth (MHB) 
by the macrodilution method, according to guidelines of the Clinical Laboratory Standards Institute 
(CLSI) (formerly the National Committee for Clinical Laboratory Standards) [176]. In brief, ten 
twofold serial dilutions of the test drug were prepared in 2 ml MHB in sterile boro-silicate glass tubes. 
Two milliliters of the antimicrobial dilutions were inoculated below the meniscus and incubated for 18 
h at 37°C without shaking. The MIC was the lowest drug concentration that inhibited visible bacterial 
growth. Tubes without visible growth were then vigorously vortexed, incubated for 4 h at 37°C 
without shaking, and assessed for viable bacteria by plating the contents of the tubes on agar. The 
lowest antimicrobial concentration, which killed ≥99.9% of the initial bacterial count (i.e. ≥3 log10 
CFU/ml) was defined as the minimum bactericidal concentration (MBC) during logarithmic growth 
(MBClog), as described in the Manual of Clinical Microbiology [204]. Killing of bacteria during 
stationary growth phase (MBCstat) was assayed in nutrient-restricted medium (0.01 M phosphate-
buffered saline, pH 7.4), as described previously [41]. In this medium, bacterial counts remained 
within ±15% of the initial inoculum in the antimicrobial-free culture for >36 h.  
 
In vitro time-kill studies. The antimicrobial activities of linezolid and rifampin, alone and in 
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combination, against the MRSA strain were evaluated by time-kill studies with inocula of 1 × 106 to 5 
× 106 CFU/ml, as described previously [144]. Antibiotic solutions with 1× and 4× the MIC of the test 
strain were prepared in 10 ml of MHB. Growth in the absence of antibiotics served as the control. 
Colony counts were determined after 0, 6 and 24 h of incubation at 37°C by plating aliquots of 
appropriate dilutions on Muller-Hinton agar (MHA). The ≥10-fold dilutions allowed accurate colony-
counts in the range of 10-250 CFU per plate and minimized the effects of drug carry-over. The 
quantification limit was set equal to 200 CFU/ml (>10 CFU in 50 µl of a 10-fold dilution). Killing 
over time was expressed as the mean reduction in the log10 CFU/ml ± the standard deviation (SD). 
Synergism was defined as a 100-fold increase in the level of killing at 24 h with the combination in 
comparison with the level of killing achieved with the most active single drug. Antagonism was 
defined as a 100-fold decrease in the level of killing at 24 h with the combination of both drugs, 
compared to the level of killing achieved with the most active single drug [144]. Cultures of the 
MRSA strain that were exposed to rifampin alone or in combination with linezolid and that showed 
visible growth after 24 h of incubation were tested for rifampin resistance. The cultures were adjusted 
to a standardized inoculum corresponding to a McFarland 0.5, spread on MHA containing rifampin (1 
µg/ml), and assessed for growth. Experiments were performed in triplicate.  
 
In vitro antimicrobial resistance studies. An assay was developed to evaluate the rate of in vitro 
emergence of rifampin resistance. The ratio of resistant to total colony counts was assessed after 24 h 
of incubation of the MRSA strain in 10 ml MHB containing rifampin alone or rifampin and linezolid at 
1× the MIC. The 24-h bacterial cultures were serially diluted 10-fold, 50 µl aliquots were plated on 
MHA containing rifampin (1 µg/ml) or no antibiotic, and the colonies were counted after 48 h of 
incubation at 37°C. The results were expressed as a ratio between the rifampin-resistant log10 CFU/ml 
and the total log10 CFU/ml. Experiments were performed in triplicate.  
 
Animal model. A foreign-body infection model in guinea pigs was used, as previously described 
[6, 71, 78, 203]. Guinea pigs were kept under specific-pathogen-free conditions in the Animal House 
of the Department of Biomedicine, University Hospital Basel, and animal experimentation guidelines 
according to the regulations of Swiss veterinary law were followed. The study protocol was approved 
by the Institutional Animal Care and Use Committee. In brief, four sterile polytetrafluorethylene 
(Teflon) cages (32 mm x 10 mm), perforated by 130 regularly spaced holes of 1 mm diameter (Angst-
Pfister AG, Zurich, Switzerland) were subcutaneously implanted in the flanks of male albino guinea 
pigs (Charles River, Sulzfeld, Germany) under aseptic conditions. Animals weighing 550 to 600 g 
were anesthetized with an intramuscular injection of ketamine (20 mg/kg) and xylazine (4 mg/kg). 
Two weeks after surgery and healing of the surgical wounds, the sterility of the cages was verified by 
culture of the aspirated cage fluid. The cages, which resulted being contaminated, were excluded from 
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further studies. Sterile cages were used for the pharmacokinetic studies. For the treatment studies, the 
cages were infected by percutaneous inoculation of 200 µl containing 2 × 104 CFU MRSA (day 0). 
Before inoculation, overnight bacterial cultures were washed twice, resuspended in 5 ml of sterile 
pyrogen-free normal saline and diluted 1:1,000. The establishment of infection was confirmed 24 h 
later by quantitative culture of aspirated cage fluid.  
 
Pharmacokinetic studies. Cage fluid was aspirated from non-infected animals during 24 h (1, 2, 
4, 6, 8, 10, 12 and 24 h) following intraperitoneal administration of a single dose of linezolid at 25, 50, 
and 75 mg/kg. Each dose was tested in three guinea pigs; therefore, 12 cages were used to relate the 
pharmacokinetic parameters to the antimicrobial treatment efficacy results. At each time point, 150-µl 
aliquots of cage fluid were aspirated from two cages from each animal (i.e., six replicates per time 
point and drug dose). The collected fluid was centrifuged (2100 × g for 7 min), and the supernatant 
was stored at -20°C until further analysis.  
 
Determination of drug concentrations. Linezolid concentrations in cage fluid were determined 
by an agar plate diffusion bioassay with S. aureus strain ATCC 29213 as the indicator organism. 
Antibiotic medium 1 (Difco, BD, Le Pont de Claix, France) was suspended with sterile pyrogen-free 
water, and the mixture was boiled at 100°C in water bath for 30 min. After the medium was boiled, it 
was cooled down to 50°C, inoculated with the overnight culture of the indicator organism (300 µl/400 
ml medium) and poured into large assay plates (30 by 30 cm). Calibration curves were plotted for each 
of the assay plates, and the regression fitting equation was extrapolated. The standard solutions were 
prepared in 31% guinea pig serum (corresponding to linezolid-albumin binding ratio in humans) by 
preparing twofold serial dilutions of the 20-mg/liter linezolid solution [205]. One hundred microliters 
of the cage fluid samples and duplicates of the linezolid standard solutions were spotted into holes 
punched into the assay plates, and the plates were incubated overnight. The diameter of the inhibition 
zone was measured with calipers.  The bioassay detection limit corresponded to the linezolid MIC of 
the indicator organism (i.e., 1.25 µg/ml). 
 
Pharmacokinetic parameters. The concentration-time data were analyzed individually for each 
animal by using the WinNonlin software package (Pharsight Corp., Mountain View, CA). Mean ± SD 
values of the peak concentration (Cmax), the time to reach Cmax (Tmax), the trough concentration at 12 h 
after dosing (Cmin), half-life (t½), and the area under the concentration-time curve from time zero to 24 
h (AUC0-24) were calculated from three animals receiving the same linezolid dose.  
 
Antimicrobial treatment studies. Antimicrobial treatment was initiated 24 h after infection (day 
1). At least three animals were randomized into each of the following treatment groups: control 
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(saline), linezolid at 25, 50 and 75 mg/kg (alone or in combination with rifampin at 12.5 mg/kg), and 
levofloxacin at 10 mg/kg in combination with rifampin at 12.5 mg/kg [84]. All antibiotics were 
administered intraperitoneally every 12 h over 4 days (i.e., total of eight doses).  
 
Efficacy of treatment against planktonic bacteria. The planktonic bacteria in aspirated cage 
fluid were enumerated before initiation of antimicrobial treatment (day 1), on the fourth day of 
treatment and before administration of the last antimicrobial dose (day 4), and 5 days after end of 
treatment (day 10). Bacterial counts were expressed as the median and interquartile range (IQR) of the 
log10 CFU/ml. The quantification limit of the planktonic bacteria was set at 1000 CFU/ml (>10 CFU in 
50 µL from dilutions ≥10- fold). Thus, negative cage fluid cultures were assigned a value of 3 log10 
CFU/ml for calculation of the log10 CFU/ml reduction and for statistical analysis. The efficacy of the 
treatment against planktonic bacteria was expressed as (i) the difference in bacterial counts in cage 
fluid (Δ log10 CFU/ml = log10 CFU/ml [day 4 or 10] - log10 CFU/ml [day 1]) and (ii) the rate of 
culture-negative cage fluid samples, i.e., the number of cage fluid samples without detectable growth 
of the MRSA strain divided by the total number of cages in the treatment group. 
 
Efficacy of treatment against adherent bacteria. To determine the efficacy of the treatment 
against adherent bacteria, the animals were sacrificed on day 10. The cages were removed under 
aseptic conditions, placed in 5 ml TSB, vortexed for 30 s and incubated at 37°C. After 48 h, 100-µl 
aliquots of the cage cultures were plated on Columbia sheep blood agar plates (Becton Dickinson) and 
assessed for bacterial growth. Cultures displaying growth were tested by the S. aureus latex test 
(Staphytect Plus; Oxoid, Basel, Switzerland). Cage cultures negative in this test were considered 
contaminated and were not used for the evaluation of treatment efficacy. The efficacy of the treatment 
against adherent bacteria was expressed as the cure rate, defined as the number of cage cultures 
without MRSA growth divided by the total number of cages in the treatment group.  
 
In vivo antimicrobial resistance studies. MRSA isolates from positive cultures in TSB 
containing explanted cages (i.e. treatment failures) were screened for the in vivo development of 
rifampin resistance. For this purpose, multiple colonies of each morphologically distinct colony type 
were collected from an agar subculture, suspended in saline to a standardized inoculum corresponding 
to the turbidity of a McFarland 0.5, and plated on MHA containing 1 µg/ml rifampin. The plates were 
incubated at 37°C and screened for growth after 48 h.  
 
Statistics. Comparisons were performed by using the Man-Whitney U-test for continuous 
variables and a two-sided χ2 or Fisher’s exact tests for categorical variables, as appropriate. For all 
tests, differences were considered significant when P values were <0.05. Figures were plotted using 
GraphPad Prism (version 4.0) software (GraphPad Software, La Jolla, CA). 
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6.4 Results 
 
In vitro antimicrobial susceptibility. Table 11 shows the in vitro susceptibility of the MRSA 
strain to linezolid, rifampin and levofloxacin. Linezolid inhibited bacterial growth at 2.5 µg/ml, 
whereas a bactericidal effect was not achieved up to 20 µg/ml either in the logarithmic or in the 
stationary growth phase. Rifampin exerted a low MIC (0.01 µg/ml) and was bactericidal in the 
logarithmic and the stationary growth phase. Levofloxacin had a MIC of 0.16 µg/ml and exhibited 
bactericidal activity only against bacteria in the logarithmic growth phase, and not those in the 
stationary phase.  
 
Table 11. In vitro susceptibility of MRSA ATCC 43300 
Antibiotic MIC MBCloga MBCstatb 
 (µg/ml) 
Linezolid 2.5 >20 >20 
Rifampin 0.01 0.08 2.5 
Levofloxacin 0.16 0.63 >20 
a MBClog, minimal bactericidal concentration in the logarithmic growth phase. 
b MBCstat, minimal bactericidal concentration in the stationary growth phase. 
 
In vitro time-kill studies. In vitro time-kill studies were performed with inocula of 1× 106 to 5 × 
106 CFU/ml to investigate the synergism or antagonism of linezolid and rifampin. In the controls, the 
bacterial counts increased by 1.7 log10 CFU/ml after 24 h. In the presence of linezolid at 1× the MIC, 
the bacterial counts remained unchanged, while at 4× MIC they decreased by 1.7 log10 CFU/ml at 24 h. 
Rifampin at both 1× and 4× the MIC similarly decreased the bacterial counts after 6 h (0.5 log10 
CFU/ml), however, regrowth to counts similar to those for the growth controls occurred after 24 h 
(figure 25). Bacteria exposed to rifampin alone showed regrowth after 24 h and were resistant to 
rifampin. When rifampin was combined with linezolid at either 1× or 4× the MIC, the bacterial counts 
at 24 h were decreased by 1.6 and 1.8 log10 CFU/ml, respectively. Due to the development of rifampin 
resistance during exposure to rifampin alone, it was not possible to evaluate whether a potential 
synergistic or antagonistic interaction between rifampin and linezolid existed, as described above. 
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Figure 25. Time-kill curves of 1× and 4× MIC linezolid (closed circles), 1x and 4x MIC rifampin (closed circle, dashed 
line), and their combination (open circles), against MRSA. Values are means ± SD. LZD, linezolid; RIF, rifampin. 
 
In vitro antimicrobial resistance. With MRSA inocula of 1× 106 to 5 × 106 CFU/ml, the ratio of 
rifampin-resistance developed after 24 h from cultures exposed to rifampin alone at 1× the MIC was 
94% ± 3%. In contrast, no rifampin-resistant strains colonies were detected after 24 h incubation with 
the rifampin-linezolid combination at 1× the MIC. 
 
Pharmacokinetic studies. Figure 26 shows the concentration-time profile in cage fluid after the 
administration of a single intraperitoneal dose in noninfected animals. The calculated values of the 
pharmacokinetic parameters are summarized in table 12. The Cmaxs of linezolid at 25, 50 or 75 mg/kg 
i.p. dose, were achieved at ≈3 h after dosing. The linezolid concentration remained above the MIC of 
the test organism for 12 h, as did the rifampin and levofloxacin concentration. The Cmax of rifampin in 
the cage fluid reached almost 100× the MIC, whereas this ratio was considerably lower for linezolid 
and levofloxacin (5× and 9× the MIC, respectively).  
 
 
Figure 26. Pharmacokinetic of linezolid in cage fluid after a single intraperitoneal dose of 25 mg/kg (left), 50 mg/kg 
(center) and 75 mg/kg (right). Graphs represent WinNonLin individual fitting curves per animal, of three animal per 
linezolid dose.  
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Table 12. Pharmacokinetic parameters in cage fluid after a single intraperitoneal administration in 
non-infected animals, linked to pharmacokinetic parameters in cage fluid a 
Antibiotic Dose  
(mg/kg) 
Cmax 
(µg/ml) 
Cmin 
(µg/ml)b 
Tmax 
(h) 
T1/2 
(h) 
AUC0-24 
(h×µg/ml) 
Cmaxc/MIC 
AUC0-24c/MIC 
(h) 
Linezolid 25 6.8 ± 1.3 3.0 ± 0.2 3.0 ± 0.4 6.8 ± 1.7 87.8 ± 2.7 2.7 35.1 
Linezolid 50 12.7 ± 2.2 3.7 ± 1.1 3.3 ± 0.2 3.5 ± 1.7 118.7 ± 23.0 5.1 47.5 
Linezolid 75 18.1 ± 1.7 2.5 ± 1.0 2.8 ± 0.2 2.6 ± 0.9 125.8 ± 20.5 7.2 50.3 
Rifampin 12.5 1.0 ± 0.3 0.1 ± 0.1 2.1 ± 0.3 2.5 ± 1.3 4.6 ± 0.5 100.0 460 
Levofloxacin 10 1.5 ± 0.2 0.3 ± 0.1 2.5 ± 0.3 4.2 ± 1.4 6.1 ± 0.8 9.4 38.1 
a Values are means ± SD from 3 animals, as predicted by WinNonlin software package.  
b Cmin (trough concentration) at 12 h after dosing. 
c Mean values of Cmax and AUC0-24 in cage fluid after a single intraperitoneal dose. Pharmacokinetic data for rifampin and levofloxacin were 
described previously [42] 
 
Antimicrobial treatment studies. Cage fluid sterility was confirmed prior to infection. At 24 h 
after infection, the median concentration of the bacteria enumerated in the cage fluid was 6.5 log10 
CFU/ml. In control animals receiving saline, the bacterial counts in the cage fluid were 7.1 and 7.9 
log10 CFU/ml after 4 and 10 days, respectively, which correspond to increases of 0.6 and 1.4 log10 
CFU/ml, respectively. No spontaneous cure of the cage-associated infection occurred in untreated 
animals.  
 
Efficacy of treatment against planktonic bacteria. Table 13 shows the counts of planktonic 
bacteria and the rates of culture-negative cage fluid samples during and after treatment. During 
treatment (day 4), the bacterial counts in the cage fluid of animals treated with linezolid alone at 25, 50 
and 75 mg/kg were decreased by a median values of 1.4, 1.2 and 1.7 log10 CFU/ml, respectively. No 
differences in treatment efficacy were observed between the three linezolid doses (P >0.05). Linezolid 
achieved culture-negativity in 8% of cage fluid samples when it was used at 25 mg/kg and 17% of 
cage fluid samples when it was used at 50 and 75 mg/kg. When the three linezolid regimens were 
combined with rifampin, they reduced the bacterial counts by >3.0 log10 CFU/ml, which was 
significantly better than the results achieved with linezolid alone (P <0.05) (figure 27A). A total of 
55% to 65% of the cage fluid samples from animals treated with rifampin-linezolid combinations were 
culture negative on day 4.  
 
Five days after the end of treatment (day 10), the planktonic bacteria in the cage fluid of animals 
treated with linezolid at 25 and 50 mg/kg showed regrowth to 7.3 and 7.1 log10 CFU/ml, respectively 
(table 13), which correspond to increases of 1.0 and 0.8 log10 CFU/ml compared to the level of growth 
on day 1 (figure 27B). Linezolid at 75 mg/kg prevented bacterial regrowth in cage fluid on day 10, and 
the bacterial counts remained comparable to the values on day 4. In animals treated with the 
combination of linezolid and rifampin, the bacterial counts remained at the levels measured on day 4, 
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independent of the linezolid dose (P >0.05). No differences in treatment efficacy were observed 
between the three-linezolid doses (P >0.05) when they were combined with rifampin. The cure rates 
for animals treated with the linezolid-rifampin combination ranged from 75% to 95%, and rifampin-
resistance did not emerge. 
 
  
Figure 27. Treatment efficacy against planktonic bacteria in cage fluid (Δ log10 CFU/ml) during treatment – day 4 (A) 
and 5 days after the end of treatment – day 10 (B). Dashed horizontal line indicates the limit of quantification (LOQ). 
LZD25, linezolid 25 mg/kg; LZD50, linezolid 50 mg/kg; LZD75, linezolid 75 mg/kg; RIF, rifampin 12.5 mg/kg and 
LVX10, levofloxacin 10 mg/kg. 
 
Table 13. Counts of planktonic bacteria in cage fluid and rate of culture-negative cage fluid samples 
during treatment (day 4) and 5 days after end of treatment (day 10)  
Treatment group, dose (N cages) 
Bacterial counts in cage fluid 
(log10 CFU/ml)a 
No. culture-negative / 
total no. cage fluid samples (%) 
 Day 4 Day 10 Day 4 Day 10 
Control (12) 7.1 (7.0 - 7.5) 7.9 (7.6 – 8.1) 0/12 (0%) 0/12 (0%) 
Linezolid, 25 mg/kg (12) 4.5 (4.1 – 5.0) 7.3 (7.1 - 7.7) 1/12 (8%) 0/12 (0%) 
Linezolid, 50 mg/kg (12) 5.1 (4.1 – 6.0) 7.1 (6.8 – 8.0) 2/12 (17%) 0/12 (0%) 
Linezolid, 75 mg/kg (12) 4.6 (3.2 – 5.0) 4.5 (4.0 – 5.2) 3/12 (25%) 2/12 (17%) 
Rifampin, 12.5 mg/kg (12) 3.1 (3.0 – 3.4) <3.0 6/12 (50%) 11/12 (92%) 
Linezolid, 25 mg/kg + rifampin, 12.5 mg/kg (20) <3.0 <3.0 13/20 (65%) 19/20 (95%) 
Linezolid, 50 mg/kg + rifampin, 12.5 mg/kg (20) <3.0 <3.0 13/20 (65%) 15/20 (75%) 
Linezolid, 75 mg/kg + rifampin, 12.5 mg/kg (20) <3.0 <3.0 11/20 (55%) 17/20 (85%) 
Levofloxacin, 10 mg/kg + rifampin, 12.5 mg/kg (24) <3.0 <3.0 7/11 (75%) 11/11 (100%) 
a Values are medians and interquartile ranges. 
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Efficacy of treatment against adherent bacteria. No cure of cage-associated infections was 
observed with linezolid alone (figure 28). The use of linezolid in combination with rifampin showed 
cure rates of 50% to 60%. All linezolid-rifampin combinations exhibited significantly better activities 
than linezolid alone against adherent bacteria (P <0.001). For comparison, the efficacy of the 
combination levofloxacin plus rifampin was tested and demonstrated a cure rate of 91%.  
 
 
Figure 28. Cure rates of cage-associated infection at day 10. The values indicate the number of cage cultures without 
growth of MRSA / the total number of cages in the treatment group. LZD25, linezolid 25 mg/kg; LZD50, linezolid 50 
mg/kg; LZD75, linezolid 75 mg/kg; RIF, rifampin 12.5 mg/kg and LVX, levofloxacin 10 mg/kg. 
 
In vivo antimicrobial resistance studies. No rifampin-resistant MRSA strains were detected 
within positive cultures of cages from animals treated with rifampin alone or in combination with 
linezolid.  
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6.5 Discussion 
 In this study, we investigated the activity of linezolid alone and in combination with rifampin 
against MRSA in vitro and in a guinea pig implant-associated infection model. The test organism was 
inhibited by linezolid at 2.5 µg/ml. However, a reduction of ≥99.9% CFU/ml was not achieved at 
concentrations up to 20 µg/ml in either the logarithmic or the stationary growth phase. This is in 
agreement with the bacteriostatic activity of linezolid against staphylococci [206]. On the basis of this 
characteristic, linezolid monotherapy does not seem to be appropriate for the treatment of 
staphylococcal implant-associated infections. 
 
In the in vitro time kill-curve studies, rifampin-resistance was detected after 24 h of incubation in 
all cultures exposed to rifampin alone (1× and 4× the MIC). In contrast, the use of rifampin in 
combination with linezolid never resulted in the emergence of rifampin resistance [196, 200, 207]. 
Thus, we can conclude that in vitro the combination linezolid-rifampin did not display any synergism 
or antagonism against the strain tested, and it was difficult to interpret whether there was any additive 
effect because of bacterial regrowth at 24 h of incubation with rifampin alone, due to resistance 
selection. However, the combination was effective in completely preventing the development of 
rifampin resistance. 
 
In the pharmacokinetic studies, linezolid peak concentrations in cage fluid increased linearly with 
increasing doses between 25 and 75 mg/kg, whereas the increase in the AUC0-24 was not proportional 
to the dose due to the faster elimination of linezolid from the cage fluid at higher doses. The peak 
linezolid concentration and AUC0-24 reached in the cage fluid with the 75-mg/kg dose were 
comparable to the values reported by Gee T. et al. [208] in the inflammatory blister fluid of healthy 
volunteers receiving 600 mg linezolid, every 12 h. The 25-mg/kg and the 50-mg/kg linezolid doses 
administered to guinea pigs more likely simulate the 400 mg and 600 mg single-dose regimens, 
respectively. The three doses of linezolid chosen guaranteed that the antimicro                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
bial concentration in cage fluid remained above its MIC for the test organism (2.5 µg/ml) for 12 h, 
and, thus, during the entire treatment. Andes et al. [209], showed that a plasma AUC0-24/ MIC ratio of 
linezolid between 50 and 100 was predictive of a successful outcome of staphylococcal infections in 
the thigh muscle model. In our studies, the AUC0-24/ MIC was only approximately 50 and was 
achieved with the highest linezolid dose (75 mg/kg). However, these values are difficult to interpret 
since we investigated a different compartment (cage fluid) and a different type of infection (an 
infection associated with an implant) comparing to those used by Andes et al..  
The rifampin dose of 12.5 mg/kg was chosen as described previously [42, 72]. The peak levels in 
tissue fluid were equal or less than the maximal concentrations reached in humans [210], and the 
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rifampin concentration in cage fluid was greater than the MIC for 12 h after administration.  
 
The cage fluid from the MRSA-infected cages implanted in guinea pigs demonstrated continuous 
bacterial growth for 10 days and no spontaneous cure. Linezolid induced a significant reduction in the 
counts of planktonic bacteria during treatment (day 4) both when it was given alone and when it was 
given in combination with rifampin (P <0.05). During treatment, no difference between the linezolid 
monotherapies was observed, but in combination with rifampin, bacterial killing was significantly 
improved (P <0.05). Five days after the end of treatment (day 10), bacterial regrowth occurred with 
linezolid doses 25 and 50 mg/kg, whereas the counts remained suppressed after the linezolid dose of 
75 mg/kg, even though the AUC0-24 was only slightly higher. As previously shown [197], linezolid is 
able to induce a postantibiotic effect in S. aureus in a dose-dependent manner in vitro. Thus, it is likely 
that the postantibiotic effect was induced by the highest linezolid dose (75 mg/kg) but not by the two 
lower doses. In addition, the accumulation of linezolid may have occurred with the highest dose, 
delaying its time of clearance from the cage fluid. All combinations of linezolid with rifampin 
inhibited bacterial regrowth five days after the last dose.  
 
None of the treatment regimens with linezolid monotherapies eradicated the cage-associated 
MRSA infections, while the combinations of linezolid with rifampin achieved cure rates between 50% 
and 60%, which is not significantly different from that achieved with rifampin monotherapy. The 
combination of rifampin and levofloxacin showed the highest cure rate (91%). Treatment failures were 
related to lack of efficacy in the killing of bacteria when they were embedded into the biofilm matrix. 
The emergence of rifampin resistance did not occur in vivo with any of the rifampin regimens tested. 
 
In conclusion, linezolid monotherapies showed a bacteriostatic activity against the MRSA strain 
tested and were not able to eradicate the adhering bacteria. Thus, linezolid should not be used alone for 
the eradication of implant-associated infections caused by MRSA. In vitro studies demonstrated the 
potential of linezolid-rifampin combination for the treatment of MRSA infections, and these findings 
were confirmed in the animal foreign-body infection model. However, levofloxacin-rifampin 
combinations achieved higher cure rates than the linezolid-rifampin combination against the 
quinolone-susceptible MRSA strain tested (91% and 50 to 60%, respectively). In contrast to our 
previous recommendations [4], the quinolone-rifampin combination seems to be a valid option for the 
treatment of MRSA infections, whereas linezolid-rifampin regimens may be used for the treatment of 
quinolone-resistant MRSA implant-associated infections. 
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In the present study we described in vitro and in vivo innovative methods developed and evaluated 
for improving the diagnosis and treatment of prosthetic joint infections. 
 
Diagnosis of infection (nuclear medicine). Nuclear medicine studies were performed in order to 
evaluate novel radiopharmaceuticals targeting bacterial infections. We established experimental 
protocols for measuring the radiotracers’ binding in vitro to bacterial cells and accumulation in vivo at 
infection sites, in a mouse tissue cage model of infection.  
In our studies, we compared published formulated kits of 99mTc-UBI, 99mTc-ciprofloxacin, 99mTcN-
ciproCS2 and 111In-DTPA-biotin with the aim to define their in vitro labelling stability, in vitro binding 
to different bacteria, and the in vivo biodistribution in our experimental settings.  
All tested radiotracers showed high labelling resolutions and a high stability, both in saline and 
serum. The in vitro binding to the E. coli and S. aureus test strains was for 99mTc-UBI, 99mTc-
ciprofloxacin and 111In-DTPA-biotin lower than 1%, independently on the temperature and non-
displaceable by an 100-fold excess of unlabeled compound. 99mTcN-ciproCS2 showed high in vitro 
binding, but no specificity could be demonstrated. However, it is known that, with the exception of 
biotin, the binding of the remaining agents to bacteria is non-receptor mediated, and thus non-
displaceable [108, 109, 112].  
In vivo 99mTc-UBI, 99mTc-ciprofloxacin and 111In-DTPA-biotin showed a rapid kinetic of 
accumulation into cage fluids, followed by an exponential clearance, slower in infected than in sterile 
cages. Differently behaved the tracer 99mTcN-ciproCS2, which gradually entered the cages, and 
persisted during 24 h. All radiotracers were fast eliminated from blood and non-target organs. The 
T/NT ratios, calculated between target (infected) and non-target (sterile) cages, were at 4 h p.i. higher 
for 99mTc-ciprofloxacin and 111In-DTPA-biotin than for 99mTc-UBI 29-41 and 99mTcN-CiproCS2. 
Whereas, at 24 h T/NT ratios > 2 where observed with 99mTc-UBI 29-41, 99mTc-ciprofloxacin and 
99mTcN-CiproCS2 and were generally higher in E. coli than in S. aureus infected cages. Differently, 
111In-DTPA-biotin was manily cleared at 24 h p.i. from all organs and tissues. The observation that 
T/NT ratio >3 were not achieved at any time and with any bacteria, in our opinion may constitute a 
limiting factor for their application in humans. 
 
In a separate study but with an experimental set up similar to the one described above, we 
evaluated the novel transcobalamin II non-binder 99mTc-PAMA(4) derivative of the vitamin B12 for 
targeting S. aureus and E. coli implant infections. Due to the lack of binding to the transcobalamin II 
transporter, in vivo the 99mTc-PAMA(4) derivative of the vitamin B12 is not accumulated systemically, 
but only by malignant cells and, eventually, bacteria. The derivative had been previously developed by 
Waibel et al. [85] and had brought successful results in targeting tumor cells in vivo.  
We performed in vitro binding studies and we demonstrated that radiolabeled Cbl (57Co-Cbl) has a 
receptor-mediated and displaceable binding to E. coli and S. aureus. Temperature dependency of the 
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binding was more evident for S. aureus than for E. coli. In addition, no binding could be measured to 
heat killed bacteria. The binding internalization was measured by pre-incubation of the bacterial 
cultures with the labeled vitamin, followed by addition of excesses of the unlabeled Cbl. Differently 
from the results gathered when incubating labeled and unlabeled Cbl simultaneously, when bacteria 
were pre-incubated with the labeled Cbl no more displacement could be measured. The latter result 
may indicate either an internalization mechanism or a maturation of the binding, which would prevent 
further displacement. Interestingly, ethanol E. coli fixed bacteria, which preserved the binding 
properties towards 57Co-Cbl, showed equal displacement in both the competition assays.  
When testing the 99mTc-PAMA(4)-Cbl derivative in vitro, the binding to S. aureus did not differ 
from the one measured with 57Co-Cbl. Whereas, when testing E. coli, the binding ratio of the 99mTc-
PAMA(4)-Cbl derivative was approximately 100-fold lower than the 57Co-Cbl. 
In the mouse tissue cage model of infection, the distribution of the agent 99mTc-DTPA served as 
negative control, and confirmed the tissue cages to be filled with a richly vascularized granulation 
tissue. Indeed, the tracer displayed an early uptake followed by rapid clearance from all cages fluids.  
99mTc-PAMA(4)-Cbl showed a fast penetration into both infected and sterile cage-fluids but a 
slower release from infected cages. The tracer retention into infected fluids became significantly 
higher at 4 h p.i. for S. aureus infected mice and 8 h p.i. for E. coli infected mice, in accordance with 
the lower in vitro binding of PAMA(4)-Cbl to E. coli. In addition, the uptake of 99mTc-PAMA(4)-Cbl 
in infected fluids was significantly higher than the one of the non-specific tracer 99mTc-DTPA, in both 
S. aureus and E. coli infected cages. The latter result suggested a specific interaction of 99mTc-
PAMA(4)-Cbl with the colonizing bacteria, rather than a non-specific retention due to the 
morphological differences between infected and sterile cages. Further studies should be addressed to 
determine an optimal SPECT/CT imaging time after i.v. injection of 99mTc-PAMA(4)-Cbl. From our 
data, we could suggest a delay of 8 h to 12 h p.i. in order to achieve a discriminative accumulation in 
both S. aureus and E.coli infected rather than sterile cages. 
Differently, 57Co-Cbl was not discriminative for S. aureus infected cages, and it became 
discriminative for E. coli infected mice at 72 h p.i. In addition, high background retention in non-target 
tissues was measured up to 72 h p.i.. 
When the infection-inflammation non-specific tracer, 67Ga-citrate, was tested (positive control), a 
discriminative accumulation of the tracer in infected rather than sterile cages was achieved from 48 h 
until 72 h p.i.. Thus, our studies demonstrated the validity of the tissue cage mouse model of infection 
for screening in vivo the radiotracer’s targeting of bacterial infections. Importantly, further studies 
should be addressed to better characterize the predictive value of our in vivo model towards diagnosis 
of infections in humans.  
 
Diagnosis of infection (calorimetry). Calorimetry is a high-potential method for sensitive 
measurements of bacterial heat production related to their growth and metabolism in culture. We 
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aimed to prove the use of calorimetry for early and accurate detection of methicillin-resistance, using 
laboratory strains and clinical isolates of S. aureus. Relative heat was calculated as ratio between the 
total heat measured for bacterial cultures in the presence and absence of 4 µg/ml cefoxitin. A cutoff of 
relative heat was generated on the basis of 20 repeated measurements performed with MSSA and 
MRSA laboratory strains at 3 h, 4 h and 5 h of incubation in the microcalorimeter. Based on the 
relative heat cutoff of 0.4, 17 of 20 (85%) MRSA clinical isolates were correctly identified after 3 
h of incubation. When the incubation was prolonged to 5 h, 19 of 20 (95%) MRSA isolates were 
correctly identified. The relative heat of all MSSA strains remained <0.4 up to 5 h of incubation. 
At 5 h of incubation, the sensitivity, specificity, positive and negative predictive values (and their 
95% confidence intervals) for detection of methicillin resistance were 95% (89%-100%), 100% 
(92%-100%), 100% (91%-100%) and 91% (85%-97%), respectively. 19  
The calorimetric protocol has the advantages of being rapid, inexpensive, easy to set up, suitable 
for automation and the processing of computer-generated results. Thus, calorimetry is a promising tool 
for the rapid discrimination between MSSA and MRSA strains. Our protocol may be further optimized 
to increase the accuracy and speed of MRSA detection. In addition, the use of calorimetry 
measurements for screening of bacterial resistance patterns could be extended to other organisms and 
antibiotic substances. 
 
Antimicrobial prophylaxis and treatment of infection. The introduction in the clinical practice 
of antimicrobials with an unconventional mechanism of action may become an innovative approach 
for prophylaxis and treatment of prosthetic joint infection. Indeed, the spread of multi-resistant 
organisms or the emergence of acquired resistance during antimicrobial treatment raises the urgency 
for new pharmaceuticals. We investigated the in vitro activity of Gallium Maltolate (GaM) against 
laboratory and clinical staphylococci in the logarithmic, stationary phase and biofilms. Gallium (III) 
acts against bacteria by substituting Iron (III) at its enzyme binding-sites, and thus, blocking all iron-
dependent metabolic reactions. Standard in vitro tests for determination of MIC, minimal bactericidal 
concentration (MBC) in the logarithmic and stationary growth phase, showed a bactericidal activity of 
GaM against S. epidermidis strains at concentrations ranging between 1500 and 6000 µg/ml (MICs 
between 94 and 200 µg/ml). Whereas, GaM was mostly bacteriostatic against S. aureus (MICs 
between 375 and 2000 µg/ml). Also when testing eradication of pre-formed biofilm, GaM showed 
higher efficacy against S. epidermidis than S. aureus strains. In addition, methicillin-resistant strains 
showed a tendency of higher susceptibility to GaM than the methicillin-susceptible strains. At sub-
inhibitory concentrations, GaM inhibited in a dose-dependent manner the bacterial heat production, 
measured using a newly developed calorimetric assay.  
The high concentrations of GaM associated with in vitro anti-staphylococcal activity would 
suggest that, the systemic application of GaM for therapeutic use in humans is rather improbable. 
However in previous studies, the subcutaneous injection of GaM (25 mg/kg) showed prevention of
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colonization by P. aeruginosa and S. aureus in a thermally injured infection mouse model, suggesting 
potential applications in local therapy of wound infections [175]. Moreover, due to its activity at sub-
inhibitory concentrations, low doses of GaM may be investigated in combination with standard 
antimicrobials to elucidate potential synergistic effects or prevention of resistance development.  
Alternatively, GaM could be a promising candidate for MRSA skin and mucosal decolonization. 
Finally, the displayed anti-biofilm activity may suggest gallium use in implant coating as preventive 
strategy against staphylococcal adherence. Animal and clinical studies are needed to further 
characterize the therapeutic and preventive potentials of gallium, together with toxicity studies.  
 
Antimicrobial treatment of infection. The combination rifampin/ levofloxacin is one of the most 
effective antimicrobial regimens against MRSA prosthetic infection. However, the diffusion of strains 
resistant to fluoroquinolones stimulated the search of novel anti-staphylococcal agents to be 
administered in combination with rifampin. Linezolid has been reported for the high activity against 
soft-tissue MRSA infections [211]. However, only case reports have been published regarding the 
potential of linezolid in combination with rifampin against MRSA prosthetic infections. Thus we 
tested linezolid alone and in combination with rifampin, against one reference MRSA strain in vitro 
and in the established guinea pig foreign-body infection model.  
The test MRSA strain was susceptible to linezolid, but only bacteriostatic concentrations of the 
antimicrobials could be achieved in vitro. In kill curve studies we demonstrated the efficacy of 
linezolid-rifampin combination to completely prevent the development of rifampin resistance, 
observed in cultures exposed to rifampin alone. 
In the animal foreign-body infection model, linezolid monotherapies showed only a slight 
reduction of planktonic MRSA and were not able to eradicate the adhering bacteria, against which 
bactericidal activity is mandatory. Thus, linezolid should not be used alone for the eradication of 
implant-associated infections caused by MRSA.  
The linezolid-rifampin combinations achieved cure rates of adherent MRSA of 50 to 60%. In 
comparison, levofloxacin-rifampin combinations displayed higher cure rates (91%) than the linezolid-
rifampin combination against the quinolone-susceptible MRSA strain tested.  
In contrast to our previous recommendations [4], the quinolone-rifampin combination seems to be 
a valid option for the treatment of MRSA infections, whereas linezolid-rifampin regimens may be used 
for the treatment of quinolone-resistant MRSA implant-associated infections. 
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